{ "schemaVersion": "deck-intelligence.v1", "id": "019de074-4969-72b8-bf99-262b9202adeb", "slug": "32d16c961ba3228c7796678a3b67d91c", "title": "ATAI | Investor Presentation Deck | 33 slides", "subtitle": "atai Life Sciences · 2023-02", "author": "atai Life Sciences", "date": "2023-02-01 00:00:00", "pageCount": 33, "kind": "pitchdeck", "orientation": "landscape", "aspectRatio": 1.7777778, "document": { "id": "019de074-4969-72b8-bf99-262b9202adeb", "slug": "32d16c961ba3228c7796678a3b67d91c", "title": "ATAI | Investor Presentation Deck | 33 slides", "rawTitle": "ATAI | Investor Presentation Deck | 33 slides", "authorId": "atai", "authorName": "atai Life Sciences", "authorDisplay": "atai Life Sciences", "kind": { "slug": "pitchdeck", "label": "Pitch deck" }, "sourceType": { "slug": "investor_relations", "label": "Investor relations" }, "fileName": "2023-02__atai__investor-pres__32d16c96.pdf", "sourceUrl": "https://www.slidebook.io/company/atai/presentation/32d16c961ba3228c7796678a3b67d91c/", "sourceDate": "2023-02-15 00:00:00", "presentationDate": "2023-02-01 00:00:00", "ingestedAt": "2026-04-30 22:13:30.703526+00", "status": "ready", "pageCount": 33, "orientation": "landscape", "aspectRatio": 1.7777778, "targetCompany": null, "targetTicker": null, "metadata": { "corpus": "slidebook", "industry": "biotechnology", "local_root": "/Users/miguelsuredasuau/Desktop/lalalalla/_scrape/slidebook/decks/2023-02__atai__investor-pres__32d16c96", "image_width": 1920, "image_format": "jpg", "deck_type_raw": "Investor Presentation Deck", "deck_type_slug": null, "source_url_pattern": "https://www.slidebook.io/company/{company_slug}/presentation/{deck_id}/" } }, "coverage": { "pageCount": 33, "pagesIndexed": 33, "pagesWithImages": 33, "pagesWithMetadata": 33, "imageCoveragePct": 100, "metadataCoveragePct": 100, "componentCount": 161, "chartCount": 13, "metricSlides": 0, "toolMatches": 10, "documentToolMatches": 0, "frameworkMatches": 17, "arcMatches": 1, "beatMatches": 5, "loopMatches": 2, "patternMatches": 0, "storymakersMatch": false, "scoreAvailable": false, "reviewAvailable": false, "activistThesisAvailable": false, "pitchdeckMetadataAvailable": false, "pitchdeckProfileAvailable": false }, "blocks": [], "matches": { "arcs": [ { "arc": { "name": "The Sequoia Pitch", "slug": "sequoia-pitch", "status": "active", "bestFor": "Investor pitches, Series A/B, board presentations", "canonId": "019dd956-5e69-75a7-a0a4-895ac1bc0444", "version": 1, "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49", "structure": "Problem -> Solution -> Why Now -> Market Size -> Competition -> Product -> Business Model -> Team -> Financials -> The Ask", "description": null, "familyLabel": null, "categoryName": "Strategy & Business", "categorySlug": "strategy-business" }, "matchId": "c1142f11-4f33-424c-b75a-7c146ec1d878", "evidence": "The presentation follows a structure similar to the Sequoia Pitch, with sections on problem statement, solution, traction, roadmap, and competitive analysis.", "isPrimary": true, "confidence": 0.8, "extraction": { "at": "2026-07-16 22:29:50.379063+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": "doc-narrative-v1" } } ], "beats": [ { "to": 9, "arc": { "name": "The Sequoia Pitch", "slug": "sequoia-pitch", "status": "active", "bestFor": "Investor pitches, Series A/B, board presentations", "canonId": "019dd956-5e69-75a7-a0a4-895ac1bc0444", "version": 1, "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49", "structure": "Problem -> Solution -> Why Now -> Market Size -> Competition -> Product -> Business Model -> Team -> Financials -> The Ask", "description": null, "familyLabel": null, "categoryName": "Strategy & Business", "categorySlug": "strategy-business" }, "from": 8, "name": "Problem", "beatId": "707b84bb-d006-4ebc-b566-ffd6845e4351", "matchId": "c1142f11-4f33-424c-b75a-7c146ec1d878", "beatType": { "name": "Problem", "slug": "sequoia-pitch-problem", "status": "active", "canonId": "019dd9b8-1ed4-767b-8e05-40e733bd2311", "version": 1, "description": null }, "evidence": "The presentation identifies a huge need for development in CIAS and Schizophrenia treatment (p8) and an urgent need for innovation in depression treatment (p15).", "position": 0, "isPrimaryArc": true, "parentBeatType": { "name": "Complication", "slug": "complication", "status": "active", "canonId": "019dd9b8-0275-7709-b2d6-4f77c3fc7579", "version": 1, "description": "The point in the narrative where the audience should feel discomfort. Required for argumentative arcs." }, "alignedBlockIds": null, "matchConfidence": 0.8 }, { "to": 7, "arc": { "name": "The Sequoia Pitch", "slug": "sequoia-pitch", "status": "active", "bestFor": "Investor pitches, Series A/B, board presentations", "canonId": "019dd956-5e69-75a7-a0a4-895ac1bc0444", "version": 1, "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49", "structure": "Problem -> Solution -> Why Now -> Market Size -> Competition -> Product -> Business Model -> Team -> Financials -> The Ask", "description": null, "familyLabel": null, "categoryName": "Strategy & Business", "categorySlug": "strategy-business" }, "from": 4, "name": "Solution", "beatId": "1742a8b1-89e9-49d8-82eb-87df36f14e25", "matchId": "c1142f11-4f33-424c-b75a-7c146ec1d878", "beatType": { "name": "Solution", "slug": "sequoia-pitch-solution", "status": "active", "canonId": "019dd9b8-1fb1-71d9-a260-07738d7f9c2f", "version": 1, "description": null }, "evidence": "The presentation presents atai Life Sciences' solution, including their strategy for delivering sustained behavioral change in patients (p4) and their robust pipeline of drug development programs (p5-6).", "position": 1, "isPrimaryArc": true, "parentBeatType": { "name": "Turn", "slug": "turn", "status": "active", "canonId": "019dd9b8-0396-702b-ac2f-9901f8dd8b54", "version": 1, "description": "The pivot — solution proposed, catalyst introduced, decision made. Common (15/20 arcs) but not universal: Triple-take, AIDA, PAS, Voyage-return and Pixar substitute it with a strong reflection or development beat." }, "alignedBlockIds": null, "matchConfidence": 0.8 }, { "to": 12, "arc": { "name": "The Sequoia Pitch", "slug": "sequoia-pitch", "status": "active", "bestFor": "Investor pitches, Series A/B, board presentations", "canonId": "019dd956-5e69-75a7-a0a4-895ac1bc0444", "version": 1, "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49", "structure": "Problem -> Solution -> Why Now -> Market Size -> Competition -> Product -> Business Model -> Team -> Financials -> The Ask", "description": null, "familyLabel": null, "categoryName": "Strategy & Business", "categorySlug": "strategy-business" }, "from": 10, "name": "Traction", "beatId": "9da964e2-70a1-4fde-828c-8254f9947c58", "matchId": "c1142f11-4f33-424c-b75a-7c146ec1d878", "beatType": null, "evidence": "The presentation showcases traction for RL-007, including its pro-cognitive effects in human clinical studies (p9) and its Phase 2b trial design (p12).", "position": 2, "isPrimaryArc": true, "parentBeatType": null, "alignedBlockIds": null, "matchConfidence": 0.8 }, { "to": 6, "arc": { "name": "The Sequoia Pitch", "slug": "sequoia-pitch", "status": "active", "bestFor": "Investor pitches, Series A/B, board presentations", "canonId": "019dd956-5e69-75a7-a0a4-895ac1bc0444", "version": 1, "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49", "structure": "Problem -> Solution -> Why Now -> Market Size -> Competition -> Product -> Business Model -> Team -> Financials -> The Ask", "description": null, "familyLabel": null, "categoryName": "Strategy & Business", "categorySlug": "strategy-business" }, "from": 5, "name": "Roadmap", "beatId": "844786c1-be36-4c8e-94b5-66319c33dac5", "matchId": "c1142f11-4f33-424c-b75a-7c146ec1d878", "beatType": null, "evidence": "The presentation outlines atai Life Sciences' roadmap, including expected R&D milestones across key programs through 2024 (p6).", "position": 3, "isPrimaryArc": true, "parentBeatType": null, "alignedBlockIds": null, "matchConfidence": 0.8 }, { "to": 14, "arc": { "name": "The Sequoia Pitch", "slug": "sequoia-pitch", "status": "active", "bestFor": "Investor pitches, Series A/B, board presentations", "canonId": "019dd956-5e69-75a7-a0a4-895ac1bc0444", "version": 1, "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49", "structure": "Problem -> Solution -> Why Now -> Market Size -> Competition -> Product -> Business Model -> Team -> Financials -> The Ask", "description": null, "familyLabel": null, "categoryName": "Strategy & Business", "categorySlug": "strategy-business" }, "from": 13, "name": "Competitive Analysis", "beatId": "34485d17-5ed8-4b0d-a98e-2eaaf208a9c8", "matchId": "c1142f11-4f33-424c-b75a-7c146ec1d878", "beatType": null, "evidence": "The presentation provides a competitive analysis for RL-007, highlighting its unique pharmacology and acute cognitive benefit (p13).", "position": 4, "isPrimaryArc": true, "parentBeatType": null, "alignedBlockIds": null, "matchConfidence": 0.8 } ], "loops": [ { "to": 9, "from": 8, "loop": { "name": "27_cost_of_inaction", "slug": "27-cost-of-inaction", "status": "active", "bestFor": "Urgent budget requests, compliance, risk mitigation", "canonId": "019dd956-70d1-7395-a15b-857ba858b394", "version": 1, "bodyDocId": "019df22a-2420-77be-bc41-ded96d08cb21", "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point", "description": "Quantify what happens if the audience does nothing", "familyLabel": null, "categoryName": "Urgency", "categorySlug": "urgency" }, "matchId": "7aa520a4-e861-4ddd-adb0-33d2e2059fa2", "evidence": "The presentation highlights the huge need for development in CIAS and Schizophrenia treatment (p8) and the urgent need for innovation in depression treatment (p15).", "position": 0, "objective": "What are the consequences of not addressing mental health disorders?", "confidence": 0.7, "extraction": { "at": "2026-07-16 22:29:50.624947+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": "doc-narrative-v1" } }, { "to": 33, "from": 3, "loop": { "name": "11_golden_circle", "slug": "11-golden-circle", "status": "active", "bestFor": "Visionary leadership, brand positioning, mission statements", "canonId": "019dd956-6a50-7202-882d-505fcb9922ed", "version": 1, "bodyDocId": "019df22a-2420-77be-bc41-ded96d08cb21", "structure": "The Why (Belief) -> The How (Process) -> The What (Result)", "description": "Invert the typical pitch by starting with why you exist, rather than what you do", "familyLabel": null, "categoryName": "Vision", "categorySlug": "vision" }, "matchId": "720e63ac-a674-4bf4-8e46-acf9a0a900ae", "evidence": "The presentation follows the Golden Circle framework, starting with why atai Life Sciences is working on mental health disorders (p3) and presenting their solution and traction.", "position": 1, "objective": "Why is atai Life Sciences' solution important?", "confidence": 0.7, "extraction": { "at": "2026-07-16 22:29:50.666122+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": "doc-narrative-v1" } } ], "tools": [ { "tool": { "name": "Executive summary", "slug": "executive-summary", "status": "active", "bestFor": null, "canonId": "019dd9e1-4b63-72d5-9734-da757d91ca61", "version": 1, "bodyDocId": null, "description": "A condensed view of the entire argument on a single slide / block.", "familyLabel": null, "categoryName": null, "categorySlug": null }, "agent": null, "layer": "slide", "agents": null, "matchId": "0e6cd3b5-1a89-459f-83e3-f019c2c21cec", "evidence": "This slide presents a concise overview of the company's situation, including key points and data.", "pageRefs": null, "priority": null, "whenToUse": null, "confidence": 0.9, "extraction": { "at": "2026-07-17 00:18:27.43002+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 3, "whyItWorks": null, "antipattern": null, "cardinality": "common", "narrativePurpose": null }, { "tool": { "name": "Problem Statement Canvas", "slug": "problem-statement-canvas", "status": "active", "bestFor": null, "canonId": "019dd956-839d-744b-ad11-9bf3e3642a18", "version": 1, "bodyDocId": null, "description": "Structured definition of the problem: What? Who? Where? When? Scale?", "familyLabel": null, "categoryName": "Block", "categorySlug": "block" }, "agent": "Architect", "layer": "slide", "agents": [ "Architect" ], "matchId": "f323fa1d-04e0-452c-aa07-aad94abd1fd6", "evidence": "This slide presents a clear problem statement and a proposed solution, including key elements such as rapid acting intervention, psychological support, and precision mental health.", "pageRefs": null, "priority": null, "whenToUse": null, "confidence": 0.7, "extraction": { "at": "2026-07-17 00:18:27.505415+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 4, "whyItWorks": null, "antipattern": null, "cardinality": null, "narrativePurpose": null }, { "tool": { "name": "Section divider", "slug": "section-divider", "status": "active", "bestFor": null, "canonId": "019dd9e1-4c66-707d-8d1f-6e14547134c7", "version": 1, "bodyDocId": null, "description": "A transitional slide marking the start of a new section.", "familyLabel": null, "categoryName": null, "categorySlug": null }, "agent": null, "layer": "slide", "agents": null, "matchId": "78234c4e-1024-4dec-8433-79a771d2006e", "evidence": "This slide serves as a clear divider between sections, with a concise title.", "pageRefs": null, "priority": null, "whenToUse": null, "confidence": 0.9, "extraction": { "at": "2026-07-17 00:18:27.657257+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 7, "whyItWorks": null, "antipattern": null, "cardinality": "common", "narrativePurpose": null }, { "tool": { "name": "Executive summary", "slug": "executive-summary", "status": "active", "bestFor": null, "canonId": "019dd9e1-4b63-72d5-9734-da757d91ca61", "version": 1, "bodyDocId": null, "description": "A condensed view of the entire argument on a single slide / block.", "familyLabel": null, "categoryName": null, "categorySlug": null }, "agent": null, "layer": "slide", "agents": null, "matchId": "02334c08-2546-46ea-a541-f46be248cf06", "evidence": "This slide presents a concise summary of RL-007's pro-cognitive effects in human clinical studies.", "pageRefs": null, "priority": null, "whenToUse": null, "confidence": 0.9, "extraction": { "at": "2026-07-17 00:18:27.769534+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 9, "whyItWorks": null, "antipattern": null, "cardinality": "common", "narrativePurpose": null }, { "tool": { "name": "Section divider", "slug": "section-divider", "status": "active", "bestFor": null, "canonId": "019dd9e1-4c66-707d-8d1f-6e14547134c7", "version": 1, "bodyDocId": null, "description": "A transitional slide marking the start of a new section.", "familyLabel": null, "categoryName": null, "categorySlug": null }, "agent": null, "layer": "slide", "agents": null, "matchId": "7180da0b-b404-470f-864a-316f9c20cf73", "evidence": "title/headline: Depression", "pageRefs": null, "priority": null, "whenToUse": null, "confidence": 0.9, "extraction": { "at": "2026-07-17 03:37:02.53609+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 14, "whyItWorks": null, "antipattern": null, "cardinality": "common", "narrativePurpose": null }, { "tool": { "name": "Storytelling: audience calibration", "slug": "audience", "status": "active", "bestFor": null, "canonId": "019df269-23ea-723a-87c0-af1d78d702d2", "version": 1, "bodyDocId": "019df269-23c5-72ec-8b94-78fc1da7b656", "description": "The same thesis, written for four different audiences, produces four", "familyLabel": "narrative-block", "categoryName": "Narrative & Transformation", "categorySlug": "narrative-transformation" }, "agent": "storyteller", "layer": "slide", "agents": [ "storyteller" ], "matchId": "e8993881-f5e5-4f76-b45f-4eb37e4e7b90", "evidence": "The slide mentions the global impact of depression, indicating consideration for the audience's perspective.", "pageRefs": null, "priority": null, "whenToUse": null, "confidence": 0.7, "extraction": { "at": "2026-07-17 03:37:02.157474+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 15, "whyItWorks": null, "antipattern": null, "cardinality": null, "narrativePurpose": null }, { "tool": { "name": "Waterfall chart", "slug": "waterfall-chart", "status": "active", "bestFor": null, "canonId": "e2799da3-725f-44a9-a093-570f1f388e64", "version": 1, "bodyDocId": null, "description": null, "familyLabel": null, "categoryName": null, "categorySlug": null }, "agent": null, "layer": "slide", "agents": null, "matchId": "f08cae56-9781-473c-9556-4822d5ca2eb9", "evidence": "Changes in Beta power from pre-dose to 3-hour post-dose", "pageRefs": null, "priority": null, "whenToUse": null, "confidence": 0.7, "extraction": { "at": "2026-07-17 00:18:17.811643+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 24, "whyItWorks": null, "antipattern": null, "cardinality": null, "narrativePurpose": null }, { "tool": { "name": "Problem Statement Canvas", "slug": "problem-statement-canvas", "status": "active", "bestFor": null, "canonId": "019dd956-839d-744b-ad11-9bf3e3642a18", "version": 1, "bodyDocId": null, "description": "Structured definition of the problem: What? Who? Where? When? Scale?", "familyLabel": null, "categoryName": "Block", "categorySlug": "block" }, "agent": "Architect", "layer": "slide", "agents": [ "Architect" ], "matchId": "8d55921f-ab1b-4bcc-bc84-9a7657b2a283", "evidence": "Substance use disorders are highly prevalent disorders characterized by an inability to control the use of a legal or illegal drugs, alcohol, or medications", "pageRefs": null, "priority": null, "whenToUse": null, "confidence": 0.5, "extraction": { "at": "2026-07-17 00:18:17.984875+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 28, "whyItWorks": null, "antipattern": null, "cardinality": null, "narrativePurpose": null }, { "tool": { "name": "Executive summary", "slug": "executive-summary", "status": "active", "bestFor": null, "canonId": "019dd9e1-4b63-72d5-9734-da757d91ca61", "version": 1, "bodyDocId": null, "description": "A condensed view of the entire argument on a single slide / block.", "familyLabel": null, "categoryName": null, "categorySlug": null }, "agent": null, "layer": "slide", "agents": null, "matchId": "3babbeb7-6df0-407b-b922-0eee0caa4de4", "evidence": "table/data: Ownership: 59.5%, Product: DMX-1002, Pharmacology: Receptor modulator, Features: Rapid withdrawal, Indications: OUD/PTSD/TBI, Status: Phase 1/2, IP: Pending claims, Highlight: Sustained reduction", "pageRefs": null, "priority": null, "whenToUse": null, "confidence": 0.7, "extraction": { "at": "2026-07-17 00:18:18.069712+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 29, "whyItWorks": null, "antipattern": null, "cardinality": "common", "narrativePurpose": null }, { "tool": { "name": "2x2 matrix", "slug": "matrix-2x2", "status": "active", "bestFor": null, "canonId": "019dd9e1-50ab-72d1-8afb-3ab0a38e32a8", "version": 1, "bodyDocId": null, "description": "BCG matrix, importance/urgency, any axes-and-quadrants frame.", "familyLabel": null, "categoryName": null, "categorySlug": null }, "agent": null, "layer": "slide", "agents": null, "matchId": "0d255183-23d3-42f8-80cb-810f1a3663aa", "evidence": "Comparison matrix of DMX-1002 vs Methadone, Buprenorphine, Naltrexone, Clonidine, and Lofexidine across 5 therapeutic criteria", "pageRefs": null, "priority": null, "whenToUse": null, "confidence": 0.5, "extraction": { "at": "2026-07-17 00:18:18.157337+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 30, "whyItWorks": null, "antipattern": null, "cardinality": "common", "narrativePurpose": null } ], "frameworks": [ { "matchId": "090da2c2-09aa-4784-9260-8f53016f010a", "evidence": "The slide provides a concise overview of the company's mission, market, strategy, and financials.", "framework": null, "confidence": 1, "extraction": { "at": "2026-05-02 12:10:51.758+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 3, "frameworkName": "executive-summary" }, { "matchId": "357561d6-1cf8-4936-ad0a-bdf2a898edd6", "evidence": "The slide maps an objective to three supporting pillars that lead to the desired outcome.", "framework": null, "confidence": 0.8, "extraction": { "at": "2026-05-02 12:10:49.13+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 4, "frameworkName": "causal-chain" }, { "matchId": "e885773d-eacf-4f57-8c2f-843dbc5939e6", "evidence": "Horizontal bars representing progress over clinical phases", "framework": null, "confidence": 0.9, "extraction": { "at": "2026-05-02 12:10:48.453+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 5, "frameworkName": "gantt-chart" }, { "matchId": "bdb8be03-03de-4fe9-97de-b87fbbafbad9", "evidence": "The slide uses a horizontal arrow-based timeline to map R&D milestones across H1'23, H2'23, and 2024.", "framework": null, "confidence": 1, "extraction": { "at": "2026-05-02 12:10:48.992+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 6, "frameworkName": "timeline" }, { "matchId": "4195dfe5-4761-4cc7-987b-247002173d68", "evidence": "Slide frames the disease burden and lack of treatment as a market opportunity.", "framework": null, "confidence": 0.9, "extraction": { "at": "2026-05-02 12:10:52.665+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 8, "frameworkName": "problem-statement" }, { "matchId": "1c2bcbb0-1a5b-42d4-b120-9d2db911b3fd", "evidence": "Structured summary of product, status, and data", "framework": null, "confidence": 1, "extraction": { "at": "2026-05-02 12:10:50.657+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 9, "frameworkName": "executive-summary" }, { "matchId": "b8e62650-0693-4b4d-9aef-8a21642a3cc3", "evidence": "Vertical flow of clinical development stages", "framework": null, "confidence": 0.8, "extraction": { "at": "2026-05-02 12:10:55.66+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 10, "frameworkName": "process" }, { "matchId": "5f3f98b5-8bd4-4b14-bedd-50d5d21e8a7f", "evidence": "Standardized flow diagram for clinical study protocols", "framework": null, "confidence": 0.9, "extraction": { "at": "2026-05-02 15:31:28.66+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 12, "frameworkName": "clinical-trial-design" }, { "matchId": "5135f6c9-2bba-40a7-972e-97b304dcedb0", "evidence": "The slide uses a feature-comparison table to differentiate the product from competitors.", "framework": null, "confidence": 0.9, "extraction": { "at": "2026-05-02 12:10:49.466+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 13, "frameworkName": "comparison_frame" }, { "matchId": "8884a7d7-6859-46dd-b949-c9e8107dfa83", "evidence": "Structured as a clear definition of the disease followed by market scale and clinical pain points.", "framework": null, "confidence": 0.9, "extraction": { "at": "2026-05-02 12:10:51.113+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 15, "frameworkName": "problem-statement" }, { "matchId": "debb48bf-8457-4845-8ffb-3c4e7cf339c8", "evidence": "The slide uses a timeline-based visual to represent clinical trial phases and milestones.", "framework": null, "confidence": 0.7, "extraction": { "at": "2026-05-02 12:10:53.914+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 17, "frameworkName": "gantt-chart" }, { "matchId": "10ecaf53-28d7-4278-a0aa-a9fd43d33299", "evidence": "Vertical list of key market statistics and pain points", "framework": null, "confidence": 0.8, "extraction": { "at": "2026-05-02 12:10:50.815+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 21, "frameworkName": "list-presentation" }, { "matchId": "f93d404e-2f7c-4f8f-a711-ef67a9157c88", "evidence": "The slide presents a structured comparison of drug classes against specific criteria.", "framework": null, "confidence": 1, "extraction": { "at": "2026-05-02 12:10:57.559+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 26, "frameworkName": "comparison_table" }, { "matchId": "3e1da3c9-19a3-4b77-a0c7-1075a8329cb1", "evidence": "Vertical sequence of data points describing the progression of the pandemic", "framework": null, "confidence": 0.8, "extraction": { "at": "2026-05-02 12:10:50.974+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 28, "frameworkName": "timeline" }, { "matchId": "7e86220d-7140-43a1-9bde-e915b929da1a", "evidence": "Structured as a high-level summary of company and clinical data.", "framework": null, "confidence": 1, "extraction": { "at": "2026-05-02 12:10:55.75+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 29, "frameworkName": "executive-summary" }, { "matchId": "aaa198a6-406c-473f-a95c-fcd683d86141", "evidence": "The slide uses a feature-comparison table to position the product against competitors.", "framework": null, "confidence": 0.95, "extraction": { "at": "2026-05-02 12:10:51.589+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 30, "frameworkName": "comparison-frame" }, { "matchId": "7bb4b171-a18e-422c-b0ed-5a31829844d0", "evidence": "Uses personal narrative to humanize the corporate mission.", "framework": null, "confidence": 0.8, "extraction": { "at": "2026-05-02 12:10:52.159+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 33, "frameworkName": "ceo-quote-contradiction" } ], "patterns": [] }, "storymakers": null, "score": null, "review": null, "activistThesis": null, "pitchdeck": { "metadata": null, "profile": null }, "slides": [ { "page": 1, "type": "setup", "function": "front_matter", "imagePath": "https://imgproxy.kitesheet.com/4SLIwvWS799HZdtIeSsxbJosHme6nhd-kl2cTB-4dBM/rs:fit:1200:1200:0/q:82/f:webp/czM6Ly9raXRlc2hlZXQvY29ycHVzL3NsaWRlcy8zMmQxNmM5NjFiYTMyMjhjNzc5NjY3OGEzYjY3ZDkxYy9wMDAxLmpwZw", "rawType": "cover", "block": null, "metadata": { "slideType": "cover", "slideTypeCanon": { "name": "Cover", "slug": "cover", "status": "active", "canonId": "019de52d-05f2-729d-9f93-e0504f0a2410", "version": 1, "description": null }, "function": "front_matter", "functionCanon": { "name": "Front matter", "slug": "front_matter", "status": "active", "canonId": "019de52d-133d-73f0-9e26-201eda96b098", "version": 1, "description": null }, "density": "sparse", "densityScore": 24, "componentCount": 4, "textChars": 141, "nDataPoints": 0, "notes": null, "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 12:10:47.822+00", "seconds": 2.327, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de074-4969-72b8-bf99-262b9202adeb/1", "deck": "/decks/019de074-4969-72b8-bf99-262b9202adeb", "deckAnchor": "/decks/019de074-4969-72b8-bf99-262b9202adeb#slide-1", "deckJson": "/decks/019de074-4969-72b8-bf99-262b9202adeb.json" }, "components": [ { "bbox": { "h": 0.15, "w": 0.2, "x": 0.05, "y": 0.05 }, "kind": "image", "text": "atai LIFE SCIENCES", "attrs": null, "canon": { "kind": { "name": "Image", "slug": "image", "status": "active", "canonId": "019de52c-f978-701f-a720-51d029d769e7", "version": 1, "description": "Photo, illustration, screenshot or icon." }, "tool": null, "subkind": { "name": "Logo", "slug": "logo", "status": "active", "canonId": "019de52c-fdaf-743d-94c4-d7c6a0e55302", "version": 1, "description": null }, "framework": null }, "subkind": "logo", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:10:47.822+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "673ee45b-f6d8-480c-acca-cde0d8d306da", "parentComponentId": null }, { "bbox": { "h": 1, "w": 0.5, "x": 0.5, "y": 0 }, "kind": "image", "text": null, "attrs": null, "canon": { "kind": { "name": "Image", "slug": "image", "status": "active", "canonId": "019de52c-f978-701f-a720-51d029d769e7", "version": 1, "description": "Photo, illustration, screenshot or icon." }, "tool": null, "subkind": { "name": "Photo", "slug": "photo", "status": "active", "canonId": "019de52c-fd37-757f-b4a8-ca26d4888875", "version": 1, "description": null }, "framework": null }, "subkind": "photo", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:10:47.822+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "3eb916d7-cb92-43ed-ab6b-db8dd14d341b", "parentComponentId": null }, { "bbox": { "h": 0.05, "w": 0.3, "x": 0.05, "y": 0.85 }, "kind": "paragraph", "text": "Company Overview – February 2023", "attrs": null, "canon": { "kind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "5f2affc0-941d-4d07-959d-4bfc1930cea4", "version": 1, "description": "Single prose block in the body of a slide." }, "tool": null, "subkind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "019de52c-fb80-75af-aa5c-a7a4bfac2433", "version": 1, "description": null }, "framework": null }, "subkind": "paragraph", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:10:47.822+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "36f8765c-112c-46ed-bc58-bc32558a3238", "parentComponentId": null }, { "bbox": { "h": 0.25, "w": 0.4, "x": 0.05, "y": 0.35 }, "kind": "title", "text": "Healing mental health disorders so that everyone everywhere can live a more fulfilled life.", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:10:47.822+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "40cf29d4-a01c-4de4-958f-102727124357", "parentComponentId": null } ], "metrics": [], "tools": [], "frameworks": [], "arcBeats": [], "loops": [], "thumbSrc": "https://imgproxy.kitesheet.com/9t1BqpG6huEWy38KVLmLdd4CG83qdE-RnL9tf0v6bh4/rs:fit:480:480:0/q:78/f:webp/czM6Ly9raXRlc2hlZXQvY29ycHVzL3NsaWRlcy8zMmQxNmM5NjFiYTMyMjhjNzc5NjY3OGEzYjY3ZDkxYy9wMDAxLmpwZw", "imagePathAlt": "https://imgproxy.kitesheet.com/svKyRRXdNwP5dv9ms8dND66V7JY8NYnRl05GcVYPOOA/rs:fit:1200:1200:0/q:82/f:webp/czM6Ly9raXRlc2hlZXQvY29ycHVzL3NsaWRlcy8zMmQxNmM5NjFiYTMyMjhjNzc5NjY3OGEzYjY3ZDkxYy9wMDAxLnBuZw", "thumbSrcAlt": "https://imgproxy.kitesheet.com/M_hvwQ45gE3_qsIwJrQEyxr2WUc0T5olnFPFK19N6qg/rs:fit:480:480:0/q:78/f:webp/czM6Ly9raXRlc2hlZXQvY29ycHVzL3NsaWRlcy8zMmQxNmM5NjFiYTMyMjhjNzc5NjY3OGEzYjY3ZDkxYy9wMDAxLnBuZw" }, { "page": 2, "type": "setup", "title": "Includes a date note at the bottom: 'Note: Unless otherwise stated, this presentation is as of January 6th, 2023'", "function": "other", "rawType": "disclaimer", "block": null, "metadata": { "slideType": "disclaimer", "slideTypeCanon": { "name": "Disclaimer", "slug": "disclaimer", "status": "active", "canonId": "019de52d-0801-727b-b98a-5ed095aeee78", "version": 1, "description": null }, "function": "other", "functionCanon": { "name": "Other (fallback)", "slug": "other", "status": "active", "canonId": "019de52d-15e1-75bc-99dc-07732380e2ce", "version": 1, "description": null }, "density": "sparse", "densityScore": 23, "componentCount": 3, "textChars": 255, "nDataPoints": 0, "notes": "Includes a date note at the bottom: 'Note: Unless otherwise stated, this presentation is as of January 6th, 2023'", "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 12:10:47.924+00", "seconds": 2.421, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de074-4969-72b8-bf99-262b9202adeb/2", "deck": "/decks/019de074-4969-72b8-bf99-262b9202adeb", "deckAnchor": "/decks/019de074-4969-72b8-bf99-262b9202adeb#slide-2", "deckJson": "/decks/019de074-4969-72b8-bf99-262b9202adeb.json" }, "components": [ { "bbox": { "h": 0.68, "w": 0.884, "x": 0.058, "y": 0.225 }, "kind": "disclaimer", "text": "All references in this presentation to “we”, “us”, “our”, “atai”, or the “Company” refer to ATAI Life Sciences N.V. and its consolidated subsidiaries... [full legal text]", "attrs": null, "canon": { "kind": { "name": "Disclaimer", "slug": "disclaimer", "status": "active", "canonId": "91173477-d91f-4024-bbaf-d4f93e3f82dc", "version": 1, "description": "Legal/cautionary text that occupies most of the body of its slide." }, "tool": null, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:10:47.924+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "0a63644f-e02f-42f8-99f6-e48815b55ffd", "parentComponentId": null }, { "bbox": { "h": 0.015, "w": 0.35, "x": 0.058, "y": 0.975 }, "kind": "source-note", "text": "Note: Unless otherwise stated, this presentation is as of January 6th, 2023", "attrs": null, "canon": { "kind": { "name": "Source note", "slug": "source-note", "status": "active", "canonId": "23484952-494b-4a5e-b1ad-550d0d70e948", "version": 1, "description": "Attribution / source / caveat placed at the slide footer. Numbered footnotes use attrs.numbered." }, "tool": null, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:10:47.924+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "e9f04365-181d-4165-afce-8150e59b2f40", "parentComponentId": null }, { "bbox": { "h": 0.035, "w": 0.175, "x": 0.058, "y": 0.085 }, "kind": "title", "text": "Disclaimer", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:10:47.924+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "1393f328-f4d1-4bff-81fb-1635a4d84c94", "parentComponentId": null } ], "metrics": [], "tools": [], "frameworks": [], "arcBeats": [], "loops": [], "locked": true }, { "page": 3, "type": "setup", "title": "The slide uses a numbered list to present five key pillars of the company's value proposition.", "function": "summarize", "rawType": "executive_summary", "block": null, "metadata": { "slideType": "executive_summary", "slideTypeCanon": { "name": "Executive summary", "slug": "executive_summary", "status": "active", "canonId": "019de52d-06be-73ff-81b3-f99fe7f0025e", "version": 1, "description": null }, "function": "summarize", "functionCanon": { "name": "Summarize", "slug": "summarize", "status": "active", "canonId": "019de52d-1541-704f-b86f-bf7b75056373", "version": 1, "description": null }, "density": "balanced", "densityScore": 47, "componentCount": 3, "textChars": 650, "nDataPoints": 6, "notes": "The slide uses a numbered list to present five key pillars of the company's value proposition.", "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 12:10:51.758+00", "seconds": 6.206, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de074-4969-72b8-bf99-262b9202adeb/3", "deck": "/decks/019de074-4969-72b8-bf99-262b9202adeb", "deckAnchor": "/decks/019de074-4969-72b8-bf99-262b9202adeb#slide-3", "deckJson": "/decks/019de074-4969-72b8-bf99-262b9202adeb.json" }, "components": [ { "bbox": { "h": 0.65, "w": 0.9, "x": 0.05, "y": 0.25 }, "kind": "list", "text": "1. Mental health disorders are one of the largest global health burdens... 2. atai's objective is to achieve clinically meaningful... 3. atai has 8 clinical stage drug development programs... 4. Validation of atai's operating model... 5. Strong cash position...", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Numbered list", "slug": "numbered", "status": "active", "canonId": "019de52c-fcc0-7718-a284-a4250c805df2", "version": 1, "description": null }, "framework": null }, "subkind": "numbered", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:10:51.758+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "4c156c99-f23b-4b1d-9373-2e45c64cbed3", "parentComponentId": null }, { "bbox": { "h": 0.05, "w": 0.5, "x": 0.05, "y": 0.93 }, "kind": "source-note", "text": "1. THE COVID STATES PROJECT report (May 21, 2021) and https://www.alliedmarketresearch.com/mental-health-market-A11770\n2. Total facility size is up to $175M, with $15M drawn to-date (in Q3 2022)\nNote: Unless otherwise stated, this presentation was updated as of January 6th, 2023", "attrs": null, "canon": { "kind": { "name": "Source note", "slug": "source-note", "status": "active", "canonId": "23484952-494b-4a5e-b1ad-550d0d70e948", "version": 1, "description": "Attribution / source / caveat placed at the slide footer. Numbered footnotes use attrs.numbered." }, "tool": null, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:10:51.758+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "5d3af6e5-1d2d-49fe-af8b-cb8fe7ee57f7", "parentComponentId": null }, { "bbox": { "h": 0.15, "w": 0.8, "x": 0.05, "y": 0.08 }, "kind": "title", "text": "atai Life Sciences: Healing mental health disorders so that everyone everywhere can live a more fulfilled life", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:10:51.758+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "8e1ff627-55bf-4da7-b8be-89229acd2905", "parentComponentId": null } ], "metrics": [], "tools": [ { "tool": { "name": "Executive summary", "slug": "executive-summary", "status": "active", "bestFor": null, "canonId": "019dd9e1-4b63-72d5-9734-da757d91ca61", "version": 1, "bodyDocId": null, "description": "A condensed view of the entire argument on a single slide / block.", "familyLabel": null, "categoryName": null, "categorySlug": null }, "agent": null, "layer": "slide", "agents": null, "matchId": "0e6cd3b5-1a89-459f-83e3-f019c2c21cec", "evidence": "This slide presents a concise overview of the company's situation, including key points and data.", "pageRefs": null, "priority": null, "whenToUse": null, "confidence": 0.9, "extraction": { "at": "2026-07-17 00:18:27.43002+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 3, "whyItWorks": null, "antipattern": null, "cardinality": "common", "narrativePurpose": null } ], "frameworks": [ { "matchId": "090da2c2-09aa-4784-9260-8f53016f010a", "evidence": "The slide provides a concise overview of the company's mission, market, strategy, and financials.", "framework": null, "confidence": 1, "extraction": { "at": "2026-05-02 12:10:51.758+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 3, "frameworkName": "executive-summary" } ], "arcBeats": [], "loops": [ { "to": 33, "from": 3, "loop": { "name": "11_golden_circle", "slug": "11-golden-circle", "status": "active", "bestFor": "Visionary leadership, brand positioning, mission statements", "canonId": "019dd956-6a50-7202-882d-505fcb9922ed", "version": 1, "bodyDocId": "019df22a-2420-77be-bc41-ded96d08cb21", "structure": "The Why (Belief) -> The How (Process) -> The What (Result)", "description": "Invert the typical pitch by starting with why you exist, rather than what you do", "familyLabel": null }, "matchId": "720e63ac-a674-4bf4-8e46-acf9a0a900ae", "evidence": "The presentation follows the Golden Circle framework, starting with why atai Life Sciences is working on mental health disorders (p3) and presenting their solution and traction.", "position": 1, "objective": "Why is atai Life Sciences' solution important?", "confidence": 0.7, "extraction": { "at": "2026-07-16 22:29:50.666122+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": "doc-narrative-v1" } } ], "locked": true }, { "page": 4, "type": "resolution", "title": "The slide uses a hierarchical structure to connect a high-level objective to three specific operational pillars.", "function": "present_solution", "rawType": "solution", "block": null, "metadata": { "slideType": "solution", "slideTypeCanon": { "name": "Solution", "slug": "solution", "status": "active", "canonId": "019de52d-0eb5-72ff-8b70-ba70a4199282", "version": 1, "description": null }, "function": "present_solution", "functionCanon": { "name": "Present solution", "slug": "present_solution", "status": "active", "canonId": "019de52d-15b8-71da-bd23-2b767850cbce", "version": 1, "description": null }, "density": "dense", "densityScore": 73, "componentCount": 7, "textChars": 787, "nDataPoints": 0, "notes": "The slide uses a hierarchical structure to connect a high-level objective to three specific operational pillars.", "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 12:10:49.13+00", "seconds": 3.344, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de074-4969-72b8-bf99-262b9202adeb/4", "deck": "/decks/019de074-4969-72b8-bf99-262b9202adeb", "deckAnchor": "/decks/019de074-4969-72b8-bf99-262b9202adeb#slide-4", "deckJson": "/decks/019de074-4969-72b8-bf99-262b9202adeb.json" }, "components": [ { "bbox": { "h": 0.15, "w": 0.5, "x": 0.25, "y": 0.3 }, "kind": "callout", "text": "Achieve clinically meaningful and sustained behavioural change in patients diagnosed with mental health disorders", "attrs": null, "canon": { "kind": { "name": "Callout", "slug": "callout", "status": "active", "canonId": "019de52c-f8d3-761a-8953-7d37080de5e2", "version": 1, "description": "Highlighted callout box." }, "tool": null, "subkind": { "name": "Primary callout", "slug": "primary", "status": "active", "canonId": "019de52c-fbd1-70eb-a9ce-8997f8674c1d", "version": 1, "description": null }, "framework": null }, "subkind": "primary", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:10:49.13+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "47ac1642-48e8-4448-b04e-a903148c7dce", "parentComponentId": null }, { "bbox": { "h": 0.15, "w": 0.8, "x": 0.1, "y": 0.55 }, "kind": "list", "text": "Rapid acting intervention (Focus: Rx) + Ongoing psychological support (Focus: DTx) + Precision mental health (Focus: Biomarkers)", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:10:49.13+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "78e13d8c-dd47-4210-a62a-49e7df471865", "parentComponentId": null }, { "bbox": { "h": 0.2, "w": 0.25, "x": 0.38, "y": 0.7 }, "kind": "paragraph", "text": "Additional ongoing psychological care provided to patients before, during and/or after initial treatment interventions", "attrs": null, "canon": { "kind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "5f2affc0-941d-4d07-959d-4bfc1930cea4", "version": 1, "description": "Single prose block in the body of a slide." }, "tool": null, "subkind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "019de52c-fb80-75af-aa5c-a7a4bfac2433", "version": 1, "description": null }, "framework": null }, "subkind": "paragraph", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:10:49.13+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "41779a83-0f99-44ab-9409-3e9662b2d342", "parentComponentId": null }, { "bbox": { "h": 0.2, "w": 0.25, "x": 0.65, "y": 0.7 }, "kind": "paragraph", "text": "The identification of patient sub-types using biological and digital biomarkers", "attrs": null, "canon": { "kind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "5f2affc0-941d-4d07-959d-4bfc1930cea4", "version": 1, "description": "Single prose block in the body of a slide." }, "tool": null, "subkind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "019de52c-fb80-75af-aa5c-a7a4bfac2433", "version": 1, "description": null }, "framework": null }, "subkind": "paragraph", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:10:49.13+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "af7d4e24-027a-449d-9f2b-b942ac567c29", "parentComponentId": null }, { "bbox": { "h": 0.2, "w": 0.25, "x": 0.1, "y": 0.7 }, "kind": "paragraph", "text": "1st, 2nd and 3rd generation compounds with the potential to show strong behavioural plasticity, rapid onset and more durable effect", "attrs": null, "canon": { "kind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "5f2affc0-941d-4d07-959d-4bfc1930cea4", "version": 1, "description": "Single prose block in the body of a slide." }, "tool": null, "subkind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "019de52c-fb80-75af-aa5c-a7a4bfac2433", "version": 1, "description": null }, "framework": null }, "subkind": "paragraph", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:10:49.13+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "d1625f79-5078-44fc-9201-25686e0f1e2f", "parentComponentId": null }, { "bbox": { "h": 0.03, "w": 0.3, "x": 0.05, "y": 0.95 }, "kind": "source-note", "text": "Note: Rx = Prescription Therapeutics; DTx = Digital Therapeutics", "attrs": null, "canon": { "kind": { "name": "Source note", "slug": "source-note", "status": "active", "canonId": "23484952-494b-4a5e-b1ad-550d0d70e948", "version": 1, "description": "Attribution / source / caveat placed at the slide footer. Numbered footnotes use attrs.numbered." }, "tool": null, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:10:49.13+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "3d0ff917-3788-4552-a350-b03c8666a993", "parentComponentId": null }, { "bbox": { "h": 0.15, "w": 0.9, "x": 0.05, "y": 0.08 }, "kind": "title", "text": "Achieving sustained behavioural change in patients through the combination of rapid acting intervention, psychological support and precision mental health", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:10:49.13+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "c65c2cbc-3c95-4f9c-af27-260fdf671889", "parentComponentId": null } ], "metrics": [], "tools": [ { "tool": { "name": "Problem Statement Canvas", "slug": "problem-statement-canvas", "status": "active", "bestFor": null, "canonId": "019dd956-839d-744b-ad11-9bf3e3642a18", "version": 1, "bodyDocId": null, "description": "Structured definition of the problem: What? Who? Where? When? Scale?", "familyLabel": null, "categoryName": "Block", "categorySlug": "block" }, "agent": "Architect", "layer": "slide", "agents": [ "Architect" ], "matchId": "f323fa1d-04e0-452c-aa07-aad94abd1fd6", "evidence": "This slide presents a clear problem statement and a proposed solution, including key elements such as rapid acting intervention, psychological support, and precision mental health.", "pageRefs": null, "priority": null, "whenToUse": null, "confidence": 0.7, "extraction": { "at": "2026-07-17 00:18:27.505415+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 4, "whyItWorks": null, "antipattern": null, "cardinality": null, "narrativePurpose": null } ], "frameworks": [ { "matchId": "357561d6-1cf8-4936-ad0a-bdf2a898edd6", "evidence": "The slide maps an objective to three supporting pillars that lead to the desired outcome.", "framework": null, "confidence": 0.8, "extraction": { "at": "2026-05-02 12:10:49.13+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 4, "frameworkName": "causal-chain" } ], "arcBeats": [ { "to": 7, "arc": { "name": "The Sequoia Pitch", "slug": "sequoia-pitch", "status": "active", "bestFor": "Investor pitches, Series A/B, board presentations", "canonId": "019dd956-5e69-75a7-a0a4-895ac1bc0444", "version": 1, "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49", "structure": "Problem -> Solution -> Why Now -> Market Size -> Competition -> Product -> Business Model -> Team -> Financials -> The Ask", "description": null, "familyLabel": null }, "from": 4, "name": "Solution", "beatId": "1742a8b1-89e9-49d8-82eb-87df36f14e25", "matchId": "c1142f11-4f33-424c-b75a-7c146ec1d878", "beatType": { "name": "Solution", "slug": "sequoia-pitch-solution", "status": "active", "canonId": "019dd9b8-1fb1-71d9-a260-07738d7f9c2f", "version": 1, "description": null }, "evidence": "The presentation presents atai Life Sciences' solution, including their strategy for delivering sustained behavioral change in patients (p4) and their robust pipeline of drug development programs (p5-6).", "position": 1, "isPrimaryArc": true, "parentBeatType": { "name": "Turn", "slug": "turn", "status": "active", "canonId": "019dd9b8-0396-702b-ac2f-9901f8dd8b54", "version": 1, "description": "The pivot — solution proposed, catalyst introduced, decision made. Common (15/20 arcs) but not universal: Triple-take, AIDA, PAS, Voyage-return and Pixar substitute it with a strong reflection or development beat." }, "alignedBlockIds": null, "matchConfidence": 0.8 } ], "loops": [ { "to": 33, "from": 3, "loop": { "name": "11_golden_circle", "slug": "11-golden-circle", "status": "active", "bestFor": "Visionary leadership, brand positioning, mission statements", "canonId": "019dd956-6a50-7202-882d-505fcb9922ed", "version": 1, "bodyDocId": "019df22a-2420-77be-bc41-ded96d08cb21", "structure": "The Why (Belief) -> The How (Process) -> The What (Result)", "description": "Invert the typical pitch by starting with why you exist, rather than what you do", "familyLabel": null }, "matchId": "720e63ac-a674-4bf4-8e46-acf9a0a900ae", "evidence": "The presentation follows the Golden Circle framework, starting with why atai Life Sciences is working on mental health disorders (p3) and presenting their solution and traction.", "position": 1, "objective": "Why is atai Life Sciences' solution important?", "confidence": 0.7, "extraction": { "at": "2026-07-16 22:29:50.666122+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": "doc-narrative-v1" } } ], "locked": true }, { "page": 5, "type": "resolution", "title": "The slide uses a Gantt-style visualization to represent drug development stages.", "function": "plan_implementation", "rawType": "roadmap", "block": null, "metadata": { "slideType": "roadmap", "slideTypeCanon": { "name": "Roadmap", "slug": "roadmap", "status": "active", "canonId": "019de52d-0a55-72bc-9b7b-a47ef109839c", "version": 1, "description": null }, "function": "plan_implementation", "functionCanon": { "name": "Plan implementation", "slug": "plan_implementation", "status": "active", "canonId": "019de52d-14a2-77ea-b210-d6a95eed4823", "version": 1, "description": null }, "density": "balanced", "densityScore": 38, "componentCount": 4, "textChars": 377, "nDataPoints": 0, "notes": "The slide uses a Gantt-style visualization to represent drug development stages.", "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 12:10:48.453+00", "seconds": 2.58, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de074-4969-72b8-bf99-262b9202adeb/5", "deck": "/decks/019de074-4969-72b8-bf99-262b9202adeb", "deckAnchor": "/decks/019de074-4969-72b8-bf99-262b9202adeb#slide-5", "deckJson": "/decks/019de074-4969-72b8-bf99-262b9202adeb.json" }, "components": [ { "bbox": { "h": 0.5, "w": 0.3, "x": 0.42, "y": 0.3 }, "kind": "chart", "text": "Horizontal bars representing clinical trial progress", "attrs": null, "canon": { "kind": { "name": "Chart", "slug": "chart", "status": "active", "canonId": "019de52c-f9a0-76ef-adc6-0b859109d1f8", "version": 1, "description": "Quantitative chart." }, "tool": null, "subkind": { "name": "Horizontal bar chart", "slug": "bar-horizontal", "status": "active", "canonId": "019de52c-fec4-7221-986b-1cb5f5e84b1f", "version": 1, "description": null }, "framework": null }, "subkind": "bar-horizontal", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:10:48.453+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "e3bf3c80-57e9-428d-b235-ceff832a9a3a", "parentComponentId": null }, { "bbox": { "h": 0.1, "w": 0.9, "x": 0.05, "y": 0.88 }, "kind": "source-note", "text": "Note: Information as of November, 2022... Chart updated as of 1/6/2023", "attrs": null, "canon": { "kind": { "name": "Source note", "slug": "source-note", "status": "active", "canonId": "23484952-494b-4a5e-b1ad-550d0d70e948", "version": 1, "description": "Attribution / source / caveat placed at the slide footer. Numbered footnotes use attrs.numbered." }, "tool": null, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:10:48.453+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "70cac3f8-45f0-48e6-9e56-8cb0b540de12", "parentComponentId": null }, { "bbox": { "h": 0.6, "w": 0.9, "x": 0.05, "y": 0.25 }, "kind": "table", "text": "Pipeline table with columns: Program, Indication, Preclinical, Phase 1, Phase 2, Phase 3, Affiliate Company", "attrs": null, "canon": { "kind": { "name": "Table", "slug": "table", "status": "active", "canonId": "019de52c-f9c8-7148-8119-eaac9594cd28", "version": 1, "description": "Tabular data layout." }, "tool": null, "subkind": { "name": "Data table", "slug": "data", "status": "active", "canonId": "019de52d-02d5-75b8-8abf-88e92bf63569", "version": 1, "description": null }, "framework": null }, "subkind": "data", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:10:48.453+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "dac69245-97f9-488f-8fb0-3436beb349fa", "parentComponentId": null }, { "bbox": { "h": 0.1, "w": 0.9, "x": 0.05, "y": 0.08 }, "kind": "title", "text": "Our strategy will be delivered through a robust pipeline of drug development programs across several mental health indications with large unmet need", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:10:48.453+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "3d669d10-64d1-4246-8288-160c039357c9", "parentComponentId": null } ], "metrics": [], "tools": [], "frameworks": [ { "matchId": "e885773d-eacf-4f57-8c2f-843dbc5939e6", "evidence": "Horizontal bars representing progress over clinical phases", "framework": null, "confidence": 0.9, "extraction": { "at": "2026-05-02 12:10:48.453+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 5, "frameworkName": "gantt-chart" } ], "arcBeats": [ { "to": 7, "arc": { "name": "The Sequoia Pitch", "slug": "sequoia-pitch", "status": "active", "bestFor": "Investor pitches, Series A/B, board presentations", "canonId": "019dd956-5e69-75a7-a0a4-895ac1bc0444", "version": 1, "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49", "structure": "Problem -> Solution -> Why Now -> Market Size -> Competition -> Product -> Business Model -> Team -> Financials -> The Ask", "description": null, "familyLabel": null }, "from": 4, "name": "Solution", "beatId": "1742a8b1-89e9-49d8-82eb-87df36f14e25", "matchId": "c1142f11-4f33-424c-b75a-7c146ec1d878", "beatType": { "name": "Solution", "slug": "sequoia-pitch-solution", "status": "active", "canonId": "019dd9b8-1fb1-71d9-a260-07738d7f9c2f", "version": 1, "description": null }, "evidence": "The presentation presents atai Life Sciences' solution, including their strategy for delivering sustained behavioral change in patients (p4) and their robust pipeline of drug development programs (p5-6).", "position": 1, "isPrimaryArc": true, "parentBeatType": { "name": "Turn", "slug": "turn", "status": "active", "canonId": "019dd9b8-0396-702b-ac2f-9901f8dd8b54", "version": 1, "description": "The pivot — solution proposed, catalyst introduced, decision made. Common (15/20 arcs) but not universal: Triple-take, AIDA, PAS, Voyage-return and Pixar substitute it with a strong reflection or development beat." }, "alignedBlockIds": null, "matchConfidence": 0.8 }, { "to": 6, "arc": { "name": "The Sequoia Pitch", "slug": "sequoia-pitch", "status": "active", "bestFor": "Investor pitches, Series A/B, board presentations", "canonId": "019dd956-5e69-75a7-a0a4-895ac1bc0444", "version": 1, "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49", "structure": "Problem -> Solution -> Why Now -> Market Size -> Competition -> Product -> Business Model -> Team -> Financials -> The Ask", "description": null, "familyLabel": null }, "from": 5, "name": "Roadmap", "beatId": "844786c1-be36-4c8e-94b5-66319c33dac5", "matchId": "c1142f11-4f33-424c-b75a-7c146ec1d878", "beatType": null, "evidence": "The presentation outlines atai Life Sciences' roadmap, including expected R&D milestones across key programs through 2024 (p6).", "position": 3, "isPrimaryArc": true, "parentBeatType": null, "alignedBlockIds": null, "matchConfidence": 0.8 } ], "loops": [ { "to": 33, "from": 3, "loop": { "name": "11_golden_circle", "slug": "11-golden-circle", "status": "active", "bestFor": "Visionary leadership, brand positioning, mission statements", "canonId": "019dd956-6a50-7202-882d-505fcb9922ed", "version": 1, "bodyDocId": "019df22a-2420-77be-bc41-ded96d08cb21", "structure": "The Why (Belief) -> The How (Process) -> The What (Result)", "description": "Invert the typical pitch by starting with why you exist, rather than what you do", "familyLabel": null }, "matchId": "720e63ac-a674-4bf4-8e46-acf9a0a900ae", "evidence": "The presentation follows the Golden Circle framework, starting with why atai Life Sciences is working on mental health disorders (p3) and presenting their solution and traction.", "position": 1, "objective": "Why is atai Life Sciences' solution important?", "confidence": 0.7, "extraction": { "at": "2026-07-16 22:29:50.666122+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": "doc-narrative-v1" } } ], "locked": true }, { "page": 6, "type": "resolution", "title": "The slide combines a historical achievement list with a forward-looking roadmap and financial runway statement.", "function": "plan_implementation", "rawType": "roadmap", "block": null, "metadata": { "slideType": "roadmap", "slideTypeCanon": { "name": "Roadmap", "slug": "roadmap", "status": "active", "canonId": "019de52d-0a55-72bc-9b7b-a47ef109839c", "version": 1, "description": null }, "function": "plan_implementation", "functionCanon": { "name": "Plan implementation", "slug": "plan_implementation", "status": "active", "canonId": "019de52d-14a2-77ea-b210-d6a95eed4823", "version": 1, "description": null }, "density": "dense", "densityScore": 64, "componentCount": 5, "textChars": 739, "nDataPoints": 2, "notes": "The slide combines a historical achievement list with a forward-looking roadmap and financial runway statement.", "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 12:10:48.992+00", "seconds": 3.097, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de074-4969-72b8-bf99-262b9202adeb/6", "deck": "/decks/019de074-4969-72b8-bf99-262b9202adeb", "deckAnchor": "/decks/019de074-4969-72b8-bf99-262b9202adeb#slide-6", "deckJson": "/decks/019de074-4969-72b8-bf99-262b9202adeb.json" }, "components": [ { "bbox": { "h": 0.08, "w": 0.9, "x": 0.05, "y": 0.78 }, "kind": "callout", "text": "$304M in cash as of September 30, 2022, plus access to up to an additional $160M from Hercules term loan facility, provides runway expected into 2025", "attrs": null, "canon": { "kind": { "name": "Callout", "slug": "callout", "status": "active", "canonId": "019de52c-f8d3-761a-8953-7d37080de5e2", "version": 1, "description": "Highlighted callout box." }, "tool": null, "subkind": { "name": "Primary callout", "slug": "primary", "status": "active", "canonId": "019de52c-fbd1-70eb-a9ce-8997f8674c1d", "version": 1, "description": null }, "framework": null }, "subkind": "primary", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:10:48.992+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "c4d10c7f-6500-4718-b838-d5cf2b5ade97", "parentComponentId": null }, { "bbox": { "h": 0.5, "w": 0.9, "x": 0.05, "y": 0.26 }, "kind": "diagram", "text": "Achieved and expected milestones", "attrs": null, "canon": { "kind": { "name": "Diagram", "slug": "diagram", "status": "active", "canonId": "019de52c-f9f0-734a-81de-15382ff28c65", "version": 1, "description": "Schematic or relational diagram." }, "tool": null, "subkind": { "name": "Timeline", "slug": "timeline", "status": "active", "canonId": "019de52d-03c5-73fc-84aa-4180cbf0f5cf", "version": 1, "description": null }, "framework": null }, "subkind": "timeline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:10:48.992+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "91d42d9b-693d-42f0-95dd-332738adda78", "parentComponentId": null }, { "bbox": { "h": 0.05, "w": 0.4, "x": 0.05, "y": 0.91 }, "kind": "disclaimer", "text": "Note: PoC = Proof of Concept. 1. Based on current expectations and projections as of the date of this presentation, and subject to change. 2. Total facility size is up to $175M, with $15M drawn to-date (in Q3 2022). Unless otherwise stated, this presentation is updated as of January 6th, 2023", "attrs": null, "canon": { "kind": { "name": "Disclaimer", "slug": "disclaimer", "status": "active", "canonId": "91173477-d91f-4024-bbaf-d4f93e3f82dc", "version": 1, "description": "Legal/cautionary text that occupies most of the body of its slide." }, "tool": null, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:10:48.992+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "05723bf7-14ec-496c-8e01-c7c2ae518427", "parentComponentId": null }, { "bbox": { "h": 0.4, "w": 0.23, "x": 0.06, "y": 0.33 }, "kind": "list", "text": "Key achievements to date: Initiation of 8 clinical programs, COMP360 Phase 2b results, RL-007 Phase 2a results, GRX-917 Phase 1 results", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:10:48.992+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "3465ab2e-248e-4069-b49a-bf163c5ab92e", "parentComponentId": null }, { "bbox": { "h": 0.15, "w": 0.9, "x": 0.05, "y": 0.08 }, "kind": "title", "text": "We expect to deliver several meaningful R&D milestones anticipated across our key programs through 2024 with cash runway into 2025", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:10:48.992+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "9571d058-974a-4baf-9751-072b02dc4ead", "parentComponentId": null } ], "metrics": [], "tools": [], "frameworks": [ { "matchId": "bdb8be03-03de-4fe9-97de-b87fbbafbad9", "evidence": "The slide uses a horizontal arrow-based timeline to map R&D milestones across H1'23, H2'23, and 2024.", "framework": null, "confidence": 1, "extraction": { "at": "2026-05-02 12:10:48.992+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 6, "frameworkName": "timeline" } ], "arcBeats": [ { "to": 7, "arc": { "name": "The Sequoia Pitch", "slug": "sequoia-pitch", "status": "active", "bestFor": "Investor pitches, Series A/B, board presentations", "canonId": "019dd956-5e69-75a7-a0a4-895ac1bc0444", "version": 1, "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49", "structure": "Problem -> Solution -> Why Now -> Market Size -> Competition -> Product -> Business Model -> Team -> Financials -> The Ask", "description": null, "familyLabel": null }, "from": 4, "name": "Solution", "beatId": "1742a8b1-89e9-49d8-82eb-87df36f14e25", "matchId": "c1142f11-4f33-424c-b75a-7c146ec1d878", "beatType": { "name": "Solution", "slug": "sequoia-pitch-solution", "status": "active", "canonId": "019dd9b8-1fb1-71d9-a260-07738d7f9c2f", "version": 1, "description": null }, "evidence": "The presentation presents atai Life Sciences' solution, including their strategy for delivering sustained behavioral change in patients (p4) and their robust pipeline of drug development programs (p5-6).", "position": 1, "isPrimaryArc": true, "parentBeatType": { "name": "Turn", "slug": "turn", "status": "active", "canonId": "019dd9b8-0396-702b-ac2f-9901f8dd8b54", "version": 1, "description": "The pivot — solution proposed, catalyst introduced, decision made. Common (15/20 arcs) but not universal: Triple-take, AIDA, PAS, Voyage-return and Pixar substitute it with a strong reflection or development beat." }, "alignedBlockIds": null, "matchConfidence": 0.8 }, { "to": 6, "arc": { "name": "The Sequoia Pitch", "slug": "sequoia-pitch", "status": "active", "bestFor": "Investor pitches, Series A/B, board presentations", "canonId": "019dd956-5e69-75a7-a0a4-895ac1bc0444", "version": 1, "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49", "structure": "Problem -> Solution -> Why Now -> Market Size -> Competition -> Product -> Business Model -> Team -> Financials -> The Ask", "description": null, "familyLabel": null }, "from": 5, "name": "Roadmap", "beatId": "844786c1-be36-4c8e-94b5-66319c33dac5", "matchId": "c1142f11-4f33-424c-b75a-7c146ec1d878", "beatType": null, "evidence": "The presentation outlines atai Life Sciences' roadmap, including expected R&D milestones across key programs through 2024 (p6).", "position": 3, "isPrimaryArc": true, "parentBeatType": null, "alignedBlockIds": null, "matchConfidence": 0.8 } ], "loops": [ { "to": 33, "from": 3, "loop": { "name": "11_golden_circle", "slug": "11-golden-circle", "status": "active", "bestFor": "Visionary leadership, brand positioning, mission statements", "canonId": "019dd956-6a50-7202-882d-505fcb9922ed", "version": 1, "bodyDocId": "019df22a-2420-77be-bc41-ded96d08cb21", "structure": "The Why (Belief) -> The How (Process) -> The What (Result)", "description": "Invert the typical pitch by starting with why you exist, rather than what you do", "familyLabel": null }, "matchId": "720e63ac-a674-4bf4-8e46-acf9a0a900ae", "evidence": "The presentation follows the Golden Circle framework, starting with why atai Life Sciences is working on mental health disorders (p3) and presenting their solution and traction.", "position": 1, "objective": "Why is atai Life Sciences' solution important?", "confidence": 0.7, "extraction": { "at": "2026-07-16 22:29:50.666122+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": "doc-narrative-v1" } } ], "locked": true }, { "page": 7, "type": "setup", "function": "transition", "rawType": "section_divider", "block": null, "metadata": { "slideType": "section_divider", "slideTypeCanon": { "name": "Section divider", "slug": "section_divider", "status": "active", "canonId": "019de52d-066a-7402-9554-6ae504999041", "version": 1, "description": null }, "function": "transition", "functionCanon": { "name": "Transition", "slug": "transition", "status": "active", "canonId": "019de52d-1365-7149-92aa-66df859e75fd", "version": 1, "description": null }, "density": "sparse", "densityScore": 5, "componentCount": 2, "textChars": 50, "nDataPoints": 0, "notes": null, "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 12:10:47.889+00", "seconds": 1.982, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de074-4969-72b8-bf99-262b9202adeb/7", "deck": "/decks/019de074-4969-72b8-bf99-262b9202adeb", "deckAnchor": "/decks/019de074-4969-72b8-bf99-262b9202adeb#slide-7", "deckJson": "/decks/019de074-4969-72b8-bf99-262b9202adeb.json" }, "components": [ { "bbox": { "h": 0.87, "w": 0.4, "x": 0.56, "y": 0.065 }, "kind": "image", "text": null, "attrs": null, "canon": { "kind": { "name": "Image", "slug": "image", "status": "active", "canonId": "019de52c-f978-701f-a720-51d029d769e7", "version": 1, "description": "Photo, illustration, screenshot or icon." }, "tool": null, "subkind": { "name": "Photo", "slug": "photo", "status": "active", "canonId": "019de52c-fd37-757f-b4a8-ca26d4888875", "version": 1, "description": null }, "framework": null }, "subkind": "photo", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:10:47.889+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "01ab819e-6f14-43be-af4d-cfd11c191eee", "parentComponentId": null }, { "bbox": { "h": 0.32, "w": 0.35, "x": 0.05, "y": 0.34 }, "kind": "title", "text": "Cognitive Impairment Associated with Schizophrenia", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:10:47.889+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "d07b3e71-38f1-4eec-9780-bfd6f6c5a991", "parentComponentId": null } ], "metrics": [], "tools": [ { "tool": { "name": "Section divider", "slug": "section-divider", "status": "active", "bestFor": null, "canonId": "019dd9e1-4c66-707d-8d1f-6e14547134c7", "version": 1, "bodyDocId": null, "description": "A transitional slide marking the start of a new section.", "familyLabel": null, "categoryName": null, "categorySlug": null }, "agent": null, "layer": "slide", "agents": null, "matchId": "78234c4e-1024-4dec-8433-79a771d2006e", "evidence": "This slide serves as a clear divider between sections, with a concise title.", "pageRefs": null, "priority": null, "whenToUse": null, "confidence": 0.9, "extraction": { "at": "2026-07-17 00:18:27.657257+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 7, "whyItWorks": null, "antipattern": null, "cardinality": "common", "narrativePurpose": null } ], "frameworks": [], "arcBeats": [ { "to": 7, "arc": { "name": "The Sequoia Pitch", "slug": "sequoia-pitch", "status": "active", "bestFor": "Investor pitches, Series A/B, board presentations", "canonId": "019dd956-5e69-75a7-a0a4-895ac1bc0444", "version": 1, "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49", "structure": "Problem -> Solution -> Why Now -> Market Size -> Competition -> Product -> Business Model -> Team -> Financials -> The Ask", "description": null, "familyLabel": null }, "from": 4, "name": "Solution", "beatId": "1742a8b1-89e9-49d8-82eb-87df36f14e25", "matchId": "c1142f11-4f33-424c-b75a-7c146ec1d878", "beatType": { "name": "Solution", "slug": "sequoia-pitch-solution", "status": "active", "canonId": "019dd9b8-1fb1-71d9-a260-07738d7f9c2f", "version": 1, "description": null }, "evidence": "The presentation presents atai Life Sciences' solution, including their strategy for delivering sustained behavioral change in patients (p4) and their robust pipeline of drug development programs (p5-6).", "position": 1, "isPrimaryArc": true, "parentBeatType": { "name": "Turn", "slug": "turn", "status": "active", "canonId": "019dd9b8-0396-702b-ac2f-9901f8dd8b54", "version": 1, "description": "The pivot — solution proposed, catalyst introduced, decision made. Common (15/20 arcs) but not universal: Triple-take, AIDA, PAS, Voyage-return and Pixar substitute it with a strong reflection or development beat." }, "alignedBlockIds": null, "matchConfidence": 0.8 } ], "loops": [ { "to": 33, "from": 3, "loop": { "name": "11_golden_circle", "slug": "11-golden-circle", "status": "active", "bestFor": "Visionary leadership, brand positioning, mission statements", "canonId": "019dd956-6a50-7202-882d-505fcb9922ed", "version": 1, "bodyDocId": "019df22a-2420-77be-bc41-ded96d08cb21", "structure": "The Why (Belief) -> The How (Process) -> The What (Result)", "description": "Invert the typical pitch by starting with why you exist, rather than what you do", "familyLabel": null }, "matchId": "720e63ac-a674-4bf4-8e46-acf9a0a900ae", "evidence": "The presentation follows the Golden Circle framework, starting with why atai Life Sciences is working on mental health disorders (p3) and presenting their solution and traction.", "position": 1, "objective": "Why is atai Life Sciences' solution important?", "confidence": 0.7, "extraction": { "at": "2026-07-16 22:29:50.666122+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": "doc-narrative-v1" } } ], "locked": true }, { "page": 8, "type": "tension", "title": "Uses a timeline-style visual to represent the 'need' metrics.", "function": "frame_problem", "rawType": "problem_statement", "block": null, "metadata": { "slideType": "problem_statement", "slideTypeCanon": { "name": "Problem statement", "slug": "problem_statement", "status": "active", "canonId": "019de52d-0879-768d-bba8-8da8a5a121d4", "version": 1, "description": null }, "function": "frame_problem", "functionCanon": { "name": "Frame problem", "slug": "frame_problem", "status": "active", "canonId": "019de52d-13db-753e-ad70-e9b2d0dab398", "version": 1, "description": null }, "density": "dense", "densityScore": 74, "componentCount": 8, "textChars": 412, "nDataPoints": 7, "notes": "Uses a timeline-style visual to represent the 'need' metrics.", "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 12:10:52.665+00", "seconds": 6.739, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de074-4969-72b8-bf99-262b9202adeb/8", "deck": "/decks/019de074-4969-72b8-bf99-262b9202adeb", "deckAnchor": "/decks/019de074-4969-72b8-bf99-262b9202adeb#slide-8", "deckJson": "/decks/019de074-4969-72b8-bf99-262b9202adeb.json" }, "components": [ { "bbox": { "h": 0.25, "w": 0.25, "x": 0.04, "y": 0.6 }, "kind": "chart", "text": "Global map of Schizophrenia prevalence", "attrs": null, "canon": { "kind": { "name": "Chart", "slug": "chart", "status": "active", "canonId": "019de52c-f9a0-76ef-adc6-0b859109d1f8", "version": 1, "description": "Quantitative chart." }, "tool": null, "subkind": null, "framework": null }, "subkind": "map", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:10:52.665+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "9075329b-9915-4676-88e5-58fe81469436", "parentComponentId": null }, { "bbox": { "h": 0.8, "w": 0.5, "x": 0.46, "y": 0.1 }, "kind": "diagram", "text": "Huge need for development metrics", "attrs": null, "canon": { "kind": { "name": "Diagram", "slug": "diagram", "status": "active", "canonId": "019de52c-f9f0-734a-81de-15382ff28c65", "version": 1, "description": "Schematic or relational diagram." }, "tool": null, "subkind": { "name": "Timeline", "slug": "timeline", "status": "active", "canonId": "019de52d-03c5-73fc-84aa-4180cbf0f5cf", "version": 1, "description": null }, "framework": null }, "subkind": "timeline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:10:52.665+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "d3335a43-b4d1-47b1-aa43-b0b475a94913", "parentComponentId": null }, { "bbox": { "h": 0.1, "w": 0.15, "x": 0.3, "y": 0.5 }, "kind": "metric", "text": "~24m Global sufferers of Schizophrenia", "attrs": null, "canon": { "kind": { "name": "Metric", "slug": "metric", "status": "active", "canonId": "019de52c-f923-73bf-8081-d0b1a8c5264d", "version": 1, "description": "Big-number or KPI value." }, "tool": null, "subkind": { "name": "Big number", "slug": "big-number", "status": "active", "canonId": "019de52c-fc70-70c8-b965-0584548a9204", "version": 1, "description": null }, "framework": null }, "subkind": "big-number", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:10:52.665+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "4f7c5e10-9c98-4cfa-8cf1-f1e067845a18", "parentComponentId": null }, { "bbox": { "h": 0.1, "w": 0.15, "x": 0.3, "y": 0.8 }, "kind": "metric", "text": "~$155bn U.S. economic burden", "attrs": null, "canon": { "kind": { "name": "Metric", "slug": "metric", "status": "active", "canonId": "019de52c-f923-73bf-8081-d0b1a8c5264d", "version": 1, "description": "Big-number or KPI value." }, "tool": null, "subkind": { "name": "Big number", "slug": "big-number", "status": "active", "canonId": "019de52c-fc70-70c8-b965-0584548a9204", "version": 1, "description": null }, "framework": null }, "subkind": "big-number", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:10:52.665+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "5be2e1bf-0928-469e-a03b-8f56eeb2e20b", "parentComponentId": null }, { "bbox": { "h": 0.1, "w": 0.15, "x": 0.3, "y": 0.65 }, "kind": "metric", "text": "15th Leading cause of disability worldwide", "attrs": null, "canon": { "kind": { "name": "Metric", "slug": "metric", "status": "active", "canonId": "019de52c-f923-73bf-8081-d0b1a8c5264d", "version": 1, "description": "Big-number or KPI value." }, "tool": null, "subkind": { "name": "Big number", "slug": "big-number", "status": "active", "canonId": "019de52c-fc70-70c8-b965-0584548a9204", "version": 1, "description": null }, "framework": null }, "subkind": "big-number", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:10:52.665+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "c24ccf9f-50ae-4e36-b474-ed8f539180fe", "parentComponentId": null }, { "bbox": { "h": 0.08, "w": 0.4, "x": 0.04, "y": 0.21 }, "kind": "paragraph", "text": "Cognitive impairment associated with Schizophrenia (CIAS) & Schizophrenia often lead to individuals making choices they feel are out of their control", "attrs": null, "canon": { "kind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "5f2affc0-941d-4d07-959d-4bfc1930cea4", "version": 1, "description": "Single prose block in the body of a slide." }, "tool": null, "subkind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "019de52c-fb80-75af-aa5c-a7a4bfac2433", "version": 1, "description": null }, "framework": null }, "subkind": "paragraph", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:10:52.665+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "e7724a80-e82f-4769-86ca-8a1dcb4876b0", "parentComponentId": null }, { "bbox": { "h": 0.05, "w": 0.9, "x": 0.04, "y": 0.92 }, "kind": "source-note", "text": "1. World Health Organization... 7. GlobalData (as of 11/15/2022)", "attrs": null, "canon": { "kind": { "name": "Source note", "slug": "source-note", "status": "active", "canonId": "23484952-494b-4a5e-b1ad-550d0d70e948", "version": 1, "description": "Attribution / source / caveat placed at the slide footer. Numbered footnotes use attrs.numbered." }, "tool": null, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:10:52.665+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "4364f8bb-05b8-4737-b101-756b0d4596e4", "parentComponentId": null }, { "bbox": { "h": 0.05, "w": 0.3, "x": 0.04, "y": 0.08 }, "kind": "title", "text": "CIAS & Schizophrenia", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:10:52.665+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "5c0cf559-ed7d-4859-b8c9-0eeff0711d90", "parentComponentId": null } ], "metrics": [], "tools": [], "frameworks": [ { "matchId": "4195dfe5-4761-4cc7-987b-247002173d68", "evidence": "Slide frames the disease burden and lack of treatment as a market opportunity.", "framework": null, "confidence": 0.9, "extraction": { "at": "2026-05-02 12:10:52.665+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 8, "frameworkName": "problem-statement" } ], "arcBeats": [ { "to": 9, "arc": { "name": "The Sequoia Pitch", "slug": "sequoia-pitch", "status": "active", "bestFor": "Investor pitches, Series A/B, board presentations", "canonId": "019dd956-5e69-75a7-a0a4-895ac1bc0444", "version": 1, "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49", "structure": "Problem -> Solution -> Why Now -> Market Size -> Competition -> Product -> Business Model -> Team -> Financials -> The Ask", "description": null, "familyLabel": null }, "from": 8, "name": "Problem", "beatId": "707b84bb-d006-4ebc-b566-ffd6845e4351", "matchId": "c1142f11-4f33-424c-b75a-7c146ec1d878", "beatType": { "name": "Problem", "slug": "sequoia-pitch-problem", "status": "active", "canonId": "019dd9b8-1ed4-767b-8e05-40e733bd2311", "version": 1, "description": null }, "evidence": "The presentation identifies a huge need for development in CIAS and Schizophrenia treatment (p8) and an urgent need for innovation in depression treatment (p15).", "position": 0, "isPrimaryArc": true, "parentBeatType": { "name": "Complication", "slug": "complication", "status": "active", "canonId": "019dd9b8-0275-7709-b2d6-4f77c3fc7579", "version": 1, "description": "The point in the narrative where the audience should feel discomfort. Required for argumentative arcs." }, "alignedBlockIds": null, "matchConfidence": 0.8 } ], "loops": [ { "to": 9, "from": 8, "loop": { "name": "27_cost_of_inaction", "slug": "27-cost-of-inaction", "status": "active", "bestFor": "Urgent budget requests, compliance, risk mitigation", "canonId": "019dd956-70d1-7395-a15b-857ba858b394", "version": 1, "bodyDocId": "019df22a-2420-77be-bc41-ded96d08cb21", "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point", "description": "Quantify what happens if the audience does nothing", "familyLabel": null }, "matchId": "7aa520a4-e861-4ddd-adb0-33d2e2059fa2", "evidence": "The presentation highlights the huge need for development in CIAS and Schizophrenia treatment (p8) and the urgent need for innovation in depression treatment (p15).", "position": 0, "objective": "What are the consequences of not addressing mental health disorders?", "confidence": 0.7, "extraction": { "at": "2026-07-16 22:29:50.624947+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": "doc-narrative-v1" } }, { "to": 33, "from": 3, "loop": { "name": "11_golden_circle", "slug": "11-golden-circle", "status": "active", "bestFor": "Visionary leadership, brand positioning, mission statements", "canonId": "019dd956-6a50-7202-882d-505fcb9922ed", "version": 1, "bodyDocId": "019df22a-2420-77be-bc41-ded96d08cb21", "structure": "The Why (Belief) -> The How (Process) -> The What (Result)", "description": "Invert the typical pitch by starting with why you exist, rather than what you do", "familyLabel": null }, "matchId": "720e63ac-a674-4bf4-8e46-acf9a0a900ae", "evidence": "The presentation follows the Golden Circle framework, starting with why atai Life Sciences is working on mental health disorders (p3) and presenting their solution and traction.", "position": 1, "objective": "Why is atai Life Sciences' solution important?", "confidence": 0.7, "extraction": { "at": "2026-07-16 22:29:50.666122+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": "doc-narrative-v1" } } ], "locked": true }, { "page": 9, "type": "setup", "title": "The slide uses a bar chart to show dose-dependent efficacy across three cognitive tests (HVLT, Symbol Coding, Category Fluency).", "function": "summarize", "rawType": "executive_summary", "block": null, "metadata": { "slideType": "executive_summary", "slideTypeCanon": { "name": "Executive summary", "slug": "executive_summary", "status": "active", "canonId": "019de52d-06be-73ff-81b3-f99fe7f0025e", "version": 1, "description": null }, "function": "summarize", "functionCanon": { "name": "Summarize", "slug": "summarize", "status": "active", "canonId": "019de52d-1541-704f-b86f-bf7b75056373", "version": 1, "description": null }, "density": "overcrowded", "densityScore": 87, "componentCount": 8, "textChars": 946, "nDataPoints": 12, "notes": "The slide uses a bar chart to show dose-dependent efficacy across three cognitive tests (HVLT, Symbol Coding, Category Fluency).", "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 12:10:50.657+00", "seconds": 4.519, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de074-4969-72b8-bf99-262b9202adeb/9", "deck": "/decks/019de074-4969-72b8-bf99-262b9202adeb", "deckAnchor": "/decks/019de074-4969-72b8-bf99-262b9202adeb#slide-9", "deckJson": "/decks/019de074-4969-72b8-bf99-262b9202adeb.json" }, "components": [ { "bbox": { "h": 0.08, "w": 0.25, "x": 0.62, "y": 0.38 }, "kind": "callout", "text": "Dose dependent, widespread qEEG changes observed across brain regions", "attrs": null, "canon": { "kind": { "name": "Callout", "slug": "callout", "status": "active", "canonId": "019de52c-f8d3-761a-8953-7d37080de5e2", "version": 1, "description": "Highlighted callout box." }, "tool": null, "subkind": { "name": "Primary callout", "slug": "primary", "status": "active", "canonId": "019de52c-fbd1-70eb-a9ce-8997f8674c1d", "version": 1, "description": null }, "framework": null }, "subkind": "primary", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:10:50.657+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "54f765bf-6bb3-43ca-b573-2f3b5d25213c", "parentComponentId": null }, { "bbox": { "h": 0.55, "w": 0.58, "x": 0.37, "y": 0.35 }, "kind": "chart", "text": "Phase 2 PoM Trial Efficacy Data showing T-Scores for HVLT, Symbol Coding, and Category Fluency across 10mg, 20mg, 40mg, and 80mg doses.", "attrs": null, "canon": { "kind": { "name": "Chart", "slug": "chart", "status": "active", "canonId": "019de52c-f9a0-76ef-adc6-0b859109d1f8", "version": 1, "description": "Quantitative chart." }, "tool": null, "subkind": { "name": "Grouped bar chart", "slug": "bar-grouped", "status": "active", "canonId": "019de52c-ff3b-751e-a8ff-f21ff11097b1", "version": 1, "description": null }, "framework": null }, "subkind": "bar-grouped", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:10:50.657+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "026479dc-d508-4edb-b24a-23d5fa2b280b", "parentComponentId": null }, { "bbox": { "h": 0.05, "w": 0.58, "x": 0.37, "y": 0.92 }, "kind": "disclaimer", "text": "Note: CIAS = Cognitive impairment associated with schizophrenia; HVLT = Hopkins Verbal Learning Test; TID = 3x/day dosing; PoC = Proof of Concept, PoM = Proof of Mechanism. Unless otherwise indicated herein, ownership percentage based on ownership of securities with voting rights as of September 30th, 2022.", "attrs": null, "canon": { "kind": { "name": "Disclaimer", "slug": "disclaimer", "status": "active", "canonId": "91173477-d91f-4024-bbaf-d4f93e3f82dc", "version": 1, "description": "Legal/cautionary text that occupies most of the body of its slide." }, "tool": null, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:10:50.657+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "0fd3e7ca-b652-4f3a-ab0d-d0679214ad4e", "parentComponentId": null }, { "bbox": { "h": 0.05, "w": 0.58, "x": 0.37, "y": 0.18 }, "kind": "quote", "text": "Symbol coding response is at a level that would correlate with better work/school performance", "attrs": null, "canon": { "kind": { "name": "Quote", "slug": "quote", "status": "active", "canonId": "019de52c-f8fb-751e-8bc6-d58e2d59562a", "version": 1, "description": "Pull quote or testimonial." }, "tool": null, "subkind": { "name": "Pull quote", "slug": "pull-quote", "status": "active", "canonId": "019de52c-fbf9-76fe-97e1-a0b7540445c9", "version": 1, "description": null }, "framework": null }, "subkind": "pull-quote", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:10:50.657+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "b34d6902-c4c6-4bd8-8deb-914c3213cbdd", "parentComponentId": null }, { "bbox": { "h": 0.15, "w": 0.08, "x": 0.87, "y": 0.57 }, "kind": "source-note", "text": "Cohen's d* (Symbol Coding): 20 mg: 0.79, 40 mg: 0.56, 80 mg: 0.38", "attrs": null, "canon": { "kind": { "name": "Source note", "slug": "source-note", "status": "active", "canonId": "23484952-494b-4a5e-b1ad-550d0d70e948", "version": 1, "description": "Attribution / source / caveat placed at the slide footer. Numbered footnotes use attrs.numbered." }, "tool": null, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:10:50.657+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "e5b3fb34-f61c-4bf9-aa2b-107577630cd2", "parentComponentId": null }, { "bbox": { "h": 0.75, "w": 0.32, "x": 0.03, "y": 0.16 }, "kind": "table", "text": "Ownership: 51.9% | Product: RL-007 | Pharmacology: GABA/nicotinic modulator | Features: Pro-cognitive effects | Indications: CIAS | Status: Phase 2a/2b | IP: Patents | Highlight: Phase 2 results", "attrs": null, "canon": { "kind": { "name": "Table", "slug": "table", "status": "active", "canonId": "019de52c-f9c8-7148-8119-eaac9594cd28", "version": 1, "description": "Tabular data layout." }, "tool": null, "subkind": { "name": "Data table", "slug": "data", "status": "active", "canonId": "019de52d-02d5-75b8-8abf-88e92bf63569", "version": 1, "description": null }, "framework": null }, "subkind": "data", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:10:50.657+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "ffd9520d-a134-4f39-a03b-e0abcbc1edc3", "parentComponentId": null }, { "bbox": { "h": 0.08, "w": 0.58, "x": 0.37, "y": 0.07 }, "kind": "title", "text": "RL-007 has previously shown pro-cognitive effects in human clinical studies", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Action title", "slug": "action-title", "status": "active", "canonId": "019de52c-fb31-734c-a0f5-a3935b73135d", "version": 1, "description": null }, "framework": null }, "subkind": "action-title", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:10:50.657+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "4c7f46f6-72d7-4d92-b52d-fe8e3793fd74", "parentComponentId": null }, { "bbox": { "h": 0.03, "w": 0.13, "x": 0.03, "y": 0.08 }, "kind": "title", "text": "SUMMARY", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:10:50.657+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "98c26bf0-90f3-46bb-b0fb-81a70cb6d49b", "parentComponentId": null } ], "metrics": [], "tools": [ { "tool": { "name": "Executive summary", "slug": "executive-summary", "status": "active", "bestFor": null, "canonId": "019dd9e1-4b63-72d5-9734-da757d91ca61", "version": 1, "bodyDocId": null, "description": "A condensed view of the entire argument on a single slide / block.", "familyLabel": null, "categoryName": null, "categorySlug": null }, "agent": null, "layer": "slide", "agents": null, "matchId": "02334c08-2546-46ea-a541-f46be248cf06", "evidence": "This slide presents a concise summary of RL-007's pro-cognitive effects in human clinical studies.", "pageRefs": null, "priority": null, "whenToUse": null, "confidence": 0.9, "extraction": { "at": "2026-07-17 00:18:27.769534+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 9, "whyItWorks": null, "antipattern": null, "cardinality": "common", "narrativePurpose": null } ], "frameworks": [ { "matchId": "1c2bcbb0-1a5b-42d4-b120-9d2db911b3fd", "evidence": "Structured summary of product, status, and data", "framework": null, "confidence": 1, "extraction": { "at": "2026-05-02 12:10:50.657+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 9, "frameworkName": "executive-summary" } ], "arcBeats": [ { "to": 9, "arc": { "name": "The Sequoia Pitch", "slug": "sequoia-pitch", "status": "active", "bestFor": "Investor pitches, Series A/B, board presentations", "canonId": "019dd956-5e69-75a7-a0a4-895ac1bc0444", "version": 1, "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49", "structure": "Problem -> Solution -> Why Now -> Market Size -> Competition -> Product -> Business Model -> Team -> Financials -> The Ask", "description": null, "familyLabel": null }, "from": 8, "name": "Problem", "beatId": "707b84bb-d006-4ebc-b566-ffd6845e4351", "matchId": "c1142f11-4f33-424c-b75a-7c146ec1d878", "beatType": { "name": "Problem", "slug": "sequoia-pitch-problem", "status": "active", "canonId": "019dd9b8-1ed4-767b-8e05-40e733bd2311", "version": 1, "description": null }, "evidence": "The presentation identifies a huge need for development in CIAS and Schizophrenia treatment (p8) and an urgent need for innovation in depression treatment (p15).", "position": 0, "isPrimaryArc": true, "parentBeatType": { "name": "Complication", "slug": "complication", "status": "active", "canonId": "019dd9b8-0275-7709-b2d6-4f77c3fc7579", "version": 1, "description": "The point in the narrative where the audience should feel discomfort. Required for argumentative arcs." }, "alignedBlockIds": null, "matchConfidence": 0.8 } ], "loops": [ { "to": 9, "from": 8, "loop": { "name": "27_cost_of_inaction", "slug": "27-cost-of-inaction", "status": "active", "bestFor": "Urgent budget requests, compliance, risk mitigation", "canonId": "019dd956-70d1-7395-a15b-857ba858b394", "version": 1, "bodyDocId": "019df22a-2420-77be-bc41-ded96d08cb21", "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point", "description": "Quantify what happens if the audience does nothing", "familyLabel": null }, "matchId": "7aa520a4-e861-4ddd-adb0-33d2e2059fa2", "evidence": "The presentation highlights the huge need for development in CIAS and Schizophrenia treatment (p8) and the urgent need for innovation in depression treatment (p15).", "position": 0, "objective": "What are the consequences of not addressing mental health disorders?", "confidence": 0.7, "extraction": { "at": "2026-07-16 22:29:50.624947+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": "doc-narrative-v1" } }, { "to": 33, "from": 3, "loop": { "name": "11_golden_circle", "slug": "11-golden-circle", "status": "active", "bestFor": "Visionary leadership, brand positioning, mission statements", "canonId": "019dd956-6a50-7202-882d-505fcb9922ed", "version": 1, "bodyDocId": "019df22a-2420-77be-bc41-ded96d08cb21", "structure": "The Why (Belief) -> The How (Process) -> The What (Result)", "description": "Invert the typical pitch by starting with why you exist, rather than what you do", "familyLabel": null }, "matchId": "720e63ac-a674-4bf4-8e46-acf9a0a900ae", "evidence": "The presentation follows the Golden Circle framework, starting with why atai Life Sciences is working on mental health disorders (p3) and presenting their solution and traction.", "position": 1, "objective": "Why is atai Life Sciences' solution important?", "confidence": 0.7, "extraction": { "at": "2026-07-16 22:29:50.666122+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": "doc-narrative-v1" } } ], "locked": true }, { "page": 10, "type": "resolution", "title": "The slide uses a vertical process flow to demonstrate the de-risking of the drug candidate.", "function": "present_solution", "rawType": "solution", "block": null, "metadata": { "slideType": "solution", "slideTypeCanon": { "name": "Solution", "slug": "solution", "status": "active", "canonId": "019de52d-0eb5-72ff-8b70-ba70a4199282", "version": 1, "description": null }, "function": "present_solution", "functionCanon": { "name": "Present solution", "slug": "present_solution", "status": "active", "canonId": "019de52d-15b8-71da-bd23-2b767850cbce", "version": 1, "description": null }, "density": "dense", "densityScore": 64, "componentCount": 5, "textChars": 792, "nDataPoints": 1, "notes": "The slide uses a vertical process flow to demonstrate the de-risking of the drug candidate.", "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 12:10:55.66+00", "seconds": 9.508, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de074-4969-72b8-bf99-262b9202adeb/10", "deck": "/decks/019de074-4969-72b8-bf99-262b9202adeb", "deckAnchor": "/decks/019de074-4969-72b8-bf99-262b9202adeb#slide-10", "deckJson": "/decks/019de074-4969-72b8-bf99-262b9202adeb.json" }, "components": [ { "bbox": { "h": 0.7, "w": 0.25, "x": 0.45, "y": 0.2 }, "kind": "diagram", "text": "Development stages from In Vitro to Phase 2a, CIAS", "attrs": null, "canon": { "kind": { "name": "Diagram", "slug": "diagram", "status": "active", "canonId": "019de52c-f9f0-734a-81de-15382ff28c65", "version": 1, "description": "Schematic or relational diagram." }, "tool": null, "subkind": { "name": "Process flow", "slug": "process", "status": "active", "canonId": "019de52d-039c-718f-ad3a-efe9c4b3c838", "version": 1, "description": null }, "framework": null }, "subkind": "process", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:10:55.66+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "d9138c90-3cfe-4f9a-9637-36c926127c73", "parentComponentId": null }, { "bbox": { "h": 0.7, "w": 0.2, "x": 0.75, "y": 0.2 }, "kind": "list", "text": "Consistent PK-PD relationship\nConfidence in active dose range\nComplete CMC package\nExcellent tolerability and safety\nMultiple clinical cognitive signals\nDe-risked path forward", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:10:55.66+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "1ddb5580-d8f3-4bcb-965a-c8d4e21ccc40", "parentComponentId": null }, { "bbox": { "h": 0.6, "w": 0.4, "x": 0.05, "y": 0.25 }, "kind": "list", "text": "1. Pharma developed product in-licensed with extensive pre-clinical & clinical data package\n2. Human Phase 1 + 2 data show replicated, clinically significant learning and memory effects\n3. Well tolerated (>500 subjects dosed)\n4. Initial indication: CIAS", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Numbered list", "slug": "numbered", "status": "active", "canonId": "019de52c-fcc0-7718-a284-a4250c805df2", "version": 1, "description": null }, "framework": null }, "subkind": "numbered", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:10:55.66+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "e8a9f531-82ff-49e8-bad9-57e021864127", "parentComponentId": null }, { "bbox": { "h": 0.05, "w": 0.9, "x": 0.05, "y": 0.95 }, "kind": "source-note", "text": "Note: CSF = Cerebrospinal Fluid, DPNP = Diabetic Peripheral Neuropathic Pain, PK = Pharmacokinetics, PD = Pharmacodynamics, CNS = Central Nervous System, CMC = Chemistry, Manufacturing, and Controls", "attrs": null, "canon": { "kind": { "name": "Source note", "slug": "source-note", "status": "active", "canonId": "23484952-494b-4a5e-b1ad-550d0d70e948", "version": 1, "description": "Attribution / source / caveat placed at the slide footer. Numbered footnotes use attrs.numbered." }, "tool": null, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:10:55.66+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "a2bc1091-ff73-4e13-b5ad-21f9eb3f7e1d", "parentComponentId": null }, { "bbox": { "h": 0.15, "w": 0.9, "x": 0.05, "y": 0.08 }, "kind": "title", "text": "RL-007: a de-risked pro-cognitive neuromodulator investigated in >500 subjects with excellent tolerability in humans", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:10:55.66+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "d0d9c21d-948c-4478-be72-8ce0f3c8c548", "parentComponentId": null } ], "metrics": [], "tools": [], "frameworks": [ { "matchId": "b8e62650-0693-4b4d-9aef-8a21642a3cc3", "evidence": "Vertical flow of clinical development stages", "framework": null, "confidence": 0.8, "extraction": { "at": "2026-05-02 12:10:55.66+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 10, "frameworkName": "process" } ], "arcBeats": [ { "to": 12, "arc": { "name": "The Sequoia Pitch", "slug": "sequoia-pitch", "status": "active", "bestFor": "Investor pitches, Series A/B, board presentations", "canonId": "019dd956-5e69-75a7-a0a4-895ac1bc0444", "version": 1, "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49", "structure": "Problem -> Solution -> Why Now -> Market Size -> Competition -> Product -> Business Model -> Team -> Financials -> The Ask", "description": null, "familyLabel": null }, "from": 10, "name": "Traction", "beatId": "9da964e2-70a1-4fde-828c-8254f9947c58", "matchId": "c1142f11-4f33-424c-b75a-7c146ec1d878", "beatType": null, "evidence": "The presentation showcases traction for RL-007, including its pro-cognitive effects in human clinical studies (p9) and its Phase 2b trial design (p12).", "position": 2, "isPrimaryArc": true, "parentBeatType": null, "alignedBlockIds": null, "matchConfidence": 0.8 } ], "loops": [ { "to": 33, "from": 3, "loop": { "name": "11_golden_circle", "slug": "11-golden-circle", "status": "active", "bestFor": "Visionary leadership, brand positioning, mission statements", "canonId": "019dd956-6a50-7202-882d-505fcb9922ed", "version": 1, "bodyDocId": "019df22a-2420-77be-bc41-ded96d08cb21", "structure": "The Why (Belief) -> The How (Process) -> The What (Result)", "description": "Invert the typical pitch by starting with why you exist, rather than what you do", "familyLabel": null }, "matchId": "720e63ac-a674-4bf4-8e46-acf9a0a900ae", "evidence": "The presentation follows the Golden Circle framework, starting with why atai Life Sciences is working on mental health disorders (p3) and presenting their solution and traction.", "position": 1, "objective": "Why is atai Life Sciences' solution important?", "confidence": 0.7, "extraction": { "at": "2026-07-16 22:29:50.666122+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": "doc-narrative-v1" } } ], "locked": true }, { "page": 11, "type": "evidence", "title": "The slide highlights the efficacy of RL-007 in cognitive endpoints during a Phase 2 study.", "function": "show_traction", "rawType": "traction", "block": null, "metadata": { "slideType": "traction", "slideTypeCanon": { "name": "Traction", "slug": "traction", "status": "active", "canonId": "019de52d-0edd-72ab-820f-3ebc71a9c542", "version": 1, "description": null }, "function": "show_traction", "functionCanon": { "name": "Show traction", "slug": "show_traction", "status": "active", "canonId": "019de52d-16a8-756a-9b38-a7d35420561d", "version": 1, "description": null }, "density": "dense", "densityScore": 65, "componentCount": 6, "textChars": 458, "nDataPoints": 6, "notes": "The slide highlights the efficacy of RL-007 in cognitive endpoints during a Phase 2 study.", "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 12:10:55.22+00", "seconds": 8.921, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de074-4969-72b8-bf99-262b9202adeb/11", "deck": "/decks/019de074-4969-72b8-bf99-262b9202adeb", "deckAnchor": "/decks/019de074-4969-72b8-bf99-262b9202adeb#slide-11", "deckJson": "/decks/019de074-4969-72b8-bf99-262b9202adeb.json" }, "components": [ { "bbox": { "h": 0.45, "w": 0.45, "x": 0.52, "y": 0.3 }, "kind": "chart", "text": "Delayed recall (DPNP)", "attrs": null, "canon": { "kind": { "name": "Chart", "slug": "chart", "status": "active", "canonId": "019de52c-f9a0-76ef-adc6-0b859109d1f8", "version": 1, "description": "Quantitative chart." }, "tool": null, "subkind": { "name": "Vertical bar chart", "slug": "bar-vertical", "status": "active", "canonId": "019de52c-fe9d-70f2-b3b7-a9ae294f5917", "version": 1, "description": null }, "framework": null }, "subkind": "bar-vertical", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:10:55.22+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "2f32bbf0-8d90-41f0-915c-9221cb0203ba", "parentComponentId": null }, { "bbox": { "h": 0.45, "w": 0.45, "x": 0.05, "y": 0.3 }, "kind": "chart", "text": "Verbal learning (DPNP)", "attrs": null, "canon": { "kind": { "name": "Chart", "slug": "chart", "status": "active", "canonId": "019de52c-f9a0-76ef-adc6-0b859109d1f8", "version": 1, "description": "Quantitative chart." }, "tool": null, "subkind": { "name": "Vertical bar chart", "slug": "bar-vertical", "status": "active", "canonId": "019de52c-fe9d-70f2-b3b7-a9ae294f5917", "version": 1, "description": null }, "framework": null }, "subkind": "bar-vertical", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:10:55.22+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "d19671a0-d62d-437b-ad3f-207ecd8b2444", "parentComponentId": null }, { "bbox": { "h": 0.03, "w": 0.3, "x": 0.35, "y": 0.8 }, "kind": "paragraph", "text": "(Phase 2 exploratory endpoints – 180 patients¹)", "attrs": null, "canon": { "kind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "5f2affc0-941d-4d07-959d-4bfc1930cea4", "version": 1, "description": "Single prose block in the body of a slide." }, "tool": null, "subkind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "019de52c-fb80-75af-aa5c-a7a4bfac2433", "version": 1, "description": null }, "framework": null }, "subkind": "paragraph", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:10:55.22+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "7ee44f76-0ae9-4a19-92a8-799336ce1e4a", "parentComponentId": null }, { "bbox": { "h": 0.05, "w": 0.4, "x": 0.05, "y": 0.92 }, "kind": "source-note", "text": "Note: * = P < 0.05 vs Placebo; **missed significance (P=0.075); Diabetic Peripheral Neuropathic Pain (DPNP); 1. N=60 patients/treatment group; dosed TID = 3x/day dosing; randomized, cross-over design", "attrs": null, "canon": { "kind": { "name": "Source note", "slug": "source-note", "status": "active", "canonId": "23484952-494b-4a5e-b1ad-550d0d70e948", "version": 1, "description": "Attribution / source / caveat placed at the slide footer. Numbered footnotes use attrs.numbered." }, "tool": null, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:10:55.22+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "29a5ab09-71bc-4317-aea8-560188a1aef2", "parentComponentId": null }, { "bbox": { "h": 0.03, "w": 0.4, "x": 0.05, "y": 0.25 }, "kind": "title", "text": "RL-007 low doses enhanced learning and memory", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Action title", "slug": "action-title", "status": "active", "canonId": "019de52c-fb31-734c-a0f5-a3935b73135d", "version": 1, "description": null }, "framework": null }, "subkind": "action-title", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:10:55.22+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "43ddabd6-c4b2-4d88-b521-8273fe45b140", "parentComponentId": null }, { "bbox": { "h": 0.1, "w": 0.9, "x": 0.05, "y": 0.08 }, "kind": "title", "text": "Additionally, a third-party Phase 2 study in DPNP of RL-007 also showed statistically significant positive cognitive signals", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:10:55.22+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "431043b7-3672-412a-9063-0fb0921164da", "parentComponentId": null } ], "metrics": [], "tools": [], "frameworks": [], "arcBeats": [ { "to": 12, "arc": { "name": "The Sequoia Pitch", "slug": "sequoia-pitch", "status": "active", "bestFor": "Investor pitches, Series A/B, board presentations", "canonId": "019dd956-5e69-75a7-a0a4-895ac1bc0444", "version": 1, "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49", "structure": "Problem -> Solution -> Why Now -> Market Size -> Competition -> Product -> Business Model -> Team -> Financials -> The Ask", "description": null, "familyLabel": null }, "from": 10, "name": "Traction", "beatId": "9da964e2-70a1-4fde-828c-8254f9947c58", "matchId": "c1142f11-4f33-424c-b75a-7c146ec1d878", "beatType": null, "evidence": "The presentation showcases traction for RL-007, including its pro-cognitive effects in human clinical studies (p9) and its Phase 2b trial design (p12).", "position": 2, "isPrimaryArc": true, "parentBeatType": null, "alignedBlockIds": null, "matchConfidence": 0.8 } ], "loops": [ { "to": 33, "from": 3, "loop": { "name": "11_golden_circle", "slug": "11-golden-circle", "status": "active", "bestFor": "Visionary leadership, brand positioning, mission statements", "canonId": "019dd956-6a50-7202-882d-505fcb9922ed", "version": 1, "bodyDocId": "019df22a-2420-77be-bc41-ded96d08cb21", "structure": "The Why (Belief) -> The How (Process) -> The What (Result)", "description": "Invert the typical pitch by starting with why you exist, rather than what you do", "familyLabel": null }, "matchId": "720e63ac-a674-4bf4-8e46-acf9a0a900ae", "evidence": "The presentation follows the Golden Circle framework, starting with why atai Life Sciences is working on mental health disorders (p3) and presenting their solution and traction.", "position": 1, "objective": "Why is atai Life Sciences' solution important?", "confidence": 0.7, "extraction": { "at": "2026-07-16 22:29:50.666122+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": "doc-narrative-v1" } } ], "locked": true }, { "page": 12, "type": "setup", "title": "The slide uses a standard clinical trial flow diagram to illustrate the study protocol.", "function": "present_framework", "rawType": "appendix_methodology", "block": null, "metadata": { "slideType": "appendix_methodology", "slideTypeCanon": { "name": "Appendix methodology", "slug": "appendix_methodology", "status": "active", "canonId": "019de52d-07d9-726c-8599-167f2d2ffaa7", "version": 1, "description": null }, "function": "present_framework", "functionCanon": { "name": "Present framework", "slug": "present_framework", "status": "active", "canonId": "019de52d-1403-7667-9100-d2ac6709f750", "version": 1, "description": null }, "density": "dense", "densityScore": 72, "componentCount": 8, "textChars": 403, "nDataPoints": 4, "notes": "The slide uses a standard clinical trial flow diagram to illustrate the study protocol.", "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 15:31:28.66+00", "seconds": 3.67, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de074-4969-72b8-bf99-262b9202adeb/12", "deck": "/decks/019de074-4969-72b8-bf99-262b9202adeb", "deckAnchor": "/decks/019de074-4969-72b8-bf99-262b9202adeb#slide-12", "deckJson": "/decks/019de074-4969-72b8-bf99-262b9202adeb.json" }, "components": [ { "bbox": { "h": 0.08, "w": 0.29, "x": 0.06, "y": 0.26 }, "kind": "callout", "text": "Primary Endpoint: MCCB change from baseline at Week 6", "attrs": null, "canon": { "kind": { "name": "Callout", "slug": "callout", "status": "active", "canonId": "019de52c-f8d3-761a-8953-7d37080de5e2", "version": 1, "description": "Highlighted callout box." }, "tool": null, "subkind": { "name": "Primary callout", "slug": "primary", "status": "active", "canonId": "019de52c-fbd1-70eb-a9ce-8997f8674c1d", "version": 1, "description": null }, "framework": null }, "subkind": "primary", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 15:31:28.66+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "838160c1-6f63-446f-a3dc-60fb44be70fd", "parentComponentId": null }, { "bbox": { "h": 0.6, "w": 0.9, "x": 0.05, "y": 0.25 }, "kind": "diagram", "text": "Phase 2b Proof-of-Concept Trial Design", "attrs": null, "canon": { "kind": { "name": "Diagram", "slug": "diagram", "status": "active", "canonId": "019de52c-f9f0-734a-81de-15382ff28c65", "version": 1, "description": "Schematic or relational diagram." }, "tool": null, "subkind": { "name": "Process flow", "slug": "process", "status": "active", "canonId": "019de52d-039c-718f-ad3a-efe9c4b3c838", "version": 1, "description": null }, "framework": null }, "subkind": "process", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 15:31:28.66+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "0c25ecf5-96e6-47fc-8968-c6658359e5c3", "parentComponentId": null }, { "bbox": { "h": 0.03, "w": 0.05, "x": 0.39, "y": 0.39 }, "kind": "metric", "text": "n = 78", "attrs": null, "canon": { "kind": { "name": "Metric", "slug": "metric", "status": "active", "canonId": "019de52c-f923-73bf-8081-d0b1a8c5264d", "version": 1, "description": "Big-number or KPI value." }, "tool": null, "subkind": { "name": "Big number", "slug": "big-number", "status": "active", "canonId": "019de52c-fc70-70c8-b965-0584548a9204", "version": 1, "description": null }, "framework": null }, "subkind": "big-number", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 15:31:28.66+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "4f972e42-14f1-4e72-baad-d471b326dd65", "parentComponentId": null }, { "bbox": { "h": 0.03, "w": 0.05, "x": 0.39, "y": 0.47 }, "kind": "metric", "text": "n = 78", "attrs": null, "canon": { "kind": { "name": "Metric", "slug": "metric", "status": "active", "canonId": "019de52c-f923-73bf-8081-d0b1a8c5264d", "version": 1, "description": "Big-number or KPI value." }, "tool": null, "subkind": { "name": "Big number", "slug": "big-number", "status": "active", "canonId": "019de52c-fc70-70c8-b965-0584548a9204", "version": 1, "description": null }, "framework": null }, "subkind": "big-number", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 15:31:28.66+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "5d37c676-be00-4713-b1f3-6abecc00ef93", "parentComponentId": null }, { "bbox": { "h": 0.03, "w": 0.05, "x": 0.39, "y": 0.32 }, "kind": "metric", "text": "n = 78", "attrs": null, "canon": { "kind": { "name": "Metric", "slug": "metric", "status": "active", "canonId": "019de52c-f923-73bf-8081-d0b1a8c5264d", "version": 1, "description": "Big-number or KPI value." }, "tool": null, "subkind": { "name": "Big number", "slug": "big-number", "status": "active", "canonId": "019de52c-fc70-70c8-b965-0584548a9204", "version": 1, "description": null }, "framework": null }, "subkind": "big-number", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 15:31:28.66+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "995af904-4710-47f3-8d7a-b4f3e3afb327", "parentComponentId": null }, { "bbox": { "h": 0.05, "w": 0.9, "x": 0.05, "y": 0.85 }, "kind": "paragraph", "text": "Trial status: Recruitment ongoing, results anticipated H1'24", "attrs": null, "canon": { "kind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "5f2affc0-941d-4d07-959d-4bfc1930cea4", "version": 1, "description": "Single prose block in the body of a slide." }, "tool": null, "subkind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "019de52c-fb80-75af-aa5c-a7a4bfac2433", "version": 1, "description": null }, "framework": null }, "subkind": "paragraph", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 15:31:28.66+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "8744b505-eaec-4117-87dc-382519d30b2f", "parentComponentId": null }, { "bbox": { "h": 0.03, "w": 0.45, "x": 0.05, "y": 0.93 }, "kind": "source-note", "text": "Note: MCCB = MATRICS Consensus Cognitive Battery; VRFCAT = Virtual Reality Capacity Assessment Tool; TID = 3x/day dosing", "attrs": null, "canon": { "kind": { "name": "Source note", "slug": "source-note", "status": "active", "canonId": "23484952-494b-4a5e-b1ad-550d0d70e948", "version": 1, "description": "Attribution / source / caveat placed at the slide footer. Numbered footnotes use attrs.numbered." }, "tool": null, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 15:31:28.66+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "9210d6f4-4ef2-401d-a337-0cb6a3ae9c60", "parentComponentId": null }, { "bbox": { "h": 0.12, "w": 0.85, "x": 0.05, "y": 0.08 }, "kind": "title", "text": "RL-007 Phase 2b trial design: randomized 6-week study of RL-007 20mg and 40mg vs placebo in 234 patients with CIAS", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 15:31:28.66+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "6aef8c36-051b-4fc2-8227-cc80391d559b", "parentComponentId": null } ], "metrics": [], "tools": [], "frameworks": [ { "matchId": "5f3f98b5-8bd4-4b14-bedd-50d5d21e8a7f", "evidence": "Standardized flow diagram for clinical study protocols", "framework": null, "confidence": 0.9, "extraction": { "at": "2026-05-02 15:31:28.66+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 12, "frameworkName": "clinical-trial-design" } ], "arcBeats": [ { "to": 12, "arc": { "name": "The Sequoia Pitch", "slug": "sequoia-pitch", "status": "active", "bestFor": "Investor pitches, Series A/B, board presentations", "canonId": "019dd956-5e69-75a7-a0a4-895ac1bc0444", "version": 1, "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49", "structure": "Problem -> Solution -> Why Now -> Market Size -> Competition -> Product -> Business Model -> Team -> Financials -> The Ask", "description": null, "familyLabel": null }, "from": 10, "name": "Traction", "beatId": "9da964e2-70a1-4fde-828c-8254f9947c58", "matchId": "c1142f11-4f33-424c-b75a-7c146ec1d878", "beatType": null, "evidence": "The presentation showcases traction for RL-007, including its pro-cognitive effects in human clinical studies (p9) and its Phase 2b trial design (p12).", "position": 2, "isPrimaryArc": true, "parentBeatType": null, "alignedBlockIds": null, "matchConfidence": 0.8 } ], "loops": [ { "to": 33, "from": 3, "loop": { "name": "11_golden_circle", "slug": "11-golden-circle", "status": "active", "bestFor": "Visionary leadership, brand positioning, mission statements", "canonId": "019dd956-6a50-7202-882d-505fcb9922ed", "version": 1, "bodyDocId": "019df22a-2420-77be-bc41-ded96d08cb21", "structure": "The Why (Belief) -> The How (Process) -> The What (Result)", "description": "Invert the typical pitch by starting with why you exist, rather than what you do", "familyLabel": null }, "matchId": "720e63ac-a674-4bf4-8e46-acf9a0a900ae", "evidence": "The presentation follows the Golden Circle framework, starting with why atai Life Sciences is working on mental health disorders (p3) and presenting their solution and traction.", "position": 1, "objective": "Why is atai Life Sciences' solution important?", "confidence": 0.7, "extraction": { "at": "2026-07-16 22:29:50.666122+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": "doc-narrative-v1" } } ], "locked": true }, { "page": 13, "type": "setup", "title": "The slide uses a feature-comparison matrix to highlight the competitive advantage of RL-007.", "function": "compare_peers", "rawType": "competitive_analysis", "block": null, "metadata": { "slideType": "competitive_analysis", "slideTypeCanon": { "name": "Competitive analysis", "slug": "competitive_analysis", "status": "active", "canonId": "019de52d-093e-776b-94c6-c1573f5f1a31", "version": 1, "description": null }, "function": "compare_peers", "functionCanon": { "name": "Compare peers", "slug": "compare_peers", "status": "active", "canonId": "019de52d-1453-72ba-a367-9ba3d34c1630", "version": 1, "description": null }, "density": "dense", "densityScore": 50, "componentCount": 3, "textChars": 698, "nDataPoints": 30, "notes": "The slide uses a feature-comparison matrix to highlight the competitive advantage of RL-007.", "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 12:10:49.466+00", "seconds": 2.922, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de074-4969-72b8-bf99-262b9202adeb/13", "deck": "/decks/019de074-4969-72b8-bf99-262b9202adeb", "deckAnchor": "/decks/019de074-4969-72b8-bf99-262b9202adeb#slide-13", "deckJson": "/decks/019de074-4969-72b8-bf99-262b9202adeb.json" }, "components": [ { "bbox": { "h": 0.05, "w": 0.9, "x": 0.05, "y": 0.92 }, "kind": "source-note", "text": "Source: Publicly available information, including company websites and clinicaltrials.gov. Note: GABA = gamma-Aminobutyric acid; GlyT1 = Glycine transporter type-1; GPR139 = G Protein-Coupled Receptor 139; 5-HT2a = Serotonin 2A receptor; TAAR1 = Trace Amine-Associated Receptor 1. 1. RL-007 compound is (2R, 3S)-2-amino-3-hydroxy-3-pyridin-4-yl-1-pyrrolidin-1-yl-propan-1-one(L)-(+) tartrate salts", "attrs": null, "canon": { "kind": { "name": "Source note", "slug": "source-note", "status": "active", "canonId": "23484952-494b-4a5e-b1ad-550d0d70e948", "version": 1, "description": "Attribution / source / caveat placed at the slide footer. Numbered footnotes use attrs.numbered." }, "tool": null, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:10:49.466+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "7d2bdc18-eddf-4a4f-b82f-d9a10f94a62f", "parentComponentId": null }, { "bbox": { "h": 0.65, "w": 0.9, "x": 0.05, "y": 0.25 }, "kind": "table", "text": "Comparison matrix of RL-007 vs competitors (Boehringer Ingelheim, Karuna, Takeda, Minerva, Sunovion) across compound, stage, MOA, and focus areas.", "attrs": null, "canon": { "kind": { "name": "Table", "slug": "table", "status": "active", "canonId": "019de52c-f9c8-7148-8119-eaac9594cd28", "version": 1, "description": "Tabular data layout." }, "tool": null, "subkind": { "name": "Data table", "slug": "data", "status": "active", "canonId": "019de52d-02d5-75b8-8abf-88e92bf63569", "version": 1, "description": null }, "framework": null }, "subkind": "data", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:10:49.466+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "b18ca949-e196-4092-8130-ebcffedc55cb", "parentComponentId": null }, { "bbox": { "h": 0.1, "w": 0.9, "x": 0.05, "y": 0.08 }, "kind": "title", "text": "CIAS & Schizophrenia landscape: RL-007's unique pharmacology, acute cognitive benefit and excellent tolerability differentiate it from pipeline competitors", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:10:49.466+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "eb036990-bf2a-4a48-ad2e-5e4c3b3b38d3", "parentComponentId": null } ], "metrics": [], "tools": [], "frameworks": [ { "matchId": "5135f6c9-2bba-40a7-972e-97b304dcedb0", "evidence": "The slide uses a feature-comparison table to differentiate the product from competitors.", "framework": null, "confidence": 0.9, "extraction": { "at": "2026-05-02 12:10:49.466+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 13, "frameworkName": "comparison_frame" } ], "arcBeats": [ { "to": 14, "arc": { "name": "The Sequoia Pitch", "slug": "sequoia-pitch", "status": "active", "bestFor": "Investor pitches, Series A/B, board presentations", "canonId": "019dd956-5e69-75a7-a0a4-895ac1bc0444", "version": 1, "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49", "structure": "Problem -> Solution -> Why Now -> Market Size -> Competition -> Product -> Business Model -> Team -> Financials -> The Ask", "description": null, "familyLabel": null }, "from": 13, "name": "Competitive Analysis", "beatId": "34485d17-5ed8-4b0d-a98e-2eaaf208a9c8", "matchId": "c1142f11-4f33-424c-b75a-7c146ec1d878", "beatType": null, "evidence": "The presentation provides a competitive analysis for RL-007, highlighting its unique pharmacology and acute cognitive benefit (p13).", "position": 4, "isPrimaryArc": true, "parentBeatType": null, "alignedBlockIds": null, "matchConfidence": 0.8 } ], "loops": [ { "to": 33, "from": 3, "loop": { "name": "11_golden_circle", "slug": "11-golden-circle", "status": "active", "bestFor": "Visionary leadership, brand positioning, mission statements", "canonId": "019dd956-6a50-7202-882d-505fcb9922ed", "version": 1, "bodyDocId": "019df22a-2420-77be-bc41-ded96d08cb21", "structure": "The Why (Belief) -> The How (Process) -> The What (Result)", "description": "Invert the typical pitch by starting with why you exist, rather than what you do", "familyLabel": null }, "matchId": "720e63ac-a674-4bf4-8e46-acf9a0a900ae", "evidence": "The presentation follows the Golden Circle framework, starting with why atai Life Sciences is working on mental health disorders (p3) and presenting their solution and traction.", "position": 1, "objective": "Why is atai Life Sciences' solution important?", "confidence": 0.7, "extraction": { "at": "2026-07-16 22:29:50.666122+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": "doc-narrative-v1" } } ], "locked": true }, { "page": 14, "type": "setup", "function": "transition", "rawType": "section_divider", "block": null, "metadata": { "slideType": "section_divider", "slideTypeCanon": { "name": "Section divider", "slug": "section_divider", "status": "active", "canonId": "019de52d-066a-7402-9554-6ae504999041", "version": 1, "description": null }, "function": "transition", "functionCanon": { "name": "Transition", "slug": "transition", "status": "active", "canonId": "019de52d-1365-7149-92aa-66df859e75fd", "version": 1, "description": null }, "density": "sparse", "densityScore": 2, "componentCount": 2, "textChars": 10, "nDataPoints": 0, "notes": null, "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 12:10:53.654+00", "seconds": 7.1, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de074-4969-72b8-bf99-262b9202adeb/14", "deck": "/decks/019de074-4969-72b8-bf99-262b9202adeb", "deckAnchor": "/decks/019de074-4969-72b8-bf99-262b9202adeb#slide-14", "deckJson": "/decks/019de074-4969-72b8-bf99-262b9202adeb.json" }, "components": [ { "bbox": { "h": 0.9, "w": 0.4, "x": 0.55, "y": 0.05 }, "kind": "image", "text": null, "attrs": null, "canon": { "kind": { "name": "Image", "slug": "image", "status": "active", "canonId": "019de52c-f978-701f-a720-51d029d769e7", "version": 1, "description": "Photo, illustration, screenshot or icon." }, "tool": null, "subkind": { "name": "Photo", "slug": "photo", "status": "active", "canonId": "019de52c-fd37-757f-b4a8-ca26d4888875", "version": 1, "description": null }, "framework": null }, "subkind": "photo", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:10:53.654+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "af8b0db8-e314-4d08-9fd4-4dbf40e5c412", "parentComponentId": null }, { "bbox": { "h": 0.1, "w": 0.3, "x": 0.05, "y": 0.45 }, "kind": "title", "text": "Depression", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:10:53.654+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "683d5299-1003-4e02-a85e-6cc517947349", "parentComponentId": null } ], "metrics": [], "tools": [ { "tool": { "name": "Section divider", "slug": "section-divider", "status": "active", "bestFor": null, "canonId": "019dd9e1-4c66-707d-8d1f-6e14547134c7", "version": 1, "bodyDocId": null, "description": "A transitional slide marking the start of a new section.", "familyLabel": null, "categoryName": null, "categorySlug": null }, "agent": null, "layer": "slide", "agents": null, "matchId": "7180da0b-b404-470f-864a-316f9c20cf73", "evidence": "title/headline: Depression", "pageRefs": null, "priority": null, "whenToUse": null, "confidence": 0.9, "extraction": { "at": "2026-07-17 03:37:02.53609+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 14, "whyItWorks": null, "antipattern": null, "cardinality": "common", "narrativePurpose": null } ], "frameworks": [], "arcBeats": [ { "to": 14, "arc": { "name": "The Sequoia Pitch", "slug": "sequoia-pitch", "status": "active", "bestFor": "Investor pitches, Series A/B, board presentations", "canonId": "019dd956-5e69-75a7-a0a4-895ac1bc0444", "version": 1, "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49", "structure": "Problem -> Solution -> Why Now -> Market Size -> Competition -> Product -> Business Model -> Team -> Financials -> The Ask", "description": null, "familyLabel": null }, "from": 13, "name": "Competitive Analysis", "beatId": "34485d17-5ed8-4b0d-a98e-2eaaf208a9c8", "matchId": "c1142f11-4f33-424c-b75a-7c146ec1d878", "beatType": null, "evidence": "The presentation provides a competitive analysis for RL-007, highlighting its unique pharmacology and acute cognitive benefit (p13).", "position": 4, "isPrimaryArc": true, "parentBeatType": null, "alignedBlockIds": null, "matchConfidence": 0.8 } ], "loops": [ { "to": 33, "from": 3, "loop": { "name": "11_golden_circle", "slug": "11-golden-circle", "status": "active", "bestFor": "Visionary leadership, brand positioning, mission statements", "canonId": "019dd956-6a50-7202-882d-505fcb9922ed", "version": 1, "bodyDocId": "019df22a-2420-77be-bc41-ded96d08cb21", "structure": "The Why (Belief) -> The How (Process) -> The What (Result)", "description": "Invert the typical pitch by starting with why you exist, rather than what you do", "familyLabel": null }, "matchId": "720e63ac-a674-4bf4-8e46-acf9a0a900ae", "evidence": "The presentation follows the Golden Circle framework, starting with why atai Life Sciences is working on mental health disorders (p3) and presenting their solution and traction.", "position": 1, "objective": "Why is atai Life Sciences' solution important?", "confidence": 0.7, "extraction": { "at": "2026-07-16 22:29:50.666122+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": "doc-narrative-v1" } } ], "locked": true }, { "page": 15, "type": "tension", "title": "The slide uses a dual-column layout: left side establishes the scale of the problem (market sizing/context), right side details the clinical pain points.", "function": "frame_problem", "rawType": "problem_statement", "block": null, "metadata": { "slideType": "problem_statement", "slideTypeCanon": { "name": "Problem statement", "slug": "problem_statement", "status": "active", "canonId": "019de52d-0879-768d-bba8-8da8a5a121d4", "version": 1, "description": null }, "function": "frame_problem", "functionCanon": { "name": "Frame problem", "slug": "frame_problem", "status": "active", "canonId": "019de52d-13db-753e-ad70-e9b2d0dab398", "version": 1, "description": null }, "density": "overcrowded", "densityScore": 81, "componentCount": 9, "textChars": 513, "nDataPoints": 7, "notes": "The slide uses a dual-column layout: left side establishes the scale of the problem (market sizing/context), right side details the clinical pain points.", "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 12:10:51.113+00", "seconds": 4.412, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de074-4969-72b8-bf99-262b9202adeb/15", "deck": "/decks/019de074-4969-72b8-bf99-262b9202adeb", "deckAnchor": "/decks/019de074-4969-72b8-bf99-262b9202adeb#slide-15", "deckJson": "/decks/019de074-4969-72b8-bf99-262b9202adeb.json" }, "components": [ { "bbox": { "h": 0.25, "w": 0.25, "x": 0.04, "y": 0.6 }, "kind": "chart", "text": "Global map of depression prevalence", "attrs": null, "canon": { "kind": { "name": "Chart", "slug": "chart", "status": "active", "canonId": "019de52c-f9a0-76ef-adc6-0b859109d1f8", "version": 1, "description": "Quantitative chart." }, "tool": null, "subkind": null, "framework": null }, "subkind": "map", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:10:51.113+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "6853d77f-2539-43d3-9c2f-454ff265b82d", "parentComponentId": null }, { "bbox": { "h": 0.12, "w": 0.42, "x": 0.04, "y": 0.31 }, "kind": "diagram", "text": "First onset depression (MDD) -> Persistent depression (MDD) -> Treatment resistant depression (TRD)", "attrs": null, "canon": { "kind": { "name": "Diagram", "slug": "diagram", "status": "active", "canonId": "019de52c-f9f0-734a-81de-15382ff28c65", "version": 1, "description": "Schematic or relational diagram." }, "tool": null, "subkind": { "name": "Process flow", "slug": "process", "status": "active", "canonId": "019de52d-039c-718f-ad3a-efe9c4b3c838", "version": 1, "description": null }, "framework": null }, "subkind": "process", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:10:51.113+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "f18c9b75-cbb4-40c0-bfd9-ca11d5ef1b64", "parentComponentId": null }, { "bbox": { "h": 0.75, "w": 0.48, "x": 0.48, "y": 0.12 }, "kind": "list", "text": "Inadequate response rate (~33%), Slow onset (4-12 weeks), Long-term side effects (~38%), Novel therapies (4)", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:10:51.113+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "cc023243-1fc5-470b-8766-6a0010095bdc", "parentComponentId": null }, { "bbox": { "h": 0.08, "w": 0.15, "x": 0.32, "y": 0.64 }, "kind": "metric", "text": "2nd Leading cause of disability worldwide", "attrs": null, "canon": { "kind": { "name": "Metric", "slug": "metric", "status": "active", "canonId": "019de52c-f923-73bf-8081-d0b1a8c5264d", "version": 1, "description": "Big-number or KPI value." }, "tool": null, "subkind": { "name": "Big number", "slug": "big-number", "status": "active", "canonId": "019de52c-fc70-70c8-b965-0584548a9204", "version": 1, "description": null }, "framework": null }, "subkind": "big-number", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:10:51.113+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "4f28d826-3280-49dd-8a83-67abf3c816bc", "parentComponentId": null }, { "bbox": { "h": 0.08, "w": 0.15, "x": 0.32, "y": 0.52 }, "kind": "metric", "text": "~300m Global sufferers of depression", "attrs": null, "canon": { "kind": { "name": "Metric", "slug": "metric", "status": "active", "canonId": "019de52c-f923-73bf-8081-d0b1a8c5264d", "version": 1, "description": "Big-number or KPI value." }, "tool": null, "subkind": { "name": "Big number", "slug": "big-number", "status": "active", "canonId": "019de52c-fc70-70c8-b965-0584548a9204", "version": 1, "description": null }, "framework": null }, "subkind": "big-number", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:10:51.113+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "749c0e8d-7e57-4fc9-ae9b-e28489055c86", "parentComponentId": null }, { "bbox": { "h": 0.08, "w": 0.15, "x": 0.32, "y": 0.76 }, "kind": "metric", "text": "~$300Bn U.S. economic burden", "attrs": null, "canon": { "kind": { "name": "Metric", "slug": "metric", "status": "active", "canonId": "019de52c-f923-73bf-8081-d0b1a8c5264d", "version": 1, "description": "Big-number or KPI value." }, "tool": null, "subkind": { "name": "Big number", "slug": "big-number", "status": "active", "canonId": "019de52c-fc70-70c8-b965-0584548a9204", "version": 1, "description": null }, "framework": null }, "subkind": "big-number", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:10:51.113+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "a82cf45c-577a-4eac-a08a-9cf7d4f4e18a", "parentComponentId": null }, { "bbox": { "h": 0.06, "w": 0.42, "x": 0.04, "y": 0.22 }, "kind": "paragraph", "text": "Depression is a mood disorder that affects the thoughts and behavior of an individual, leading to psychological, physical, and social problems", "attrs": null, "canon": { "kind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "5f2affc0-941d-4d07-959d-4bfc1930cea4", "version": 1, "description": "Single prose block in the body of a slide." }, "tool": null, "subkind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "019de52c-fb80-75af-aa5c-a7a4bfac2433", "version": 1, "description": null }, "framework": null }, "subkind": "paragraph", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:10:51.113+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "4a97349f-e490-4bac-8f16-3eb582aca9b4", "parentComponentId": null }, { "bbox": { "h": 0.06, "w": 0.92, "x": 0.04, "y": 0.92 }, "kind": "source-note", "text": "References 1-7", "attrs": null, "canon": { "kind": { "name": "Source note", "slug": "source-note", "status": "active", "canonId": "23484952-494b-4a5e-b1ad-550d0d70e948", "version": 1, "description": "Attribution / source / caveat placed at the slide footer. Numbered footnotes use attrs.numbered." }, "tool": null, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:10:51.113+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "e8d02a78-e3ad-4798-9b8e-7c5c25ad70cc", "parentComponentId": null }, { "bbox": { "h": 0.04, "w": 0.18, "x": 0.04, "y": 0.08 }, "kind": "title", "text": "Depression", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:10:51.113+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "be71adec-4fe3-4b0d-811d-b8b8980d5945", "parentComponentId": null } ], "metrics": [], "tools": [ { "tool": { "name": "Storytelling: audience calibration", "slug": "audience", "status": "active", "bestFor": null, "canonId": "019df269-23ea-723a-87c0-af1d78d702d2", "version": 1, "bodyDocId": "019df269-23c5-72ec-8b94-78fc1da7b656", "description": "The same thesis, written for four different audiences, produces four", "familyLabel": "narrative-block", "categoryName": "Narrative & Transformation", "categorySlug": "narrative-transformation" }, "agent": "storyteller", "layer": "slide", "agents": [ "storyteller" ], "matchId": "e8993881-f5e5-4f76-b45f-4eb37e4e7b90", "evidence": "The slide mentions the global impact of depression, indicating consideration for the audience's perspective.", "pageRefs": null, "priority": null, "whenToUse": null, "confidence": 0.7, "extraction": { "at": "2026-07-17 03:37:02.157474+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 15, "whyItWorks": null, "antipattern": null, "cardinality": null, "narrativePurpose": null } ], "frameworks": [ { "matchId": "8884a7d7-6859-46dd-b949-c9e8107dfa83", "evidence": "Structured as a clear definition of the disease followed by market scale and clinical pain points.", "framework": null, "confidence": 0.9, "extraction": { "at": "2026-05-02 12:10:51.113+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 15, "frameworkName": "problem-statement" } ], "arcBeats": [], "loops": [ { "to": 33, "from": 3, "loop": { "name": "11_golden_circle", "slug": "11-golden-circle", "status": "active", "bestFor": "Visionary leadership, brand positioning, mission statements", "canonId": "019dd956-6a50-7202-882d-505fcb9922ed", "version": 1, "bodyDocId": "019df22a-2420-77be-bc41-ded96d08cb21", "structure": "The Why (Belief) -> The How (Process) -> The What (Result)", "description": "Invert the typical pitch by starting with why you exist, rather than what you do", "familyLabel": null }, "matchId": "720e63ac-a674-4bf4-8e46-acf9a0a900ae", "evidence": "The presentation follows the Golden Circle framework, starting with why atai Life Sciences is working on mental health disorders (p3) and presenting their solution and traction.", "position": 1, "objective": "Why is atai Life Sciences' solution important?", "confidence": 0.7, "extraction": { "at": "2026-07-16 22:29:50.666122+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": "doc-narrative-v1" } } ], "locked": true }, { "page": 16, "type": "evidence", "title": "The slide uses a line chart to demonstrate the efficacy of different dosages of COMP360 over 12 weeks.", "function": "show_traction", "rawType": "traction", "block": null, "metadata": { "slideType": "traction", "slideTypeCanon": { "name": "Traction", "slug": "traction", "status": "active", "canonId": "019de52d-0edd-72ab-820f-3ebc71a9c542", "version": 1, "description": null }, "function": "show_traction", "functionCanon": { "name": "Show traction", "slug": "show_traction", "status": "active", "canonId": "019de52d-16a8-756a-9b38-a7d35420561d", "version": 1, "description": null }, "density": "dense", "densityScore": 74, "componentCount": 6, "textChars": 662, "nDataPoints": 21, "notes": "The slide uses a line chart to demonstrate the efficacy of different dosages of COMP360 over 12 weeks.", "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 12:10:49.779+00", "seconds": 2.957, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de074-4969-72b8-bf99-262b9202adeb/16", "deck": "/decks/019de074-4969-72b8-bf99-262b9202adeb", "deckAnchor": "/decks/019de074-4969-72b8-bf99-262b9202adeb#slide-16", "deckJson": "/decks/019de074-4969-72b8-bf99-262b9202adeb.json" }, "components": [ { "bbox": { "h": 0.09, "w": 0.26, "x": 0.65, "y": 0.37 }, "kind": "callout", "text": "Primary Endpoint: Difference vs 1mg at Week 3: 25mg Diff = -6.6, p value = <0.001; 10mg Diff = -2.5, p value = 0.184", "attrs": null, "canon": { "kind": { "name": "Callout", "slug": "callout", "status": "active", "canonId": "019de52c-f8d3-761a-8953-7d37080de5e2", "version": 1, "description": "Highlighted callout box." }, "tool": null, "subkind": { "name": "Primary callout", "slug": "primary", "status": "active", "canonId": "019de52c-fbd1-70eb-a9ce-8997f8674c1d", "version": 1, "description": null }, "framework": null }, "subkind": "primary", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:10:49.779+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "ad7308ea-17a9-413e-9040-00f150b2703c", "parentComponentId": null }, { "bbox": { "h": 0.55, "w": 0.55, "x": 0.38, "y": 0.32 }, "kind": "chart", "text": "Line chart showing MADRS score change over 12 weeks for 25mg, 10mg, and 1mg doses.", "attrs": null, "canon": { "kind": { "name": "Chart", "slug": "chart", "status": "active", "canonId": "019de52c-f9a0-76ef-adc6-0b859109d1f8", "version": 1, "description": "Quantitative chart." }, "tool": null, "subkind": { "name": "Line chart", "slug": "line", "status": "active", "canonId": "019de52c-ff62-778f-8f6c-a952ceae8677", "version": 1, "description": null }, "framework": null }, "subkind": "line", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:10:49.779+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "8926225f-4e08-48c0-98f2-cc0db2dbea9e", "parentComponentId": null }, { "bbox": { "h": 0.65, "w": 0.3, "x": 0.04, "y": 0.17 }, "kind": "list", "text": "OWNERSHIP: 22.5% | PRODUCT: Oral Psilocybin (COMP360) | PHARMACOLOGY: 5-HT2A-R agonist | PRODUCT FEATURES: Rapid onset, potential for sustained efficacy | INDICATIONS: TRD, Anorexia, PTSD | STATUS: Phase 3 (TRD) | IP: Proprietary formulation", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:10:49.779+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "6d432cc2-ce26-4908-96f3-f60e105e4435", "parentComponentId": null }, { "bbox": { "h": 0.08, "w": 0.6, "x": 0.37, "y": 0.9 }, "kind": "source-note", "text": "Source: Schedule 13D filed with the SEC as of November 29th, 2021, as amended. Note: MADRS = Montgomery-Åsberg Depression Rating Scale.", "attrs": null, "canon": { "kind": { "name": "Source note", "slug": "source-note", "status": "active", "canonId": "23484952-494b-4a5e-b1ad-550d0d70e948", "version": 1, "description": "Attribution / source / caveat placed at the slide footer. Numbered footnotes use attrs.numbered." }, "tool": null, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:10:49.779+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "762f3914-9798-48fa-b3e4-d7bc22a9b1ac", "parentComponentId": null }, { "bbox": { "h": 0.06, "w": 0.55, "x": 0.37, "y": 0.08 }, "kind": "title", "text": "COMP360 Phase 2b trial showed a rapid, sustained reduction in depressive symptoms", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Action title", "slug": "action-title", "status": "active", "canonId": "019de52c-fb31-734c-a0f5-a3935b73135d", "version": 1, "description": null }, "framework": null }, "subkind": "action-title", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:10:49.779+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "6793c97e-c254-41d2-8ed7-feaf7f394a4b", "parentComponentId": null }, { "bbox": { "h": 0.03, "w": 0.13, "x": 0.04, "y": 0.08 }, "kind": "title", "text": "SUMMARY", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:10:49.779+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "7e567d5e-c542-4b2a-bee8-3dccab795184", "parentComponentId": null } ], "metrics": [], "tools": [], "frameworks": [], "arcBeats": [], "loops": [ { "to": 33, "from": 3, "loop": { "name": "11_golden_circle", "slug": "11-golden-circle", "status": "active", "bestFor": "Visionary leadership, brand positioning, mission statements", "canonId": "019dd956-6a50-7202-882d-505fcb9922ed", "version": 1, "bodyDocId": "019df22a-2420-77be-bc41-ded96d08cb21", "structure": "The Why (Belief) -> The How (Process) -> The What (Result)", "description": "Invert the typical pitch by starting with why you exist, rather than what you do", "familyLabel": null }, "matchId": "720e63ac-a674-4bf4-8e46-acf9a0a900ae", "evidence": "The presentation follows the Golden Circle framework, starting with why atai Life Sciences is working on mental health disorders (p3) and presenting their solution and traction.", "position": 1, "objective": "Why is atai Life Sciences' solution important?", "confidence": 0.7, "extraction": { "at": "2026-07-16 22:29:50.666122+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": "doc-narrative-v1" } } ], "locked": true }, { "page": 17, "type": "resolution", "title": "The slide uses a timeline-based process diagram to illustrate clinical trial protocols.", "function": "plan_implementation", "rawType": "roadmap", "block": null, "metadata": { "slideType": "roadmap", "slideTypeCanon": { "name": "Roadmap", "slug": "roadmap", "status": "active", "canonId": "019de52d-0a55-72bc-9b7b-a47ef109839c", "version": 1, "description": null }, "function": "plan_implementation", "functionCanon": { "name": "Plan implementation", "slug": "plan_implementation", "status": "active", "canonId": "019de52d-14a2-77ea-b210-d6a95eed4823", "version": 1, "description": null }, "density": "dense", "densityScore": 60, "componentCount": 5, "textChars": 542, "nDataPoints": 4, "notes": "The slide uses a timeline-based process diagram to illustrate clinical trial protocols.", "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 12:10:53.914+00", "seconds": 6.929, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de074-4969-72b8-bf99-262b9202adeb/17", "deck": "/decks/019de074-4969-72b8-bf99-262b9202adeb", "deckAnchor": "/decks/019de074-4969-72b8-bf99-262b9202adeb#slide-17", "deckJson": "/decks/019de074-4969-72b8-bf99-262b9202adeb.json" }, "components": [ { "bbox": { "h": 0.65, "w": 0.6, "x": 0.05, "y": 0.22 }, "kind": "diagram", "text": "Pivotal Phase 3 Trial Designs", "attrs": null, "canon": { "kind": { "name": "Diagram", "slug": "diagram", "status": "active", "canonId": "019de52c-f9f0-734a-81de-15382ff28c65", "version": 1, "description": "Schematic or relational diagram." }, "tool": null, "subkind": { "name": "Timeline", "slug": "timeline", "status": "active", "canonId": "019de52d-03c5-73fc-84aa-4180cbf0f5cf", "version": 1, "description": null }, "framework": null }, "subkind": "timeline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:10:53.914+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "df5dac9c-4450-4741-8b63-0bcb320acc61", "parentComponentId": null }, { "bbox": { "h": 0.1, "w": 0.2, "x": 0.76, "y": 0.315 }, "kind": "paragraph", "text": "Randomization = 2:1 Target N = 378 Topline data expected: end of 2024", "attrs": null, "canon": { "kind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "5f2affc0-941d-4d07-959d-4bfc1930cea4", "version": 1, "description": "Single prose block in the body of a slide." }, "tool": null, "subkind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "019de52c-fb80-75af-aa5c-a7a4bfac2433", "version": 1, "description": null }, "framework": null }, "subkind": "paragraph", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:10:53.914+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "145d3216-759a-49da-a983-aae304030cbc", "parentComponentId": null }, { "bbox": { "h": 0.1, "w": 0.2, "x": 0.76, "y": 0.68 }, "kind": "paragraph", "text": "Randomization = 2:1:1 Target N = 568 Topline data expected: mid-2025", "attrs": null, "canon": { "kind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "5f2affc0-941d-4d07-959d-4bfc1930cea4", "version": 1, "description": "Single prose block in the body of a slide." }, "tool": null, "subkind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "019de52c-fb80-75af-aa5c-a7a4bfac2433", "version": 1, "description": null }, "framework": null }, "subkind": "paragraph", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:10:53.914+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "89817a12-68f4-4a19-874c-0198d7e24be8", "parentComponentId": null }, { "bbox": { "h": 0.06, "w": 0.5, "x": 0.05, "y": 0.91 }, "kind": "source-note", "text": "Source: Compass Pathways Capital Markets Day presentation as of October 12, 2022. 1. Primary endpoint = Change from baseline in MADRS total score at week 6. 2. The participant population (TRD definition and core inclusion / exclusion criteria) remains unchanged compared to phase 2b", "attrs": null, "canon": { "kind": { "name": "Source note", "slug": "source-note", "status": "active", "canonId": "23484952-494b-4a5e-b1ad-550d0d70e948", "version": 1, "description": "Attribution / source / caveat placed at the slide footer. Numbered footnotes use attrs.numbered." }, "tool": null, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:10:53.914+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "68af2143-a7cf-4ea9-94e7-8b4ff10c5776", "parentComponentId": null }, { "bbox": { "h": 0.08, "w": 0.9, "x": 0.05, "y": 0.08 }, "kind": "title", "text": "COMPASS Pathways pivotal phase 3 studies are expected to deliver topline data by 2024 and 2025", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:10:53.914+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "4dc03700-4f6f-4a9c-919b-a5ee111df0dd", "parentComponentId": null } ], "metrics": [], "tools": [], "frameworks": [ { "matchId": "debb48bf-8457-4845-8ffb-3c4e7cf339c8", "evidence": "The slide uses a timeline-based visual to represent clinical trial phases and milestones.", "framework": null, "confidence": 0.7, "extraction": { "at": "2026-05-02 12:10:53.914+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 17, "frameworkName": "gantt-chart" } ], "arcBeats": [], "loops": [ { "to": 33, "from": 3, "loop": { "name": "11_golden_circle", "slug": "11-golden-circle", "status": "active", "bestFor": "Visionary leadership, brand positioning, mission statements", "canonId": "019dd956-6a50-7202-882d-505fcb9922ed", "version": 1, "bodyDocId": "019df22a-2420-77be-bc41-ded96d08cb21", "structure": "The Why (Belief) -> The How (Process) -> The What (Result)", "description": "Invert the typical pitch by starting with why you exist, rather than what you do", "familyLabel": null }, "matchId": "720e63ac-a674-4bf4-8e46-acf9a0a900ae", "evidence": "The presentation follows the Golden Circle framework, starting with why atai Life Sciences is working on mental health disorders (p3) and presenting their solution and traction.", "position": 1, "objective": "Why is atai Life Sciences' solution important?", "confidence": 0.7, "extraction": { "at": "2026-07-16 22:29:50.666122+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": "doc-narrative-v1" } } ], "locked": true }, { "page": 18, "type": "setup", "title": "The slide uses a split layout: a left-hand sidebar for product summary and a right-hand side for clinical data visualization.", "function": "summarize", "rawType": "executive_summary", "block": null, "metadata": { "slideType": "executive_summary", "slideTypeCanon": { "name": "Executive summary", "slug": "executive_summary", "status": "active", "canonId": "019de52d-06be-73ff-81b3-f99fe7f0025e", "version": 1, "description": null }, "function": "summarize", "functionCanon": { "name": "Summarize", "slug": "summarize", "status": "active", "canonId": "019de52d-1541-704f-b86f-bf7b75056373", "version": 1, "description": null }, "density": "dense", "densityScore": 61, "componentCount": 5, "textChars": 545, "nDataPoints": 8, "notes": "The slide uses a split layout: a left-hand sidebar for product summary and a right-hand side for clinical data visualization.", "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 12:10:50.255+00", "seconds": 3.227, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de074-4969-72b8-bf99-262b9202adeb/18", "deck": "/decks/019de074-4969-72b8-bf99-262b9202adeb", "deckAnchor": "/decks/019de074-4969-72b8-bf99-262b9202adeb#slide-18", "deckJson": "/decks/019de074-4969-72b8-bf99-262b9202adeb.json" }, "components": [ { "bbox": { "h": 0.6, "w": 0.6, "x": 0.37, "y": 0.25 }, "kind": "chart", "text": "Double-blind, randomized placebo-controlled trial with Ayahuasca in 29 patients with TRD", "attrs": null, "canon": { "kind": { "name": "Chart", "slug": "chart", "status": "active", "canonId": "019de52c-f9a0-76ef-adc6-0b859109d1f8", "version": 1, "description": "Quantitative chart." }, "tool": null, "subkind": { "name": "Line chart", "slug": "line", "status": "active", "canonId": "019de52c-ff62-778f-8f6c-a952ceae8677", "version": 1, "description": null }, "framework": null }, "subkind": "line", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:10:50.255+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "1694d90d-ab7d-4342-9291-cf0f8daa658f", "parentComponentId": null }, { "bbox": { "h": 0.7, "w": 0.3, "x": 0.05, "y": 0.15 }, "kind": "list", "text": "OWNERSHIP: 100% | PRODUCT: VLS-01 (DMT) | PHARMACOLOGY: 5-HT2A-R agonist | FEATURES: Rapid onset, short duration | INDICATIONS: TRD, Eating Disorders, SUD | STATUS: Phase 1 | IP: Filed provisionals | HIGHLIGHT: Improved duration/tolerability", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:10:50.255+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "af59a1dd-a864-4ecc-a801-52c9f597eb23", "parentComponentId": null }, { "bbox": { "h": 0.05, "w": 0.6, "x": 0.37, "y": 0.9 }, "kind": "source-note", "text": "Note: MADRS = Montgomery-Asberg Depression Rate Scale, DMT = Dimethyltryptamine. 1. Ownership... 2. Palhano-Fontes et al.", "attrs": null, "canon": { "kind": { "name": "Source note", "slug": "source-note", "status": "active", "canonId": "23484952-494b-4a5e-b1ad-550d0d70e948", "version": 1, "description": "Attribution / source / caveat placed at the slide footer. Numbered footnotes use attrs.numbered." }, "tool": null, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:10:50.255+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "a4386e2b-6505-4bbb-a521-c07f0eab6025", "parentComponentId": null }, { "bbox": { "h": 0.08, "w": 0.6, "x": 0.37, "y": 0.08 }, "kind": "title", "text": "VLS-01 may increase patient accessibility by reducing patient and clinic time commitment", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Action title", "slug": "action-title", "status": "active", "canonId": "019de52c-fb31-734c-a0f5-a3935b73135d", "version": 1, "description": null }, "framework": null }, "subkind": "action-title", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:10:50.255+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "0a5b181c-4f8e-4cb8-97a4-48a1df196f4f", "parentComponentId": null }, { "bbox": { "h": 0.04, "w": 0.15, "x": 0.05, "y": 0.08 }, "kind": "title", "text": "SUMMARY", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:10:50.255+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "7ba69d11-e661-4363-b4e9-248b51611db2", "parentComponentId": null } ], "metrics": [], "tools": [], "frameworks": [], "arcBeats": [], "loops": [ { "to": 33, "from": 3, "loop": { "name": "11_golden_circle", "slug": "11-golden-circle", "status": "active", "bestFor": "Visionary leadership, brand positioning, mission statements", "canonId": "019dd956-6a50-7202-882d-505fcb9922ed", "version": 1, "bodyDocId": "019df22a-2420-77be-bc41-ded96d08cb21", "structure": "The Why (Belief) -> The How (Process) -> The What (Result)", "description": "Invert the typical pitch by starting with why you exist, rather than what you do", "familyLabel": null }, "matchId": "720e63ac-a674-4bf4-8e46-acf9a0a900ae", "evidence": "The presentation follows the Golden Circle framework, starting with why atai Life Sciences is working on mental health disorders (p3) and presenting their solution and traction.", "position": 1, "objective": "Why is atai Life Sciences' solution important?", "confidence": 0.7, "extraction": { "at": "2026-07-16 22:29:50.666122+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": "doc-narrative-v1" } } ], "locked": true }, { "page": 19, "type": "setup", "title": "The slide uses a dark sidebar for product specs and a white main area for trial design and results.", "function": "summarize", "rawType": "executive_summary", "block": null, "metadata": { "slideType": "executive_summary", "slideTypeCanon": { "name": "Executive summary", "slug": "executive_summary", "status": "active", "canonId": "019de52d-06be-73ff-81b3-f99fe7f0025e", "version": 1, "description": null }, "function": "summarize", "functionCanon": { "name": "Summarize", "slug": "summarize", "status": "active", "canonId": "019de52d-1541-704f-b86f-bf7b75056373", "version": 1, "description": null }, "density": "dense", "densityScore": 72, "componentCount": 6, "textChars": 674, "nDataPoints": 6, "notes": "The slide uses a dark sidebar for product specs and a white main area for trial design and results.", "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 12:10:50.805+00", "seconds": 3.6, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de074-4969-72b8-bf99-262b9202adeb/19", "deck": "/decks/019de074-4969-72b8-bf99-262b9202adeb", "deckAnchor": "/decks/019de074-4969-72b8-bf99-262b9202adeb#slide-19", "deckJson": "/decks/019de074-4969-72b8-bf99-262b9202adeb.json" }, "components": [ { "bbox": { "h": 0.25, "w": 0.6, "x": 0.36, "y": 0.25 }, "kind": "diagram", "text": "PCN-101 Phase 2a study design flow from screening to treatment to follow-up", "attrs": null, "canon": { "kind": { "name": "Diagram", "slug": "diagram", "status": "active", "canonId": "019de52c-f9f0-734a-81de-15382ff28c65", "version": 1, "description": "Schematic or relational diagram." }, "tool": null, "subkind": { "name": "Process flow", "slug": "process", "status": "active", "canonId": "019de52d-039c-718f-ad3a-efe9c4b3c838", "version": 1, "description": null }, "framework": null }, "subkind": "process", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:10:50.805+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "88c562db-a9ab-4cbd-a53e-2e50d6d84600", "parentComponentId": null }, { "bbox": { "h": 0.08, "w": 0.6, "x": 0.36, "y": 0.9 }, "kind": "disclaimer", "text": "Note: MADRS = Montgomery-Asberg Depression Rate Scale... 1. Unless otherwise indicated... 2. Leal et al... 3. NCT05414422", "attrs": null, "canon": { "kind": { "name": "Disclaimer", "slug": "disclaimer", "status": "active", "canonId": "91173477-d91f-4024-bbaf-d4f93e3f82dc", "version": 1, "description": "Legal/cautionary text that occupies most of the body of its slide." }, "tool": null, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:10:50.805+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "06cb2faa-0ad8-4c54-929f-222784522dbf", "parentComponentId": null }, { "bbox": { "h": 0.7, "w": 0.32, "x": 0.02, "y": 0.15 }, "kind": "list", "text": "OWNERSHIP 58.9% | PRODUCT Subcutaneous R-ketamine | PHARMACOLOGY Glutamatergic modulator | FEATURES Rapid-acting, non-dissociative | INDICATIONS TRD | STATUS Phase 2a results Jan 2023 | IP Issued methods | HIGHLIGHT Third party study", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:10:50.805+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "c78b9d0d-2206-47d6-82e7-d2fae5281831", "parentComponentId": null }, { "bbox": { "h": 0.3, "w": 0.6, "x": 0.36, "y": 0.6 }, "kind": "list", "text": "1. Study did not meet primary endpoint. 2. Mean change on MADRS was -15.3 vs -13.7. 3. Encouraging signals of efficacy. 4. Generally well-tolerated.", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Numbered list", "slug": "numbered", "status": "active", "canonId": "019de52c-fcc0-7718-a284-a4250c805df2", "version": 1, "description": null }, "framework": null }, "subkind": "numbered", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:10:50.805+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "949f9670-8cbd-4f00-a661-703cf8ea9076", "parentComponentId": null }, { "bbox": { "h": 0.03, "w": 0.15, "x": 0.02, "y": 0.07 }, "kind": "title", "text": "SUMMARY", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:10:50.805+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "9e5e2a55-4cb3-4aeb-a6e1-d5afac4179ec", "parentComponentId": null }, { "bbox": { "h": 0.08, "w": 0.6, "x": 0.36, "y": 0.06 }, "kind": "title", "text": "We’ve completed a Phase 2a study for PCN-101 and are evaluating next steps for the program", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:10:50.805+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "d39f08a6-9fdc-41d8-aa7c-eb02379e4f37", "parentComponentId": null } ], "metrics": [], "tools": [], "frameworks": [], "arcBeats": [], "loops": [ { "to": 33, "from": 3, "loop": { "name": "11_golden_circle", "slug": "11-golden-circle", "status": "active", "bestFor": "Visionary leadership, brand positioning, mission statements", "canonId": "019dd956-6a50-7202-882d-505fcb9922ed", "version": 1, "bodyDocId": "019df22a-2420-77be-bc41-ded96d08cb21", "structure": "The Why (Belief) -> The How (Process) -> The What (Result)", "description": "Invert the typical pitch by starting with why you exist, rather than what you do", "familyLabel": null }, "matchId": "720e63ac-a674-4bf4-8e46-acf9a0a900ae", "evidence": "The presentation follows the Golden Circle framework, starting with why atai Life Sciences is working on mental health disorders (p3) and presenting their solution and traction.", "position": 1, "objective": "Why is atai Life Sciences' solution important?", "confidence": 0.7, "extraction": { "at": "2026-07-16 22:29:50.666122+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": "doc-narrative-v1" } } ], "locked": true }, { "page": 20, "type": "setup", "function": "transition", "rawType": "section_divider", "block": null, "metadata": { "slideType": "section_divider", "slideTypeCanon": { "name": "Section divider", "slug": "section_divider", "status": "active", "canonId": "019de52d-066a-7402-9554-6ae504999041", "version": 1, "description": null }, "function": "transition", "functionCanon": { "name": "Transition", "slug": "transition", "status": "active", "canonId": "019de52d-1365-7149-92aa-66df859e75fd", "version": 1, "description": null }, "density": "sparse", "densityScore": 2, "componentCount": 2, "textChars": 7, "nDataPoints": 0, "notes": null, "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 12:10:49.762+00", "seconds": 2.457, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de074-4969-72b8-bf99-262b9202adeb/20", "deck": "/decks/019de074-4969-72b8-bf99-262b9202adeb", "deckAnchor": "/decks/019de074-4969-72b8-bf99-262b9202adeb#slide-20", "deckJson": "/decks/019de074-4969-72b8-bf99-262b9202adeb.json" }, "components": [ { "bbox": { "h": 0.82, "w": 0.38, "x": 0.58, "y": 0.09 }, "kind": "image", "text": null, "attrs": null, "canon": { "kind": { "name": "Image", "slug": "image", "status": "active", "canonId": "019de52c-f978-701f-a720-51d029d769e7", "version": 1, "description": "Photo, illustration, screenshot or icon." }, "tool": null, "subkind": { "name": "Photo", "slug": "photo", "status": "active", "canonId": "019de52c-fd37-757f-b4a8-ca26d4888875", "version": 1, "description": null }, "framework": null }, "subkind": "photo", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:10:49.762+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "06b6a8c4-bca4-4774-a8f4-12440d67265e", "parentComponentId": null }, { "bbox": { "h": 0.1, "w": 0.2, "x": 0.05, "y": 0.45 }, "kind": "title", "text": "Anxiety", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:10:49.762+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "b026d996-7cd4-4451-9988-c6793fce7197", "parentComponentId": null } ], "metrics": [], "tools": [], "frameworks": [], "arcBeats": [], "loops": [ { "to": 33, "from": 3, "loop": { "name": "11_golden_circle", "slug": "11-golden-circle", "status": "active", "bestFor": "Visionary leadership, brand positioning, mission statements", "canonId": "019dd956-6a50-7202-882d-505fcb9922ed", "version": 1, "bodyDocId": "019df22a-2420-77be-bc41-ded96d08cb21", "structure": "The Why (Belief) -> The How (Process) -> The What (Result)", "description": "Invert the typical pitch by starting with why you exist, rather than what you do", "familyLabel": null }, "matchId": "720e63ac-a674-4bf4-8e46-acf9a0a900ae", "evidence": "The presentation follows the Golden Circle framework, starting with why atai Life Sciences is working on mental health disorders (p3) and presenting their solution and traction.", "position": 1, "objective": "Why is atai Life Sciences' solution important?", "confidence": 0.7, "extraction": { "at": "2026-07-16 22:29:50.666122+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": "doc-narrative-v1" } } ], "locked": true }, { "page": 21, "type": "tension", "title": "The slide uses a combination of a disease overview, a map-based infographic, and a vertical timeline-style list to highlight the market opportunity.", "function": "frame_problem", "rawType": "problem_statement", "block": null, "metadata": { "slideType": "problem_statement", "slideTypeCanon": { "name": "Problem statement", "slug": "problem_statement", "status": "active", "canonId": "019de52d-0879-768d-bba8-8da8a5a121d4", "version": 1, "description": null }, "function": "frame_problem", "functionCanon": { "name": "Frame problem", "slug": "frame_problem", "status": "active", "canonId": "019de52d-13db-753e-ad70-e9b2d0dab398", "version": 1, "description": null }, "density": "dense", "densityScore": 74, "componentCount": 9, "textChars": 369, "nDataPoints": 6, "notes": "The slide uses a combination of a disease overview, a map-based infographic, and a vertical timeline-style list to highlight the market opportunity.", "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 12:10:50.815+00", "seconds": 3.412, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de074-4969-72b8-bf99-262b9202adeb/21", "deck": "/decks/019de074-4969-72b8-bf99-262b9202adeb", "deckAnchor": "/decks/019de074-4969-72b8-bf99-262b9202adeb#slide-21", "deckJson": "/decks/019de074-4969-72b8-bf99-262b9202adeb.json" }, "components": [ { "bbox": { "h": 0.2, "w": 0.35, "x": 0.05, "y": 0.3 }, "kind": "image", "text": "Circles representing GAD, Panic Disorder, SAD, PTSD, OCD", "attrs": null, "canon": { "kind": { "name": "Image", "slug": "image", "status": "active", "canonId": "019de52c-f978-701f-a720-51d029d769e7", "version": 1, "description": "Photo, illustration, screenshot or icon." }, "tool": null, "subkind": { "name": "Icon grid", "slug": "icon-grid", "status": "active", "canonId": "019de52c-fdfe-749d-9990-1db465a3eed4", "version": 1, "description": null }, "framework": null }, "subkind": "icon-grid", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:10:50.815+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "fd6a5472-61ca-45d2-8a24-f4b4488bf102", "parentComponentId": null }, { "bbox": { "h": 0.25, "w": 0.25, "x": 0.05, "y": 0.6 }, "kind": "image", "text": "World map", "attrs": null, "canon": { "kind": { "name": "Image", "slug": "image", "status": "active", "canonId": "019de52c-f978-701f-a720-51d029d769e7", "version": 1, "description": "Photo, illustration, screenshot or icon." }, "tool": null, "subkind": { "name": "Map", "slug": "map", "status": "active", "canonId": "019de52c-fe4d-77bd-b0a4-d72d58b9e5a4", "version": 1, "description": null }, "framework": null }, "subkind": "map", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:10:50.815+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "314b42a8-470a-452a-8f3f-e698537d19dd", "parentComponentId": null }, { "bbox": { "h": 0.8, "w": 0.5, "x": 0.46, "y": 0.08 }, "kind": "list", "text": "Massive unaddressed need: GAD patients, low treatment rate, comorbidity, lack of novel molecules", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Timeline item", "slug": "timeline-item", "status": "active", "canonId": "019de52c-fd0e-74ce-9443-440fbd8c23b4", "version": 1, "description": null }, "framework": null }, "subkind": "timeline-item", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:10:50.815+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "42634df1-eb1e-4f99-bcd6-04f871a9b689", "parentComponentId": null }, { "bbox": { "h": 0.05, "w": 0.1, "x": 0.32, "y": 0.8 }, "kind": "metric", "text": "~$42bn", "attrs": null, "canon": { "kind": { "name": "Metric", "slug": "metric", "status": "active", "canonId": "019de52c-f923-73bf-8081-d0b1a8c5264d", "version": 1, "description": "Big-number or KPI value." }, "tool": null, "subkind": { "name": "Big number", "slug": "big-number", "status": "active", "canonId": "019de52c-fc70-70c8-b965-0584548a9204", "version": 1, "description": null }, "framework": null }, "subkind": "big-number", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:10:50.815+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "6ab50dec-8934-44b2-88cd-90d83deb1379", "parentComponentId": null }, { "bbox": { "h": 0.05, "w": 0.1, "x": 0.32, "y": 0.5 }, "kind": "metric", "text": "~40m", "attrs": null, "canon": { "kind": { "name": "Metric", "slug": "metric", "status": "active", "canonId": "019de52c-f923-73bf-8081-d0b1a8c5264d", "version": 1, "description": "Big-number or KPI value." }, "tool": null, "subkind": { "name": "Big number", "slug": "big-number", "status": "active", "canonId": "019de52c-fc70-70c8-b965-0584548a9204", "version": 1, "description": null }, "framework": null }, "subkind": "big-number", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:10:50.815+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "79408014-9793-4aa5-aef3-0a892ba46a53", "parentComponentId": null }, { "bbox": { "h": 0.05, "w": 0.1, "x": 0.32, "y": 0.65 }, "kind": "metric", "text": "#1", "attrs": null, "canon": { "kind": { "name": "Metric", "slug": "metric", "status": "active", "canonId": "019de52c-f923-73bf-8081-d0b1a8c5264d", "version": 1, "description": "Big-number or KPI value." }, "tool": null, "subkind": { "name": "Big number", "slug": "big-number", "status": "active", "canonId": "019de52c-fc70-70c8-b965-0584548a9204", "version": 1, "description": null }, "framework": null }, "subkind": "big-number", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:10:50.815+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "919dba76-2533-487b-b852-51338953afe6", "parentComponentId": null }, { "bbox": { "h": 0.05, "w": 0.9, "x": 0.05, "y": 0.92 }, "kind": "source-note", "text": "1. Anxiety and Depression Association of America (2021)...", "attrs": null, "canon": { "kind": { "name": "Source note", "slug": "source-note", "status": "active", "canonId": "23484952-494b-4a5e-b1ad-550d0d70e948", "version": 1, "description": "Attribution / source / caveat placed at the slide footer. Numbered footnotes use attrs.numbered." }, "tool": null, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:10:50.815+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "3f2e7df9-61a7-4e37-9fc2-0f25d0ecdbf4", "parentComponentId": null }, { "bbox": { "h": 0.08, "w": 0.35, "x": 0.05, "y": 0.21 }, "kind": "subtitle", "text": "Anxiety disorders develop when feelings of apprehension and unease persist over an extended period and potentially worsen over time", "attrs": null, "canon": { "kind": { "name": "Subtitle", "slug": "subtitle", "status": "active", "canonId": "82d821ee-2793-42e7-8f16-c6131385a3ce", "version": 1, "description": "Header-zone supporting text near the title (= ex body.description with bbox)." }, "tool": null, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:10:50.815+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "f3c7d65f-c30a-4457-b050-34f8d5f2cfd1", "parentComponentId": null }, { "bbox": { "h": 0.05, "w": 0.15, "x": 0.05, "y": 0.08 }, "kind": "title", "text": "Anxiety", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:10:50.815+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "8a98e474-f7f1-4db3-a62f-9146fd3ad5ef", "parentComponentId": null } ], "metrics": [], "tools": [], "frameworks": [ { "matchId": "10ecaf53-28d7-4278-a0aa-a9fd43d33299", "evidence": "Vertical list of key market statistics and pain points", "framework": null, "confidence": 0.8, "extraction": { "at": "2026-05-02 12:10:50.815+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 21, "frameworkName": "list-presentation" } ], "arcBeats": [], "loops": [ { "to": 33, "from": 3, "loop": { "name": "11_golden_circle", "slug": "11-golden-circle", "status": "active", "bestFor": "Visionary leadership, brand positioning, mission statements", "canonId": "019dd956-6a50-7202-882d-505fcb9922ed", "version": 1, "bodyDocId": "019df22a-2420-77be-bc41-ded96d08cb21", "structure": "The Why (Belief) -> The How (Process) -> The What (Result)", "description": "Invert the typical pitch by starting with why you exist, rather than what you do", "familyLabel": null }, "matchId": "720e63ac-a674-4bf4-8e46-acf9a0a900ae", "evidence": "The presentation follows the Golden Circle framework, starting with why atai Life Sciences is working on mental health disorders (p3) and presenting their solution and traction.", "position": 1, "objective": "Why is atai Life Sciences' solution important?", "confidence": 0.7, "extraction": { "at": "2026-07-16 22:29:50.666122+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": "doc-narrative-v1" } } ], "locked": true }, { "page": 22, "type": "setup", "title": "The slide uses a split-layout with a left-hand summary table and a right-hand clinical data visualization.", "function": "summarize", "rawType": "executive_summary", "block": null, "metadata": { "slideType": "executive_summary", "slideTypeCanon": { "name": "Executive summary", "slug": "executive_summary", "status": "active", "canonId": "019de52d-06be-73ff-81b3-f99fe7f0025e", "version": 1, "description": null }, "function": "summarize", "functionCanon": { "name": "Summarize", "slug": "summarize", "status": "active", "canonId": "019de52d-1541-704f-b86f-bf7b75056373", "version": 1, "description": null }, "density": "dense", "densityScore": 67, "componentCount": 6, "textChars": 476, "nDataPoints": 8, "notes": "The slide uses a split-layout with a left-hand summary table and a right-hand clinical data visualization.", "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 12:10:50.879+00", "seconds": 3.317, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de074-4969-72b8-bf99-262b9202adeb/22", "deck": "/decks/019de074-4969-72b8-bf99-262b9202adeb", "deckAnchor": "/decks/019de074-4969-72b8-bf99-262b9202adeb#slide-22", "deckJson": "/decks/019de074-4969-72b8-bf99-262b9202adeb.json" }, "components": [ { "bbox": { "h": 0.25, "w": 0.35, "x": 0.61, "y": 0.315 }, "kind": "chart", "text": "Third Party Study: Non Inferiority Test comparing Etifoxine and Lorazepam over 35 days", "attrs": null, "canon": { "kind": { "name": "Chart", "slug": "chart", "status": "active", "canonId": "019de52c-f9a0-76ef-adc6-0b859109d1f8", "version": 1, "description": "Quantitative chart." }, "tool": null, "subkind": { "name": "Grouped bar chart", "slug": "bar-grouped", "status": "active", "canonId": "019de52c-ff3b-751e-a8ff-f21ff11097b1", "version": 1, "description": null }, "framework": null }, "subkind": "bar-grouped", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:10:50.879+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "a7d7c588-80b7-4f21-af82-e052debab8c7", "parentComponentId": null }, { "bbox": { "h": 0.2, "w": 0.6, "x": 0.37, "y": 0.68 }, "kind": "diagram", "text": "Completed Phase 1 Trial: Part 1 Single Ascending Dose and Part 2 Multiple Ascending Dose", "attrs": null, "canon": { "kind": { "name": "Diagram", "slug": "diagram", "status": "active", "canonId": "019de52c-f9f0-734a-81de-15382ff28c65", "version": 1, "description": "Schematic or relational diagram." }, "tool": null, "subkind": { "name": "Process flow", "slug": "process", "status": "active", "canonId": "019de52d-039c-718f-ad3a-efe9c4b3c838", "version": 1, "description": null }, "framework": null }, "subkind": "process", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:10:50.879+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "69a237b0-6805-486f-a235-b27a1032ff13", "parentComponentId": null }, { "bbox": { "h": 0.25, "w": 0.22, "x": 0.37, "y": 0.32 }, "kind": "paragraph", "text": "Etifoxine works as rapidly as lorazepam... Etifoxine has a strong safety record...", "attrs": null, "canon": { "kind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "5f2affc0-941d-4d07-959d-4bfc1930cea4", "version": 1, "description": "Single prose block in the body of a slide." }, "tool": null, "subkind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "019de52c-fb80-75af-aa5c-a7a4bfac2433", "version": 1, "description": null }, "framework": null }, "subkind": "paragraph", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:10:50.879+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "e45c7661-7c0c-4e3a-8d6f-263b70975cdd", "parentComponentId": null }, { "bbox": { "h": 0.06, "w": 0.6, "x": 0.37, "y": 0.92 }, "kind": "source-note", "text": "Note: HAM-A = Hamilton Anxiety Rating Scale... 1. Ownership... 2. Nguyen et al... 3. Cottin et al...", "attrs": null, "canon": { "kind": { "name": "Source note", "slug": "source-note", "status": "active", "canonId": "23484952-494b-4a5e-b1ad-550d0d70e948", "version": 1, "description": "Attribution / source / caveat placed at the slide footer. Numbered footnotes use attrs.numbered." }, "tool": null, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:10:50.879+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "6d511dca-3f3f-4e0f-a3fb-26d55b7c04b4", "parentComponentId": null }, { "bbox": { "h": 0.75, "w": 0.32, "x": 0.03, "y": 0.16 }, "kind": "table", "text": "Ownership, Product, Pharmacology, Product Features, Indications, Current Status, Intellectual Property, Highlight", "attrs": null, "canon": { "kind": { "name": "Table", "slug": "table", "status": "active", "canonId": "019de52c-f9c8-7148-8119-eaac9594cd28", "version": 1, "description": "Tabular data layout." }, "tool": null, "subkind": { "name": "Data table", "slug": "data", "status": "active", "canonId": "019de52d-02d5-75b8-8abf-88e92bf63569", "version": 1, "description": null }, "framework": null }, "subkind": "data", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:10:50.879+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "459f0e2e-86cc-4e6e-b344-3f985c501f35", "parentComponentId": null }, { "bbox": { "h": 0.03, "w": 0.12, "x": 0.03, "y": 0.08 }, "kind": "title", "text": "SUMMARY", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:10:50.879+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "5f01c151-3805-42c2-bddf-741f148a78c6", "parentComponentId": null } ], "metrics": [], "tools": [], "frameworks": [], "arcBeats": [], "loops": [ { "to": 33, "from": 3, "loop": { "name": "11_golden_circle", "slug": "11-golden-circle", "status": "active", "bestFor": "Visionary leadership, brand positioning, mission statements", "canonId": "019dd956-6a50-7202-882d-505fcb9922ed", "version": 1, "bodyDocId": "019df22a-2420-77be-bc41-ded96d08cb21", "structure": "The Why (Belief) -> The How (Process) -> The What (Result)", "description": "Invert the typical pitch by starting with why you exist, rather than what you do", "familyLabel": null }, "matchId": "720e63ac-a674-4bf4-8e46-acf9a0a900ae", "evidence": "The presentation follows the Golden Circle framework, starting with why atai Life Sciences is working on mental health disorders (p3) and presenting their solution and traction.", "position": 1, "objective": "Why is atai Life Sciences' solution important?", "confidence": 0.7, "extraction": { "at": "2026-07-16 22:29:50.666122+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": "doc-narrative-v1" } } ], "locked": true }, { "page": 23, "type": "analysis", "title": "The slide uses a numbered list to highlight key safety findings alongside a detailed data table.", "function": "analyze_data", "rawType": "appendix_data", "block": null, "metadata": { "slideType": "appendix_data", "slideTypeCanon": { "name": "Appendix data", "slug": "appendix_data", "status": "active", "canonId": "019de52d-078a-745b-9ee4-c15f2f539acd", "version": 1, "description": null }, "function": "analyze_data", "functionCanon": { "name": "Analyze data", "slug": "analyze_data", "status": "active", "canonId": "019de52d-1590-7413-8c82-cc218cff40b4", "version": 1, "description": null }, "density": "dense", "densityScore": 72, "componentCount": 5, "textChars": 1355, "nDataPoints": 84, "notes": "The slide uses a numbered list to highlight key safety findings alongside a detailed data table.", "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 12:10:50.603+00", "seconds": 2.989, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de074-4969-72b8-bf99-262b9202adeb/23", "deck": "/decks/019de074-4969-72b8-bf99-262b9202adeb", "deckAnchor": "/decks/019de074-4969-72b8-bf99-262b9202adeb#slide-23", "deckJson": "/decks/019de074-4969-72b8-bf99-262b9202adeb.json" }, "components": [ { "bbox": { "h": 0.05, "w": 0.25, "x": 0.73, "y": 0.92 }, "kind": "callout", "text": "Preliminary data, subject to change", "attrs": null, "canon": { "kind": { "name": "Callout", "slug": "callout", "status": "active", "canonId": "019de52c-f8d3-761a-8953-7d37080de5e2", "version": 1, "description": "Highlighted callout box." }, "tool": null, "subkind": { "name": "Primary callout", "slug": "primary", "status": "active", "canonId": "019de52c-fbd1-70eb-a9ce-8997f8674c1d", "version": 1, "description": null }, "framework": null }, "subkind": "primary", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:10:50.603+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "fe6e726d-6714-48eb-8508-db20ea26d516", "parentComponentId": null }, { "bbox": { "h": 0.6, "w": 0.35, "x": 0.05, "y": 0.28 }, "kind": "list", "text": "1. Given every 12 hours for 7 days, GRX-917 was well-tolerated with no dose-limiting toxicities identified up to the highest dose of 300mg\n2. There were no serious adverse events reported nor dose-related discontinuations due to adverse events\n3. Adverse events in both single- and multiple-ascending dose (SAD and MAD) regimens were comparable to placebo-treated subjects\n4. No significant evidence of sedation or other benzodiazepine-like side effects at any doses tested", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Numbered list", "slug": "numbered", "status": "active", "canonId": "019de52c-fcc0-7718-a284-a4250c805df2", "version": 1, "description": null }, "framework": null }, "subkind": "numbered", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:10:50.603+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "4a5a01f4-c81a-4144-b62b-05a4b973e124", "parentComponentId": null }, { "bbox": { "h": 0.08, "w": 0.7, "x": 0.05, "y": 0.91 }, "kind": "source-note", "text": "Note: TEAE = Treatment-emergent Adverse Event, SAD = Single Ascending Dose, MAD = Multiple Ascending Dose. 1. n = number of subjects reporting at least one TEAE in that category, % = proportion of cohort total. 2. Defined as an adverse event that began after the start of trial medication treatment. 3. Non-exhaustive. Other recorded TEAEs included Upper respiratory tract infection (3%), Rash erythematous (3%), Dysmenorrhoea (3%), Catheter site pain (3%). 4. Of the 565 patients given XANAX in Ph.3 placebo-controlled trials for anxiety disorders, 41% reported drowsiness versus 22% of those administered placebo (as reported in XANAX FDA label)", "attrs": null, "canon": { "kind": { "name": "Source note", "slug": "source-note", "status": "active", "canonId": "23484952-494b-4a5e-b1ad-550d0d70e948", "version": 1, "description": "Attribution / source / caveat placed at the slide footer. Numbered footnotes use attrs.numbered." }, "tool": null, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:10:50.603+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "d5ffb505-c06e-43d6-8850-c6d89f98acd2", "parentComponentId": null }, { "bbox": { "h": 0.7, "w": 0.55, "x": 0.42, "y": 0.23 }, "kind": "table", "text": "GRX-917 Phase 1 MAD study safety data table showing TEAEs by dose group", "attrs": null, "canon": { "kind": { "name": "Table", "slug": "table", "status": "active", "canonId": "019de52c-f9c8-7148-8119-eaac9594cd28", "version": 1, "description": "Tabular data layout." }, "tool": null, "subkind": { "name": "Data table", "slug": "data", "status": "active", "canonId": "019de52d-02d5-75b8-8abf-88e92bf63569", "version": 1, "description": null }, "framework": null }, "subkind": "data", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:10:50.603+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "dfda47c2-3080-4e88-8a0b-5f5524121e77", "parentComponentId": null }, { "bbox": { "h": 0.1, "w": 0.85, "x": 0.05, "y": 0.08 }, "kind": "title", "text": "GRX-917 Phase 1 data: No severe or serious adverse events, with minimal sedation or dizziness, confirms favourable safety profile", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:10:50.603+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "4eecca1e-c02f-44ae-b001-19902a981163", "parentComponentId": null } ], "metrics": [], "tools": [], "frameworks": [], "arcBeats": [], "loops": [ { "to": 33, "from": 3, "loop": { "name": "11_golden_circle", "slug": "11-golden-circle", "status": "active", "bestFor": "Visionary leadership, brand positioning, mission statements", "canonId": "019dd956-6a50-7202-882d-505fcb9922ed", "version": 1, "bodyDocId": "019df22a-2420-77be-bc41-ded96d08cb21", "structure": "The Why (Belief) -> The How (Process) -> The What (Result)", "description": "Invert the typical pitch by starting with why you exist, rather than what you do", "familyLabel": null }, "matchId": "720e63ac-a674-4bf4-8e46-acf9a0a900ae", "evidence": "The presentation follows the Golden Circle framework, starting with why atai Life Sciences is working on mental health disorders (p3) and presenting their solution and traction.", "position": 1, "objective": "Why is atai Life Sciences' solution important?", "confidence": 0.7, "extraction": { "at": "2026-07-16 22:29:50.666122+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": "doc-narrative-v1" } } ], "locked": true }, { "page": 24, "type": "evidence", "title": "The slide uses topographical brain maps to visualize EEG data changes across three cohorts.", "function": "analyze_data", "rawType": "traction", "block": null, "metadata": { "slideType": "traction", "slideTypeCanon": { "name": "Traction", "slug": "traction", "status": "active", "canonId": "019de52d-0edd-72ab-820f-3ebc71a9c542", "version": 1, "description": null }, "function": "analyze_data", "functionCanon": { "name": "Analyze data", "slug": "analyze_data", "status": "active", "canonId": "019de52d-1590-7413-8c82-cc218cff40b4", "version": 1, "description": null }, "density": "dense", "densityScore": 62, "componentCount": 5, "textChars": 619, "nDataPoints": 3, "notes": "The slide uses topographical brain maps to visualize EEG data changes across three cohorts.", "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 12:10:50.434+00", "seconds": 2.55, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de074-4969-72b8-bf99-262b9202adeb/24", "deck": "/decks/019de074-4969-72b8-bf99-262b9202adeb", "deckAnchor": "/decks/019de074-4969-72b8-bf99-262b9202adeb#slide-24", "deckJson": "/decks/019de074-4969-72b8-bf99-262b9202adeb.json" }, "components": [ { "bbox": { "h": 0.05, "w": 0.2, "x": 0.75, "y": 0.92 }, "kind": "callout", "text": "Preliminary data, subject to change", "attrs": null, "canon": { "kind": { "name": "Callout", "slug": "callout", "status": "active", "canonId": "019de52c-f8d3-761a-8953-7d37080de5e2", "version": 1, "description": "Highlighted callout box." }, "tool": null, "subkind": { "name": "Primary callout", "slug": "primary", "status": "active", "canonId": "019de52c-fbd1-70eb-a9ce-8997f8674c1d", "version": 1, "description": null }, "framework": null }, "subkind": "primary", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:10:50.434+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "33afa377-6102-4740-bf01-53e6eedeea62", "parentComponentId": null }, { "bbox": { "h": 0.55, "w": 0.9, "x": 0.05, "y": 0.25 }, "kind": "chart", "text": "Changes in Beta power from pre-dose to 3-hour post-dose", "attrs": null, "canon": { "kind": { "name": "Chart", "slug": "chart", "status": "active", "canonId": "019de52c-f9a0-76ef-adc6-0b859109d1f8", "version": 1, "description": "Quantitative chart." }, "tool": null, "subkind": { "name": "Heatmap", "slug": "heatmap", "status": "active", "canonId": "019de52d-00cd-71ee-bf36-233b7817c304", "version": 1, "description": null }, "framework": null }, "subkind": "heatmap", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:10:50.434+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "0d7aece6-1698-4650-96c5-7dcc6fc92f16", "parentComponentId": null }, { "bbox": { "h": 0.08, "w": 0.9, "x": 0.05, "y": 0.84 }, "kind": "paragraph", "text": "Channels with significant differences (paired t-test; p<0.05, after FDR correction for multiple comparison) are marked with black circles. Topographical maps show distribution of beta power (13-30 Hz) across the scalp.", "attrs": null, "canon": { "kind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "5f2affc0-941d-4d07-959d-4bfc1930cea4", "version": 1, "description": "Single prose block in the body of a slide." }, "tool": null, "subkind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "019de52c-fb80-75af-aa5c-a7a4bfac2433", "version": 1, "description": null }, "framework": null }, "subkind": "paragraph", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:10:50.434+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "0784abc3-42b1-4ab9-a996-c8dbc5876d57", "parentComponentId": null }, { "bbox": { "h": 0.05, "w": 0.3, "x": 0.05, "y": 0.92 }, "kind": "source-note", "text": "Note: FDR = False Discovery Rate, EEG = Electroencephalogram. 1. Power is NOT in log scale and the unit of measurement is uV2. 2. Given twice daily every 12 hours", "attrs": null, "canon": { "kind": { "name": "Source note", "slug": "source-note", "status": "active", "canonId": "23484952-494b-4a5e-b1ad-550d0d70e948", "version": 1, "description": "Attribution / source / caveat placed at the slide footer. Numbered footnotes use attrs.numbered." }, "tool": null, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:10:50.434+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "7df90d20-ed5c-447a-8e6c-2ce14372f054", "parentComponentId": null }, { "bbox": { "h": 0.1, "w": 0.9, "x": 0.05, "y": 0.08 }, "kind": "title", "text": "GRX-917 Phase 1 data: Dose-dependent increase in frontal beta power was demonstrated, providing evidence of target engagement and mechanism of action", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:10:50.434+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "674d47aa-640f-4fe8-aae2-b4e352ab4849", "parentComponentId": null } ], "metrics": [], "tools": [ { "tool": { "name": "Waterfall chart", "slug": "waterfall-chart", "status": "active", "bestFor": null, "canonId": "e2799da3-725f-44a9-a093-570f1f388e64", "version": 1, "bodyDocId": null, "description": null, "familyLabel": null, "categoryName": null, "categorySlug": null }, "agent": null, "layer": "slide", "agents": null, "matchId": "f08cae56-9781-473c-9556-4822d5ca2eb9", "evidence": "Changes in Beta power from pre-dose to 3-hour post-dose", "pageRefs": null, "priority": null, "whenToUse": null, "confidence": 0.7, "extraction": { "at": "2026-07-17 00:18:17.811643+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 24, "whyItWorks": null, "antipattern": null, "cardinality": null, "narrativePurpose": null } ], "frameworks": [], "arcBeats": [], "loops": [ { "to": 33, "from": 3, "loop": { "name": "11_golden_circle", "slug": "11-golden-circle", "status": "active", "bestFor": "Visionary leadership, brand positioning, mission statements", "canonId": "019dd956-6a50-7202-882d-505fcb9922ed", "version": 1, "bodyDocId": "019df22a-2420-77be-bc41-ded96d08cb21", "structure": "The Why (Belief) -> The How (Process) -> The What (Result)", "description": "Invert the typical pitch by starting with why you exist, rather than what you do", "familyLabel": null }, "matchId": "720e63ac-a674-4bf4-8e46-acf9a0a900ae", "evidence": "The presentation follows the Golden Circle framework, starting with why atai Life Sciences is working on mental health disorders (p3) and presenting their solution and traction.", "position": 1, "objective": "Why is atai Life Sciences' solution important?", "confidence": 0.7, "extraction": { "at": "2026-07-16 22:29:50.666122+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": "doc-narrative-v1" } } ], "locked": true }, { "page": 25, "type": "evidence", "title": "The chart uses error bars and statistical significance markers (asterisks) to compare dose groups against a zero baseline.", "function": "analyze_data", "rawType": "traction", "block": null, "metadata": { "slideType": "traction", "slideTypeCanon": { "name": "Traction", "slug": "traction", "status": "active", "canonId": "019de52d-0edd-72ab-820f-3ebc71a9c542", "version": 1, "description": null }, "function": "analyze_data", "functionCanon": { "name": "Analyze data", "slug": "analyze_data", "status": "active", "canonId": "019de52d-1590-7413-8c82-cc218cff40b4", "version": 1, "description": null }, "density": "balanced", "densityScore": 49, "componentCount": 4, "textChars": 423, "nDataPoints": 14, "notes": "The chart uses error bars and statistical significance markers (asterisks) to compare dose groups against a zero baseline.", "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 12:10:50.845+00", "seconds": 2.76, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de074-4969-72b8-bf99-262b9202adeb/25", "deck": "/decks/019de074-4969-72b8-bf99-262b9202adeb", "deckAnchor": "/decks/019de074-4969-72b8-bf99-262b9202adeb#slide-25", "deckJson": "/decks/019de074-4969-72b8-bf99-262b9202adeb.json" }, "components": [ { "bbox": { "h": 0.6, "w": 0.6, "x": 0.05, "y": 0.26 }, "kind": "chart", "text": "Group average changes in Beta power for low dose and high dose groups per time point", "attrs": null, "canon": { "kind": { "name": "Chart", "slug": "chart", "status": "active", "canonId": "019de52c-f9a0-76ef-adc6-0b859109d1f8", "version": 1, "description": "Quantitative chart." }, "tool": null, "subkind": { "name": "Grouped bar chart", "slug": "bar-grouped", "status": "active", "canonId": "019de52c-ff3b-751e-a8ff-f21ff11097b1", "version": 1, "description": null }, "framework": null }, "subkind": "bar-grouped", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:10:50.845+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "6ca19853-3253-4d3d-9af0-6cf47e33bada", "parentComponentId": null }, { "bbox": { "h": 0.05, "w": 0.25, "x": 0.73, "y": 0.92 }, "kind": "disclaimer", "text": "Preliminary data, subject to change", "attrs": null, "canon": { "kind": { "name": "Disclaimer", "slug": "disclaimer", "status": "active", "canonId": "91173477-d91f-4024-bbaf-d4f93e3f82dc", "version": 1, "description": "Legal/cautionary text that occupies most of the body of its slide." }, "tool": null, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:10:50.845+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "8682f822-5a19-451c-a61d-2762a5222401", "parentComponentId": null }, { "bbox": { "h": 0.2, "w": 0.3, "x": 0.65, "y": 0.5 }, "kind": "list", "text": "Average differences in each time point is compared to zero and time points with significant changes (t-test, p<.05) were marked with asterisk * p<.05 ** p<.01 *** p<.001", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:10:50.845+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "edde558f-4e4e-44e8-98da-024f966b2e9c", "parentComponentId": null }, { "bbox": { "h": 0.15, "w": 0.9, "x": 0.05, "y": 0.08 }, "kind": "title", "text": "GRX-917 Phase 1 data: The EEG beta effect was also time-dependent, showing a rapid onset of effect with a delayed pharmacodynamic curve", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:10:50.845+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "13fa5f05-d5f6-46fd-80af-57547c4a2c1a", "parentComponentId": null } ], "metrics": [], "tools": [], "frameworks": [], "arcBeats": [], "loops": [ { "to": 33, "from": 3, "loop": { "name": "11_golden_circle", "slug": "11-golden-circle", "status": "active", "bestFor": "Visionary leadership, brand positioning, mission statements", "canonId": "019dd956-6a50-7202-882d-505fcb9922ed", "version": 1, "bodyDocId": "019df22a-2420-77be-bc41-ded96d08cb21", "structure": "The Why (Belief) -> The How (Process) -> The What (Result)", "description": "Invert the typical pitch by starting with why you exist, rather than what you do", "familyLabel": null }, "matchId": "720e63ac-a674-4bf4-8e46-acf9a0a900ae", "evidence": "The presentation follows the Golden Circle framework, starting with why atai Life Sciences is working on mental health disorders (p3) and presenting their solution and traction.", "position": 1, "objective": "Why is atai Life Sciences' solution important?", "confidence": 0.7, "extraction": { "at": "2026-07-16 22:29:50.666122+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": "doc-narrative-v1" } } ], "locked": true }, { "page": 26, "type": "setup", "title": "The table uses checkmarks to indicate positive attributes across different drug classes.", "function": "compare_peers", "rawType": "competitive_analysis", "block": null, "metadata": { "slideType": "competitive_analysis", "slideTypeCanon": { "name": "Competitive analysis", "slug": "competitive_analysis", "status": "active", "canonId": "019de52d-093e-776b-94c6-c1573f5f1a31", "version": 1, "description": null }, "function": "compare_peers", "functionCanon": { "name": "Compare peers", "slug": "compare_peers", "status": "active", "canonId": "019de52d-1453-72ba-a367-9ba3d34c1630", "version": 1, "description": null }, "density": "dense", "densityScore": 70, "componentCount": 5, "textChars": 992, "nDataPoints": 18, "notes": "The table uses checkmarks to indicate positive attributes across different drug classes.", "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 12:10:57.559+00", "seconds": 9.446, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de074-4969-72b8-bf99-262b9202adeb/26", "deck": "/decks/019de074-4969-72b8-bf99-262b9202adeb", "deckAnchor": "/decks/019de074-4969-72b8-bf99-262b9202adeb#slide-26", "deckJson": "/decks/019de074-4969-72b8-bf99-262b9202adeb.json" }, "components": [ { "bbox": { "h": 0.2, "w": 0.2, "x": 0.03, "y": 0.75 }, "kind": "paragraph", "text": "Benzodiazepines are second-line treatment, offering fast and effective relief, but carrying significant risk of: 1. Sedation 2. Impaired cognition 3. Dependence/addiction", "attrs": null, "canon": { "kind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "5f2affc0-941d-4d07-959d-4bfc1930cea4", "version": 1, "description": "Single prose block in the body of a slide." }, "tool": null, "subkind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "019de52c-fb80-75af-aa5c-a7a4bfac2433", "version": 1, "description": null }, "framework": null }, "subkind": "paragraph", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:10:57.559+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "a25a1785-2a39-46b2-bdac-55aaebc365f3", "parentComponentId": null }, { "bbox": { "h": 0.25, "w": 0.2, "x": 0.03, "y": 0.22 }, "kind": "paragraph", "text": "There is an unmet need in GAD for therapies with rapid onset, high efficacy, and minimal side effects. SSRI/SNRI's are current standard of care for GAD but require 4-6 weeks for onset of effect and have several disadvantages.", "attrs": null, "canon": { "kind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "5f2affc0-941d-4d07-959d-4bfc1930cea4", "version": 1, "description": "Single prose block in the body of a slide." }, "tool": null, "subkind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "019de52c-fb80-75af-aa5c-a7a4bfac2433", "version": 1, "description": null }, "framework": null }, "subkind": "paragraph", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:10:57.559+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "f2189361-d76f-4cce-944c-454a534f4193", "parentComponentId": null }, { "bbox": { "h": 0.08, "w": 0.7, "x": 0.25, "y": 0.9 }, "kind": "source-note", "text": "Note: GABA = Gamma aminobutyric acid, SERT = serotonin transporter, NET = serotonin transporter; MoA = Mechanism of Action; 5HT1a = serotonin 1A receptor; VDCC = voltage dependent calcium channel; TSPO = mitochondrial translocator protein. Source: Publicly available information, including company websites and clinicaltrials.gov, GlobalData, Evaluate Pharma (both as of 2022). 1. DeMartini et al., “Generalized Anxiety Disorder” (2019)", "attrs": null, "canon": { "kind": { "name": "Source note", "slug": "source-note", "status": "active", "canonId": "23484952-494b-4a5e-b1ad-550d0d70e948", "version": 1, "description": "Attribution / source / caveat placed at the slide footer. Numbered footnotes use attrs.numbered." }, "tool": null, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:10:57.559+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "5b587dc2-5515-48d2-ae9b-e336e5d04005", "parentComponentId": null }, { "bbox": { "h": 0.65, "w": 0.7, "x": 0.25, "y": 0.2 }, "kind": "table", "text": "Comparison table of GAD therapeutic options", "attrs": null, "canon": { "kind": { "name": "Table", "slug": "table", "status": "active", "canonId": "019de52c-f9c8-7148-8119-eaac9594cd28", "version": 1, "description": "Tabular data layout." }, "tool": null, "subkind": { "name": "Data table", "slug": "data", "status": "active", "canonId": "019de52d-02d5-75b8-8abf-88e92bf63569", "version": 1, "description": null }, "framework": null }, "subkind": "data", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:10:57.559+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "560d4421-f6f0-417b-ab7e-830f554e778e", "parentComponentId": null }, { "bbox": { "h": 0.1, "w": 0.7, "x": 0.25, "y": 0.05 }, "kind": "title", "text": "GRX-917 is developed to address unmet need in Generalized Anxiety Disorder (GAD) with rapid onset and favorable safety", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:10:57.559+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "14ff62a7-9632-4e15-b31b-533debc80e4e", "parentComponentId": null } ], "metrics": [], "tools": [], "frameworks": [ { "matchId": "f93d404e-2f7c-4f8f-a711-ef67a9157c88", "evidence": "The slide presents a structured comparison of drug classes against specific criteria.", "framework": null, "confidence": 1, "extraction": { "at": "2026-05-02 12:10:57.559+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 26, "frameworkName": "comparison_table" } ], "arcBeats": [], "loops": [ { "to": 33, "from": 3, "loop": { "name": "11_golden_circle", "slug": "11-golden-circle", "status": "active", "bestFor": "Visionary leadership, brand positioning, mission statements", "canonId": "019dd956-6a50-7202-882d-505fcb9922ed", "version": 1, "bodyDocId": "019df22a-2420-77be-bc41-ded96d08cb21", "structure": "The Why (Belief) -> The How (Process) -> The What (Result)", "description": "Invert the typical pitch by starting with why you exist, rather than what you do", "familyLabel": null }, "matchId": "720e63ac-a674-4bf4-8e46-acf9a0a900ae", "evidence": "The presentation follows the Golden Circle framework, starting with why atai Life Sciences is working on mental health disorders (p3) and presenting their solution and traction.", "position": 1, "objective": "Why is atai Life Sciences' solution important?", "confidence": 0.7, "extraction": { "at": "2026-07-16 22:29:50.666122+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": "doc-narrative-v1" } } ], "locked": true }, { "page": 27, "type": "setup", "function": "transition", "rawType": "section_divider", "block": null, "metadata": { "slideType": "section_divider", "slideTypeCanon": { "name": "Section divider", "slug": "section_divider", "status": "active", "canonId": "019de52d-066a-7402-9554-6ae504999041", "version": 1, "description": null }, "function": "transition", "functionCanon": { "name": "Transition", "slug": "transition", "status": "active", "canonId": "019de52d-1365-7149-92aa-66df859e75fd", "version": 1, "description": null }, "density": "sparse", "densityScore": 3, "componentCount": 2, "textChars": 22, "nDataPoints": 0, "notes": null, "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 12:10:49.603+00", "seconds": 1.474, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de074-4969-72b8-bf99-262b9202adeb/27", "deck": "/decks/019de074-4969-72b8-bf99-262b9202adeb", "deckAnchor": "/decks/019de074-4969-72b8-bf99-262b9202adeb#slide-27", "deckJson": "/decks/019de074-4969-72b8-bf99-262b9202adeb.json" }, "components": [ { "bbox": { "h": 0.9, "w": 0.4, "x": 0.55, "y": 0.05 }, "kind": "image", "text": null, "attrs": null, "canon": { "kind": { "name": "Image", "slug": "image", "status": "active", "canonId": "019de52c-f978-701f-a720-51d029d769e7", "version": 1, "description": "Photo, illustration, screenshot or icon." }, "tool": null, "subkind": { "name": "Photo", "slug": "photo", "status": "active", "canonId": "019de52c-fd37-757f-b4a8-ca26d4888875", "version": 1, "description": null }, "framework": null }, "subkind": "photo", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:10:49.603+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "00e96977-da37-4b2d-a42d-38baf4f7adbe", "parentComponentId": null }, { "bbox": { "h": 0.3, "w": 0.3, "x": 0.05, "y": 0.35 }, "kind": "title", "text": "Substance Use Disorder", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:10:49.603+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "e1518298-f247-4301-a892-86e97a7e32e0", "parentComponentId": null } ], "metrics": [], "tools": [], "frameworks": [], "arcBeats": [], "loops": [ { "to": 33, "from": 3, "loop": { "name": "11_golden_circle", "slug": "11-golden-circle", "status": "active", "bestFor": "Visionary leadership, brand positioning, mission statements", "canonId": "019dd956-6a50-7202-882d-505fcb9922ed", "version": 1, "bodyDocId": "019df22a-2420-77be-bc41-ded96d08cb21", "structure": "The Why (Belief) -> The How (Process) -> The What (Result)", "description": "Invert the typical pitch by starting with why you exist, rather than what you do", "familyLabel": null }, "matchId": "720e63ac-a674-4bf4-8e46-acf9a0a900ae", "evidence": "The presentation follows the Golden Circle framework, starting with why atai Life Sciences is working on mental health disorders (p3) and presenting their solution and traction.", "position": 1, "objective": "Why is atai Life Sciences' solution important?", "confidence": 0.7, "extraction": { "at": "2026-07-16 22:29:50.666122+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": "doc-narrative-v1" } } ], "locked": true }, { "page": 28, "type": "tension", "title": "Uses a timeline-style visual to list key statistics about the OUD crisis.", "function": "frame_problem", "rawType": "problem_statement", "block": null, "metadata": { "slideType": "problem_statement", "slideTypeCanon": { "name": "Problem statement", "slug": "problem_statement", "status": "active", "canonId": "019de52d-0879-768d-bba8-8da8a5a121d4", "version": 1, "description": null }, "function": "frame_problem", "functionCanon": { "name": "Frame problem", "slug": "frame_problem", "status": "active", "canonId": "019de52d-13db-753e-ad70-e9b2d0dab398", "version": 1, "description": null }, "density": "dense", "densityScore": 51, "componentCount": 5, "textChars": 332, "nDataPoints": 7, "notes": "Uses a timeline-style visual to list key statistics about the OUD crisis.", "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 12:10:50.974+00", "seconds": 2.798, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de074-4969-72b8-bf99-262b9202adeb/28", "deck": "/decks/019de074-4969-72b8-bf99-262b9202adeb", "deckAnchor": "/decks/019de074-4969-72b8-bf99-262b9202adeb#slide-28", "deckJson": "/decks/019de074-4969-72b8-bf99-262b9202adeb.json" }, "components": [ { "bbox": { "h": 0.4, "w": 0.4, "x": 0.05, "y": 0.5 }, "kind": "chart", "text": "SUD in numbers", "attrs": null, "canon": { "kind": { "name": "Chart", "slug": "chart", "status": "active", "canonId": "019de52c-f9a0-76ef-adc6-0b859109d1f8", "version": 1, "description": "Quantitative chart." }, "tool": null, "subkind": { "name": "Vertical bar chart", "slug": "bar-vertical", "status": "active", "canonId": "019de52c-fe9d-70f2-b3b7-a9ae294f5917", "version": 1, "description": null }, "framework": null }, "subkind": "bar-vertical", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:10:50.974+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "73e6d8fa-0bf1-476a-9a97-089bb74110d6", "parentComponentId": null }, { "bbox": { "h": 0.8, "w": 0.45, "x": 0.5, "y": 0.1 }, "kind": "diagram", "text": "An ongoing pandemic", "attrs": null, "canon": { "kind": { "name": "Diagram", "slug": "diagram", "status": "active", "canonId": "019de52c-f9f0-734a-81de-15382ff28c65", "version": 1, "description": "Schematic or relational diagram." }, "tool": null, "subkind": { "name": "Timeline", "slug": "timeline", "status": "active", "canonId": "019de52d-03c5-73fc-84aa-4180cbf0f5cf", "version": 1, "description": null }, "framework": null }, "subkind": "timeline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:10:50.974+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "e1d1abc3-747f-4c47-9fe9-a860033e88bc", "parentComponentId": null }, { "bbox": { "h": 0.05, "w": 0.9, "x": 0.05, "y": 0.92 }, "kind": "source-note", "text": "1. SAMSHA... 2. Azadfard... 3. Ahmad... 4. Murphy... 5. Sinha... 6. National Center...", "attrs": null, "canon": { "kind": { "name": "Source note", "slug": "source-note", "status": "active", "canonId": "23484952-494b-4a5e-b1ad-550d0d70e948", "version": 1, "description": "Attribution / source / caveat placed at the slide footer. Numbered footnotes use attrs.numbered." }, "tool": null, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:10:50.974+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "5974d009-a8df-469f-b117-66cb7f4ce74b", "parentComponentId": null }, { "bbox": { "h": 0.08, "w": 0.4, "x": 0.05, "y": 0.21 }, "kind": "subtitle", "text": "Substance use disorders are highly prevalent disorders characterized by an inability to control the use of a legal or illegal drugs, alcohol, or medications (e.g., prescription opioids)", "attrs": null, "canon": { "kind": { "name": "Subtitle", "slug": "subtitle", "status": "active", "canonId": "82d821ee-2793-42e7-8f16-c6131385a3ce", "version": 1, "description": "Header-zone supporting text near the title (= ex body.description with bbox)." }, "tool": null, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:10:50.974+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "e605aa56-ec39-46c8-b765-99af97d1f514", "parentComponentId": null }, { "bbox": { "h": 0.04, "w": 0.35, "x": 0.05, "y": 0.08 }, "kind": "title", "text": "Substance Use Disorder (SUD)", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:10:50.974+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "94108634-642b-44d5-8fab-a69e8e0a9496", "parentComponentId": null } ], "metrics": [], "tools": [ { "tool": { "name": "Problem Statement Canvas", "slug": "problem-statement-canvas", "status": "active", "bestFor": null, "canonId": "019dd956-839d-744b-ad11-9bf3e3642a18", "version": 1, "bodyDocId": null, "description": "Structured definition of the problem: What? Who? Where? When? Scale?", "familyLabel": null, "categoryName": "Block", "categorySlug": "block" }, "agent": "Architect", "layer": "slide", "agents": [ "Architect" ], "matchId": "8d55921f-ab1b-4bcc-bc84-9a7657b2a283", "evidence": "Substance use disorders are highly prevalent disorders characterized by an inability to control the use of a legal or illegal drugs, alcohol, or medications", "pageRefs": null, "priority": null, "whenToUse": null, "confidence": 0.5, "extraction": { "at": "2026-07-17 00:18:17.984875+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 28, "whyItWorks": null, "antipattern": null, "cardinality": null, "narrativePurpose": null } ], "frameworks": [ { "matchId": "3e1da3c9-19a3-4b77-a0c7-1075a8329cb1", "evidence": "Vertical sequence of data points describing the progression of the pandemic", "framework": null, "confidence": 0.8, "extraction": { "at": "2026-05-02 12:10:50.974+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 28, "frameworkName": "timeline" } ], "arcBeats": [], "loops": [ { "to": 33, "from": 3, "loop": { "name": "11_golden_circle", "slug": "11-golden-circle", "status": "active", "bestFor": "Visionary leadership, brand positioning, mission statements", "canonId": "019dd956-6a50-7202-882d-505fcb9922ed", "version": 1, "bodyDocId": "019df22a-2420-77be-bc41-ded96d08cb21", "structure": "The Why (Belief) -> The How (Process) -> The What (Result)", "description": "Invert the typical pitch by starting with why you exist, rather than what you do", "familyLabel": null }, "matchId": "720e63ac-a674-4bf4-8e46-acf9a0a900ae", "evidence": "The presentation follows the Golden Circle framework, starting with why atai Life Sciences is working on mental health disorders (p3) and presenting their solution and traction.", "position": 1, "objective": "Why is atai Life Sciences' solution important?", "confidence": 0.7, "extraction": { "at": "2026-07-16 22:29:50.666122+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": "doc-narrative-v1" } } ], "locked": true }, { "page": 29, "type": "setup", "title": "The slide uses a split-layout: a left-hand sidebar for company/product facts and a right-hand main area for clinical data and trial design.", "function": "summarize", "rawType": "executive_summary", "block": null, "metadata": { "slideType": "executive_summary", "slideTypeCanon": { "name": "Executive summary", "slug": "executive_summary", "status": "active", "canonId": "019de52d-06be-73ff-81b3-f99fe7f0025e", "version": 1, "description": null }, "function": "summarize", "functionCanon": { "name": "Summarize", "slug": "summarize", "status": "active", "canonId": "019de52d-1541-704f-b86f-bf7b75056373", "version": 1, "description": null }, "density": "dense", "densityScore": 72, "componentCount": 6, "textChars": 637, "nDataPoints": 12, "notes": "The slide uses a split-layout: a left-hand sidebar for company/product facts and a right-hand main area for clinical data and trial design.", "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 12:10:55.75+00", "seconds": 7.058, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de074-4969-72b8-bf99-262b9202adeb/29", "deck": "/decks/019de074-4969-72b8-bf99-262b9202adeb", "deckAnchor": "/decks/019de074-4969-72b8-bf99-262b9202adeb#slide-29", "deckJson": "/decks/019de074-4969-72b8-bf99-262b9202adeb.json" }, "components": [ { "bbox": { "h": 0.28, "w": 0.58, "x": 0.37, "y": 0.28 }, "kind": "chart", "text": "Prior evidence in humans (third party study) showing HCQN subscale reduction over time", "attrs": null, "canon": { "kind": { "name": "Chart", "slug": "chart", "status": "active", "canonId": "019de52c-f9a0-76ef-adc6-0b859109d1f8", "version": 1, "description": "Quantitative chart." }, "tool": null, "subkind": { "name": "Line chart", "slug": "line", "status": "active", "canonId": "019de52c-ff62-778f-8f6c-a952ceae8677", "version": 1, "description": null }, "framework": null }, "subkind": "line", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:10:55.75+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "7d5f0d77-30de-4926-9936-9654e4f4686b", "parentComponentId": null }, { "bbox": { "h": 0.22, "w": 0.58, "x": 0.37, "y": 0.68 }, "kind": "diagram", "text": "Ongoing Phase 1/2 trial structure: Stage 1 (Max Tolerated Dose) and Stage 2 (Proof of Concept)", "attrs": null, "canon": { "kind": { "name": "Diagram", "slug": "diagram", "status": "active", "canonId": "019de52c-f9f0-734a-81de-15382ff28c65", "version": 1, "description": "Schematic or relational diagram." }, "tool": null, "subkind": { "name": "Process flow", "slug": "process", "status": "active", "canonId": "019de52d-039c-718f-ad3a-efe9c4b3c838", "version": 1, "description": null }, "framework": null }, "subkind": "process", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:10:55.75+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "d0a1489b-6bee-4cf9-97e9-1771ecf3230c", "parentComponentId": null }, { "bbox": { "h": 0.06, "w": 0.6, "x": 0.37, "y": 0.91 }, "kind": "disclaimer", "text": "Note: HCQN = Heroin Craving Questionnaire, PK = Pharmacokinetics. 1. Ownership percentage... 2. Mash et al., 'Ibogaine Detoxification...'", "attrs": null, "canon": { "kind": { "name": "Disclaimer", "slug": "disclaimer", "status": "active", "canonId": "91173477-d91f-4024-bbaf-d4f93e3f82dc", "version": 1, "description": "Legal/cautionary text that occupies most of the body of its slide." }, "tool": null, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:10:55.75+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "e791f66d-32c6-4cd5-a6bc-727da7c4f529", "parentComponentId": null }, { "bbox": { "h": 0.75, "w": 0.33, "x": 0.03, "y": 0.15 }, "kind": "table", "text": "Ownership: 59.5%, Product: DMX-1002, Pharmacology: Receptor modulator, Features: Rapid withdrawal, Indications: OUD/PTSD/TBI, Status: Phase 1/2, IP: Pending claims, Highlight: Sustained reduction", "attrs": null, "canon": { "kind": { "name": "Table", "slug": "table", "status": "active", "canonId": "019de52c-f9c8-7148-8119-eaac9594cd28", "version": 1, "description": "Tabular data layout." }, "tool": null, "subkind": { "name": "Data table", "slug": "data", "status": "active", "canonId": "019de52d-02d5-75b8-8abf-88e92bf63569", "version": 1, "description": null }, "framework": null }, "subkind": "data", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:10:55.75+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "293479dc-162c-42da-8769-b28ae07f324f", "parentComponentId": null }, { "bbox": { "h": 0.08, "w": 0.6, "x": 0.37, "y": 0.07 }, "kind": "title", "text": "A single-dose of ibogaine showed potential for sustained reductions in opioid cravings in 75 opioid-dependent patients", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Action title", "slug": "action-title", "status": "active", "canonId": "019de52c-fb31-734c-a0f5-a3935b73135d", "version": 1, "description": null }, "framework": null }, "subkind": "action-title", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:10:55.75+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "a1cf7064-3254-4c8f-bcbd-d15dce68331b", "parentComponentId": null }, { "bbox": { "h": 0.03, "w": 0.13, "x": 0.03, "y": 0.07 }, "kind": "title", "text": "SUMMARY", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:10:55.75+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "eac87db3-5a43-411a-bf4b-8e78ea3d227c", "parentComponentId": null } ], "metrics": [], "tools": [ { "tool": { "name": "Executive summary", "slug": "executive-summary", "status": "active", "bestFor": null, "canonId": "019dd9e1-4b63-72d5-9734-da757d91ca61", "version": 1, "bodyDocId": null, "description": "A condensed view of the entire argument on a single slide / block.", "familyLabel": null, "categoryName": null, "categorySlug": null }, "agent": null, "layer": "slide", "agents": null, "matchId": "3babbeb7-6df0-407b-b922-0eee0caa4de4", "evidence": "table/data: Ownership: 59.5%, Product: DMX-1002, Pharmacology: Receptor modulator, Features: Rapid withdrawal, Indications: OUD/PTSD/TBI, Status: Phase 1/2, IP: Pending claims, Highlight: Sustained reduction", "pageRefs": null, "priority": null, "whenToUse": null, "confidence": 0.7, "extraction": { "at": "2026-07-17 00:18:18.069712+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 29, "whyItWorks": null, "antipattern": null, "cardinality": "common", "narrativePurpose": null } ], "frameworks": [ { "matchId": "7e86220d-7140-43a1-9bde-e915b929da1a", "evidence": "Structured as a high-level summary of company and clinical data.", "framework": null, "confidence": 1, "extraction": { "at": "2026-05-02 12:10:55.75+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 29, "frameworkName": "executive-summary" } ], "arcBeats": [], "loops": [ { "to": 33, "from": 3, "loop": { "name": "11_golden_circle", "slug": "11-golden-circle", "status": "active", "bestFor": "Visionary leadership, brand positioning, mission statements", "canonId": "019dd956-6a50-7202-882d-505fcb9922ed", "version": 1, "bodyDocId": "019df22a-2420-77be-bc41-ded96d08cb21", "structure": "The Why (Belief) -> The How (Process) -> The What (Result)", "description": "Invert the typical pitch by starting with why you exist, rather than what you do", "familyLabel": null }, "matchId": "720e63ac-a674-4bf4-8e46-acf9a0a900ae", "evidence": "The presentation follows the Golden Circle framework, starting with why atai Life Sciences is working on mental health disorders (p3) and presenting their solution and traction.", "position": 1, "objective": "Why is atai Life Sciences' solution important?", "confidence": 0.7, "extraction": { "at": "2026-07-16 22:29:50.666122+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": "doc-narrative-v1" } } ], "locked": true }, { "page": 30, "type": "setup", "title": "The slide uses a feature-comparison matrix to highlight the unique value proposition of DMX-1002 (Ibogaine) against standard MAT and withdrawal support drugs.", "function": "compare_peers", "rawType": "competitive_analysis", "block": null, "metadata": { "slideType": "competitive_analysis", "slideTypeCanon": { "name": "Competitive analysis", "slug": "competitive_analysis", "status": "active", "canonId": "019de52d-093e-776b-94c6-c1573f5f1a31", "version": 1, "description": null }, "function": "compare_peers", "functionCanon": { "name": "Compare peers", "slug": "compare_peers", "status": "active", "canonId": "019de52d-1453-72ba-a367-9ba3d34c1630", "version": 1, "description": null }, "density": "dense", "densityScore": 51, "componentCount": 4, "textChars": 819, "nDataPoints": 0, "notes": "The slide uses a feature-comparison matrix to highlight the unique value proposition of DMX-1002 (Ibogaine) against standard MAT and withdrawal support drugs.", "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 12:10:51.589+00", "seconds": 2.804, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de074-4969-72b8-bf99-262b9202adeb/30", "deck": "/decks/019de074-4969-72b8-bf99-262b9202adeb", "deckAnchor": "/decks/019de074-4969-72b8-bf99-262b9202adeb#slide-30", "deckJson": "/decks/019de074-4969-72b8-bf99-262b9202adeb.json" }, "components": [ { "bbox": { "h": 0.25, "w": 0.2, "x": 0.052, "y": 0.218 }, "kind": "paragraph", "text": "DMX-1002 could potentially become a paradigm-shifting therapy for Opioid Use Disorder (OUD). Current standard of care for OUD is medication therapy, requiring opioid substitutes that carry significant side effects. Current strategies for withdrawal support have high rates of relapse.", "attrs": null, "canon": { "kind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "5f2affc0-941d-4d07-959d-4bfc1930cea4", "version": 1, "description": "Single prose block in the body of a slide." }, "tool": null, "subkind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "019de52c-fb80-75af-aa5c-a7a4bfac2433", "version": 1, "description": null }, "framework": null }, "subkind": "paragraph", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:10:51.589+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "fd6ec8b5-8038-4f16-b2a7-edde5924da50", "parentComponentId": null }, { "bbox": { "h": 0.05, "w": 0.65, "x": 0.265, "y": 0.91 }, "kind": "source-note", "text": "Note: OUD = Opioid Use Disorder. Source: Publicly available information, including company websites and clinicaltrials.gov, GlobalData, Evaluate Pharma (both as of 2022). 1. Current Standard of Care. 2. Rarely used given high rates of relapse. Used primarily in institutional or penitentiary settings", "attrs": null, "canon": { "kind": { "name": "Source note", "slug": "source-note", "status": "active", "canonId": "23484952-494b-4a5e-b1ad-550d0d70e948", "version": 1, "description": "Attribution / source / caveat placed at the slide footer. Numbered footnotes use attrs.numbered." }, "tool": null, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:10:51.589+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "253f5fe5-df4c-4721-a3d9-8be4603281cc", "parentComponentId": null }, { "bbox": { "h": 0.65, "w": 0.7, "x": 0.265, "y": 0.218 }, "kind": "table", "text": "Comparison matrix of DMX-1002 vs Methadone, Buprenorphine, Naltrexone, Clonidine, and Lofexidine across 5 therapeutic criteria.", "attrs": null, "canon": { "kind": { "name": "Table", "slug": "table", "status": "active", "canonId": "019de52c-f9c8-7148-8119-eaac9594cd28", "version": 1, "description": "Tabular data layout." }, "tool": null, "subkind": { "name": "Data table", "slug": "data", "status": "active", "canonId": "019de52d-02d5-75b8-8abf-88e92bf63569", "version": 1, "description": null }, "framework": null }, "subkind": "data", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:10:51.589+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "4dbe695a-bdd0-43ee-bb12-96af024d68c8", "parentComponentId": null }, { "bbox": { "h": 0.075, "w": 0.7, "x": 0.265, "y": 0.078 }, "kind": "title", "text": "DMX-1002 has the potential to become the first & best in-class treatment for OUD, minimizing risk of relapse", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:10:51.589+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "776a458c-bb78-4876-934b-e79eeca1b2c5", "parentComponentId": null } ], "metrics": [], "tools": [ { "tool": { "name": "2x2 matrix", "slug": "matrix-2x2", "status": "active", "bestFor": null, "canonId": "019dd9e1-50ab-72d1-8afb-3ab0a38e32a8", "version": 1, "bodyDocId": null, "description": "BCG matrix, importance/urgency, any axes-and-quadrants frame.", "familyLabel": null, "categoryName": null, "categorySlug": null }, "agent": null, "layer": "slide", "agents": null, "matchId": "0d255183-23d3-42f8-80cb-810f1a3663aa", "evidence": "Comparison matrix of DMX-1002 vs Methadone, Buprenorphine, Naltrexone, Clonidine, and Lofexidine across 5 therapeutic criteria", "pageRefs": null, "priority": null, "whenToUse": null, "confidence": 0.5, "extraction": { "at": "2026-07-17 00:18:18.157337+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 30, "whyItWorks": null, "antipattern": null, "cardinality": "common", "narrativePurpose": null } ], "frameworks": [ { "matchId": "aaa198a6-406c-473f-a95c-fcd683d86141", "evidence": "The slide uses a feature-comparison table to position the product against competitors.", "framework": null, "confidence": 0.95, "extraction": { "at": "2026-05-02 12:10:51.589+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 30, "frameworkName": "comparison-frame" } ], "arcBeats": [], "loops": [ { "to": 33, "from": 3, "loop": { "name": "11_golden_circle", "slug": "11-golden-circle", "status": "active", "bestFor": "Visionary leadership, brand positioning, mission statements", "canonId": "019dd956-6a50-7202-882d-505fcb9922ed", "version": 1, "bodyDocId": "019df22a-2420-77be-bc41-ded96d08cb21", "structure": "The Why (Belief) -> The How (Process) -> The What (Result)", "description": "Invert the typical pitch by starting with why you exist, rather than what you do", "familyLabel": null }, "matchId": "720e63ac-a674-4bf4-8e46-acf9a0a900ae", "evidence": "The presentation follows the Golden Circle framework, starting with why atai Life Sciences is working on mental health disorders (p3) and presenting their solution and traction.", "position": 1, "objective": "Why is atai Life Sciences' solution important?", "confidence": 0.7, "extraction": { "at": "2026-07-16 22:29:50.666122+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": "doc-narrative-v1" } } ], "locked": true }, { "page": 31, "type": "setup", "function": "transition", "rawType": "section_divider", "block": null, "metadata": { "slideType": "section_divider", "slideTypeCanon": { "name": "Section divider", "slug": "section_divider", "status": "active", "canonId": "019de52d-066a-7402-9554-6ae504999041", "version": 1, "description": null }, "function": "transition", "functionCanon": { "name": "Transition", "slug": "transition", "status": "active", "canonId": "019de52d-1365-7149-92aa-66df859e75fd", "version": 1, "description": null }, "density": "sparse", "densityScore": 1, "componentCount": 1, "textChars": 13, "nDataPoints": 0, "notes": null, "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 12:10:52.618+00", "seconds": 3.582, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de074-4969-72b8-bf99-262b9202adeb/31", "deck": "/decks/019de074-4969-72b8-bf99-262b9202adeb", "deckAnchor": "/decks/019de074-4969-72b8-bf99-262b9202adeb#slide-31", "deckJson": "/decks/019de074-4969-72b8-bf99-262b9202adeb.json" }, "components": [ { "bbox": { "h": 0.2, "w": 0.25, "x": 0.05, "y": 0.45 }, "kind": "title", "text": "Enabling Tech", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:10:52.618+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "6211ec92-cd20-48ef-9ca8-09de0043145e", "parentComponentId": null } ], "metrics": [], "tools": [], "frameworks": [], "arcBeats": [], "loops": [ { "to": 33, "from": 3, "loop": { "name": "11_golden_circle", "slug": "11-golden-circle", "status": "active", "bestFor": "Visionary leadership, brand positioning, mission statements", "canonId": "019dd956-6a50-7202-882d-505fcb9922ed", "version": 1, "bodyDocId": "019df22a-2420-77be-bc41-ded96d08cb21", "structure": "The Why (Belief) -> The How (Process) -> The What (Result)", "description": "Invert the typical pitch by starting with why you exist, rather than what you do", "familyLabel": null }, "matchId": "720e63ac-a674-4bf4-8e46-acf9a0a900ae", "evidence": "The presentation follows the Golden Circle framework, starting with why atai Life Sciences is working on mental health disorders (p3) and presenting their solution and traction.", "position": 1, "objective": "Why is atai Life Sciences' solution important?", "confidence": 0.7, "extraction": { "at": "2026-07-16 22:29:50.666122+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": "doc-narrative-v1" } } ], "locked": true }, { "page": 32, "type": "appendix", "function": "present_solution", "rawType": "other", "block": null, "metadata": { "slideType": "other", "slideTypeCanon": { "name": "Other (fallback)", "slug": "other", "status": "active", "canonId": "019de52d-0af5-71ed-83de-d51ae245fc43", "version": 1, "description": null }, "function": "present_solution", "functionCanon": { "name": "Present solution", "slug": "present_solution", "status": "active", "canonId": "019de52d-15b8-71da-bd23-2b767850cbce", "version": 1, "description": null }, "density": "dense", "densityScore": 68, "componentCount": 6, "textChars": 879, "nDataPoints": 0, "notes": null, "elementsJson": null, "confidence": 0.95, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 12:10:52.229+00", "seconds": 3.013, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de074-4969-72b8-bf99-262b9202adeb/32", "deck": "/decks/019de074-4969-72b8-bf99-262b9202adeb", "deckAnchor": "/decks/019de074-4969-72b8-bf99-262b9202adeb#slide-32", "deckJson": "/decks/019de074-4969-72b8-bf99-262b9202adeb.json" }, "components": [ { "bbox": { "h": 0.03, "w": 0.5, "x": 0.05, "y": 0.95 }, "kind": "disclaimer", "text": "Note: HTR = Head Twitch Response, DTx = Digital Therapeutics, CNS = Central Nervous System, OTF = Oral Thin Film, DMT = Dimethyltryptamine", "attrs": null, "canon": { "kind": { "name": "Disclaimer", "slug": "disclaimer", "status": "active", "canonId": "91173477-d91f-4024-bbaf-d4f93e3f82dc", "version": 1, "description": "Legal/cautionary text that occupies most of the body of its slide." }, "tool": null, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:10:52.229+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "d08f749a-438f-4d51-910a-b7553aa82366", "parentComponentId": null }, { "bbox": { "h": 0.65, "w": 0.22, "x": 0.28, "y": 0.235 }, "kind": "list", "text": "EntheogeniX: AI-enabled computational biophysics drug discovery platform. Developing NCEs. Recent milestones: Discovered novel chemical series.", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:10:52.229+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "4a6f14a2-f699-4d72-88c2-f2e7ebfea362", "parentComponentId": null }, { "bbox": { "h": 0.65, "w": 0.22, "x": 0.51, "y": 0.235 }, "kind": "list", "text": "InnaristBio: Sol-gel based, nose-to-brain drug delivery platform. Recent milestones: Initiated Ph.1 proof-of-concept study.", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:10:52.229+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "539cfc58-3c03-4c83-a270-e964ef62d398", "parentComponentId": null }, { "bbox": { "h": 0.65, "w": 0.22, "x": 0.05, "y": 0.235 }, "kind": "list", "text": "Introspect: Digital therapeutics platform enabling personalized care. Developing digital tools for psychotherapy. Recent milestones: IDEA-01 incorporated into clinical plans.", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:10:52.229+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "71bbc4af-2d63-4f39-ba4f-53766202b4d7", "parentComponentId": null }, { "bbox": { "h": 0.65, "w": 0.22, "x": 0.74, "y": 0.235 }, "kind": "list", "text": "IntelGenx: Oral Thin Film (OTF) manufacturer. Developing OTF formulation of Viridia's VLS-01. Recent milestones: Initiated first-in-human clinical study.", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:10:52.229+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "8672d474-4976-4ab6-81cb-b9d6531b51cf", "parentComponentId": null }, { "bbox": { "h": 0.1, "w": 0.9, "x": 0.05, "y": 0.08 }, "kind": "title", "text": "Enabling technologies: Our formulation & biomarker stratification companies provide an additional avenue of growth & innovation to the atai platform", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:10:52.229+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "64709a83-49e3-4235-b518-4b325c62fc96", "parentComponentId": null } ], "metrics": [], "tools": [], "frameworks": [], "arcBeats": [], "loops": [ { "to": 33, "from": 3, "loop": { "name": "11_golden_circle", "slug": "11-golden-circle", "status": "active", "bestFor": "Visionary leadership, brand positioning, mission statements", "canonId": "019dd956-6a50-7202-882d-505fcb9922ed", "version": 1, "bodyDocId": "019df22a-2420-77be-bc41-ded96d08cb21", "structure": "The Why (Belief) -> The How (Process) -> The What (Result)", "description": "Invert the typical pitch by starting with why you exist, rather than what you do", "familyLabel": null }, "matchId": "720e63ac-a674-4bf4-8e46-acf9a0a900ae", "evidence": "The presentation follows the Golden Circle framework, starting with why atai Life Sciences is working on mental health disorders (p3) and presenting their solution and traction.", "position": 1, "objective": "Why is atai Life Sciences' solution important?", "confidence": 0.7, "extraction": { "at": "2026-07-16 22:29:50.666122+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": "doc-narrative-v1" } } ], "locked": true }, { "page": 33, "type": "tension", "title": "The slide uses a personal narrative to establish the 'why' behind the company's mission.", "function": "inspire_vision", "rawType": "ceo_quote", "block": null, "metadata": { "slideType": "ceo_quote", "slideTypeCanon": { "name": "CEO quote", "slug": "ceo_quote", "status": "active", "canonId": "019de52d-09b6-71c8-93a5-f90a9772a8fa", "version": 1, "description": null }, "function": "inspire_vision", "functionCanon": { "name": "Inspire vision", "slug": "inspire_vision", "status": "active", "canonId": "019de52d-16d0-7756-83de-376eeac6fa40", "version": 1, "description": null }, "density": "sparse", "densityScore": 17, "componentCount": 2, "textChars": 250, "nDataPoints": 0, "notes": "The slide uses a personal narrative to establish the 'why' behind the company's mission.", "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 12:10:52.159+00", "seconds": 2.746, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de074-4969-72b8-bf99-262b9202adeb/33", "deck": "/decks/019de074-4969-72b8-bf99-262b9202adeb", "deckAnchor": "/decks/019de074-4969-72b8-bf99-262b9202adeb#slide-33", "deckJson": "/decks/019de074-4969-72b8-bf99-262b9202adeb.json" }, "components": [ { "bbox": { "h": 0.05, "w": 0.3, "x": 0.05, "y": 0.85 }, "kind": "paragraph", "text": "Florian Brand | CEO | atai life sciences", "attrs": null, "canon": { "kind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "5f2affc0-941d-4d07-959d-4bfc1930cea4", "version": 1, "description": "Single prose block in the body of a slide." }, "tool": null, "subkind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "019de52c-fb80-75af-aa5c-a7a4bfac2433", "version": 1, "description": null }, "framework": null }, "subkind": "paragraph", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:10:52.159+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "3d583d2b-550b-49cc-9d76-0fff11786164", "parentComponentId": null }, { "bbox": { "h": 0.5, "w": 0.65, "x": 0.05, "y": 0.25 }, "kind": "quote", "text": "Watching my best friend and business partner suffer, being let down by existing treatments and finally finding comfort in psychedelic therapies, was all the inspiration I needed to commit my life to this cause.", "attrs": null, "canon": { "kind": { "name": "Quote", "slug": "quote", "status": "active", "canonId": "019de52c-f8fb-751e-8bc6-d58e2d59562a", "version": 1, "description": "Pull quote or testimonial." }, "tool": null, "subkind": { "name": "Pull quote", "slug": "pull-quote", "status": "active", "canonId": "019de52c-fbf9-76fe-97e1-a0b7540445c9", "version": 1, "description": null }, "framework": null }, "subkind": "pull-quote", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:10:52.159+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "2cf3de0b-c2ba-4bb6-93fd-d95380220a76", "parentComponentId": null } ], "metrics": [], "tools": [], "frameworks": [ { "matchId": "7bb4b171-a18e-422c-b0ed-5a31829844d0", "evidence": "Uses personal narrative to humanize the corporate mission.", "framework": null, "confidence": 0.8, "extraction": { "at": "2026-05-02 12:10:52.159+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 33, "frameworkName": "ceo-quote-contradiction" } ], "arcBeats": [], "loops": [ { "to": 33, "from": 3, "loop": { "name": "11_golden_circle", "slug": "11-golden-circle", "status": "active", "bestFor": "Visionary leadership, brand positioning, mission statements", "canonId": "019dd956-6a50-7202-882d-505fcb9922ed", "version": 1, "bodyDocId": "019df22a-2420-77be-bc41-ded96d08cb21", "structure": "The Why (Belief) -> The How (Process) -> The What (Result)", "description": "Invert the typical pitch by starting with why you exist, rather than what you do", "familyLabel": null }, "matchId": "720e63ac-a674-4bf4-8e46-acf9a0a900ae", "evidence": "The presentation follows the Golden Circle framework, starting with why atai Life Sciences is working on mental health disorders (p3) and presenting their solution and traction.", "position": 1, "objective": "Why is atai Life Sciences' solution important?", "confidence": 0.7, "extraction": { "at": "2026-07-16 22:29:50.666122+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": "doc-narrative-v1" } } ], "locked": true } ], "arcBeats": [ { "from": 8, "to": 9, "label": "Problem", "description": "The presentation identifies a huge need for development in CIAS and Schizophrenia treatment (p8) and an urgent need for innovation in depression treatment (p15)." }, { "from": 4, "to": 7, "label": "Solution", "description": "The presentation presents atai Life Sciences' solution, including their strategy for delivering sustained behavioral change in patients (p4) and their robust pipeline of drug development programs (p5-6)." }, { "from": 10, "to": 12, "label": "Traction", "description": "The presentation showcases traction for RL-007, including its pro-cognitive effects in human clinical studies (p9) and its Phase 2b trial design (p12)." }, { "from": 5, "to": 6, "label": "Roadmap", "description": "The presentation outlines atai Life Sciences' roadmap, including expected R&D milestones across key programs through 2024 (p6)." }, { "from": 13, "to": 14, "label": "Competitive Analysis", "description": "The presentation provides a competitive analysis for RL-007, highlighting its unique pharmacology and acute cognitive benefit (p13)." } ], "loops": [ { "from": 8, "to": 9, "label": "Cost Of Inaction", "description": "What are the consequences of not addressing mental health disorders?" }, { "from": 3, "to": 33, "label": "Golden Circle", "description": "Why is atai Life Sciences' solution important?" } ] }